IL-2	B
gene	O
expression	O
and	O
NF-kappa	B
B	O
activation	O
through	O
CD28	B
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B
expression	O
via	O
NF-kappa	B
B	O
activation	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	B
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B
enhancer	O
activation	O
following	O
stimulation	O
of	O
monocytic	B
but	O
not	O
T-cell	B
lines	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B
B	O
factor	O
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B
and	O
T	B
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O

The	O
inability	O
of	O
E1A	B
gene	O
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B
cells	O
or	O
by	O
viral	B
gene	O
effects	O
on	O
class	B
I	O
MHC	O
antigen	O
expression	O
on	O
target	B
cells	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B
antibodies	O
(	O
mAb	B
)	O
which	O
recognize	O
different	O
CD4	B
epitopes	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B
on	O
the	O
CD4	B
coreceptor	O
involved	O
in	O
activation	O
of	O
the	O
Ras	B
/protein	B
kinase	O
C	O
and	O
calcium	O
pathways	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down-regulation	O
of	O
many	O
erythroid	B
cell-specific	O
genes	O
,	O
including	O
alpha-	O
and	O
beta-	O
globin	O
,	O
band	B
3	O
,	O
band	B
4.1	O
,	O
and	O
the	O
erythroid	B
cell-specific	O
histone	O
H5	B
.	O

ER	B
-mediated	O
repression	O
of	O
GATA-1	B
activity	O
occurs	O
on	O
an	O
artificial	B
promoter	O
containing	O
a	O
single	O
GATA-binding	B
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	B
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B
.	O

We	O
have	O
shown	O
that	O
interleukin-1	B
(	O
IL-1	B
)	O
and	O
IL-2	B
control	O
IL-2	B
receptor	O
alpha	O
(	O
IL-2R	B
alpha	O
)	O
gene	O
transcription	O
in	O
CD4-CD8-	B
murine	O
T	O
lymphocyte	O
precursors	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase,	O
in	O
which	O
IL-2	B
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	B
alpha	O
transcripts	O
.	O

IL-2	B
responsiveness	O
requires	O
three	O
distinct	O
elements	B
within	O
the	O
enhancer	B
.	O

A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B
factors	O
important	O
in	O
specifying	O
hematopoietic	B
cell	O
types	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	B
cells	O
and	O
epithelial	B
cells	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	B
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection.	O

In	O
addition,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B
gene	O
in	O
infected	O
thymocytes	B
was	O
transcribed	O
from	O
the	O
Fp	B
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B
promoter	O
which	O
is	O
used	O
in	O
latently	B
infected	O
B	B
cells	O
.	O

Rather,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B
genes	O
are	O
transcribed.	O

In	O
turn,	O
secreted	O
IL-2	B
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	B
lymphocytes	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B
human	O
lymphocyte	O
line	O
,	O
termed	O
YT	B
.	O

The	O
cell	B
cycle-dependent	O
transcription	O
factor	O
,	O
E2F-1	B
,	O
regulates	O
the	O
cyclin	B
-like	O
species	O
of	O
the	O
DNA	B
repair	O
enzyme	O
uracil-DNA	B
glycosylase	O
(	O
UDG	B
)	O
gene	O
in	O
human	B
osteosarcoma	O
(	O
Saos-2	B
)	O
cells	O
.	O

High	O
levels	O
of	O
UDG	B
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B
specific	O
for	O
E2F	B
-mediated	O
transcription	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B
production	O
induced	O
by	O
IL-2	B
and	O
IL-12	B
in	O
a	O
human	B
NK	O
cell	O
line	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B
line	O
NK3.3	O
derived	O
from	O
human	B
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL-2	B
and	O
IL-12	B
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN-gamma	B
and	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
contrast,	O
IL-12	B
induction	O
of	O
IFN-gamma	B
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B
kinase	O
C	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B
and	O
IL-12	B
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B
and	O
GM-CSF	B
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B
cell	O
line	O
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways.	O

It	O
contains	O
a	O
number	O
of	O
structural	B
motifs	O
,	O
including	O
Src	B
homology	O
2	O
,	O
Src	B
homology	O
3	O
,	O
and	O
pleckstrin	B
homology	O
domains	O
and	O
a	O
putative	B
guanine	O
nucleotide	O
exchange	O
domain	O
.	O

In	O
contrast,	O
NFAT	B
activation	O
by	O
a	O
G-protein-coupled	B
receptor	O
is	O
not	O
modulated	O
by	O
p95vav	B
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B
signaling	O
pathways	O
.	O

To	O
further	O
dissect	O
p95vav	B
involvement	O
in	O
TCR	B
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	B
mutants	O
deficient	O
in	O
TCR	B
signaling	O
function	O
or	O
TCR	B
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	B
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B
to	O
function.	O

The	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B
enhancer	O
binding-protein	O
2	O
(	O
PEBP2	B
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

PEBP2	B
alpha	B
A1	O
,	O
alpha	B
B1	O
,	O
and	O
alpha	B
B2	O
proteins	O
bound	O
the	O
PEBP2	B
site	O
within	O
the	O
mouse	B
GM-CSF	B
promoter	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B
site-binding	O
protein	O
(s)	O
that	O
cross-reacted	O
with	O
antimouse	B
alpha	B
A1	O
antibodies	O
.	O

The	O
induction	O
of	O
cytokine	B
expression	O
in	O
monocytes	B
/	O
macrophages	B
by	O
bacterial	B
endotoxin	O
or	O
lipopolysaccharide	O
is	O
a	O
critical,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

Priming	O
by	O
IFN-gamma	B
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B
mRNA	O
accumulation	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B
factor-kappa	O
B	O
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B
NF-kappa	B
B	O
oligonucleotide	O
.	O

H-89	O
substantially	O
suppressed	O
LPS	O
-induced	O
TNF	B
mRNA	O
accumulation	O
in	O
unprimed	B
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B
monocytes	B
following	O
LPS	O
stimulation	O
.	O

In	O
this	O
report,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	B
promoter	O
has	O
four	O
factor	B
binding	O
sites	O
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function.	O

This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	B
G3AG4AG3	O
motif	O
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	B
promoter	O
of	O
the	O
c-myc	B
gene	O
.	O

The	O
protein	B
products	O
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B
motif	O
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B
factors	O
that	O
bind	O
to	O
the	O
canonical	B
DNA	O
sequence	O
CANNTG	O
as	O
protein	B
heterodimers	O
.	O

An	O
Epo	B
-inducible	O
TAL1	B
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	B
and	O
protein	B
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	B
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein-labeled	O
amplicon	O
(probe)	O
and	O
unlabeled	O
amplicon	O
(target)	O
during	O
hybridization	O
.	O

Induction	O
of	O
Sp1	B
phosphorylation	O
and	O
NF-kappa	B
B	O
-independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	B
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

Responsiveness	O
of	O
LTR	B
constructs	O
deleted	O
of	O
kappa	B
B	O
elements	O
to	O
HIV	B
Tat	O
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B
stimulation	O
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B
proteins	O
activated	O
in	O
peripheral	B
blood	O
lymphocytes	O
(	O
PBLs	B
)	O
by	O
cytokines	B
with	O
shared	O
and	O
distinct	O
actions.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B
can	O
activate	O
different	O
combinations	O
of	O
Stat	B
proteins	O
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B
can	O
activate	O
the	O
same	O
Stat	B
protein	O
.	O

This	O
liberates	O
NF-kappa	B
B	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B
important	O
for	O
the	O
defense	O
of	O
the	O
organism.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	B
erythropoietin	O
receptor	O
gene	O
by	O
proteins	O
binding	O
to	O
GATA-1	B
and	O
Sp1	B
motifs	O
.	O

The	O
150	B
bp	O
hEpoR	O
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B
and	O
K562	B
cells	O
,	O
respectively,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B
expression	O
.	O

Interestingly,	O
when	O
we	O
mutated	O
the	O
Sp1	B
site	O
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B
promoter	O
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	B
levels	O
in	O
OCIM1	B
cells	O
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

DR-nm23	B
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B
purified	O
CD34+	O
cells	O
.	O

Expression	O
of	O
the	O
IgG	B
Fc	O
receptor	O
type	O
I	O
(	O
Fc	B
gamma	O
RI	O
)	O
on	O
myeloid	B
cells	O
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	B
(	O
IFN-gamma	B
).	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B
gamma	O
RIC	O
gene	O
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B
initiation	O
site	O
without	O
a	O
TATA	B
box	O
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B
alpha	O
protein	O
bound	O
to	O
the	O
Fc	B
gamma	O
RIC	O
GIRE	O
in	O
response	O
to	O
IFN-gamma	B
treatment	O
of	O
U937	B
cells	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(also	O
termed	O
HTLV-I	O
-associated	O
myelopathy	O
).	O

Nitric	O
oxide	O
decreases	O
cytokine	B
-induced	O
endothelial	O
activation	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	B
alpha	O
,	O
IL-1	B
beta	O
,	O
IL-4	B
,	O
tumor	B
necrosis	O
factor	O
(	O
TNF	B
alpha	O
),	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B
cell	O
types	O
.	O

In	O
this	O
communication,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B
cell	O
line	O
U937	B
is	O
different	O
from	O
that	O
in	O
Jurkat	B
cells	O
.	O

A	O
mutation	O
of	O
the	O
MNP	B
site	O
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B
promoter	O
in	O
U937	B
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B
cells	O
.	O

After	O
short-term,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place.	O

IL-5	B
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B
.	O

We	O
found	O
that	O
IL-5	B
induces	O
two	O
GAS-binding	B
proteins	O
in	O
eosinophils	B
,	O
one	O
of	O
which	O
is	O
STAT1	B
.	O

It	O
is	O
a	O
potent	O
transcriptional	B
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

Our	O
results	O
suggest	O
that	O
Rb	B
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

However,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	B
cell	O
types	O
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B
kinase	O
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

The	O
major	B
histocompatibility	O
(MHC)	O
class	O
II	O
genes	O
encode	O
cell	B
surface	O
proteins	O
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B
.	O

Therefore,	O
we	O
examined	O
the	O
RB	B
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(BLS)	O
patients.	O

CIITA	B
is	O
a	O
class	B
II	O
gene	O
transactivator	O
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B
class	O
II	O
by	O
IFN-gamma	B
.	O

Interleukin	B
12	O
(	O
IL-12	B
)	O
is	O
an	O
important	O
immunoregulatory	B
cytokine	O
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B
receptor	O
superfamily	O
.	O

Furthermore,	O
we	O
show	O
that	O
IL-12	B
stimulates	O
formation	O
of	O
a	O
DNA-binding	B
complex	O
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B
proteins	O
and	O
that	O
this	O
complex	O
contains	O
STAT4	B
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B
receptor	O
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

MEASUREMENTS:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B
receptors	O
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations.	O

However,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B
receptor	O
was	O
observed.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B
receptor	O
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B
receptors	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B
receptor	O
number	O
and	O
affinity.	O

In	O
the	O
human	B
monocytic	O
cell	O
line	O
THP-1	O
,	O
either	O
integrin	B
-dependent	O
cell	O
adhesion	O
to	O
fibronectin	B
or	O
ligation	O
of	O
beta	B
1	O
integrins	O
with	O
antibodies	B
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	B
of	O
about	O
65-75	O
and	O
120-125	O
kDa	O
.	O

In	O
contrast,	O
integrin	B
ligation	O
with	O
antibodies	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B
but	O
not	O
of	O
FAK	B
or	O
paxillin	B
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B
receptor	O
(	O
GR	B
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[3H]dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B
lymphoid	O
cells	O
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
),	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

Scatchard	O
analysis	O
of	O
[3H]dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

The	O
mRNA	B
for	O
the	O
Duffy	B
blood	O
group	O
antigen	O
,	O
the	O
erythrocyte	B
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	B
receptor	O
.	O

Activation	O
of	O
pp90rsk	B
and	O
early	B
growth	O
response-1	O
gene	O
expression	O
by	O
pokeweed	B
mitogen	O
in	O
human	B
B	O
cells	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B
kinase	O
(	O
pp90rsk	B
),	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B
and	O
serum	O
response	O
factor	O
(SRF)	O
peptides	O
,	O
in	O
PWM	B
treated	O
B	O
cells	O
.	O

It	O
contains	O
a	O
core	B
sequence	O
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	B
sequences	O
in	O
each	O
gene.	O

In	O
different	O
genes	B
,	O
the	O
core	B
sequences	O
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	B
turns	O
.	O

A	O
new	O
gene	B
,	O
TINUR	B
,	O
was	O
cloned	O
from	O
apoptotic	B
PEER	O
cells	O
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	B
family	O
can	O
be	O
classified	O
into	O
two	O
subtypes.	O

METHODS	O
AND	O
RESULTS:	O
Gel-shift	O
analyses	O
demonstrated	O
dose-dependent	O
inhibition	O
of	O
TNF	B
-induced	O
NF-kappa	B
B	O
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective.	O

In	O
the	O
present	O
study,	O
the	O
role	O
of	O
serine/threonine	B
phosphatases	O
in	O
the	O
regulation	O
of	O
I	B
kappa	O
B	O
alpha	O
phosphorylation	O
was	O
investigated.	O

However,	O
induction	O
of	O
I	B
kappa	O
B	O
alpha	O
phosphorylation	O
by	O
both	O
TNF-alpha	B
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B
kappa	O
B	O
alpha	O
.	O

The	O
5'	B
flanking	O
region	O
of	O
the	O
human	B
alpha-globin	O
gene	O
is	O
highly	O
G	B
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B
sequence	O
for	O
the	O
Sp1	B
binding	O
site	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha-globin	B
G	O
+	O
C-rich	O
5'	O
flanking	O
region	O
augments	O
alpha-globin	B
promoter	O
activity	O
in	O
a	O
chromatin	B
-dependent	O
manner	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B
CD4+	O
T	O
cells	O
with	O
SEA	O
presented	O
on	O
Chinese	B
hamster	O
ovary	O
(CHO)-DR	O
transfectants	O
coexpressing	O
either	O
B7	B
or	O
LFA-3	B
resulted	O
in	O
distinct	O
cytokine	B
profiles	O
.	O

LFA-3	B
induced	O
moderate	O
levels	O
of	O
AP-1	B
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B
B	O
,	O
while	O
B7	B
costimulation	O
strongly	O
induced	O
both	O
AP-1	B
and	O
substantially	O
enhanced	O
NF-kappa	B
B	O
binding	O
proteins	O
.	O

The	O
AP-1	B
binding	O
proteins	O
contained	O
c-Jun	B
,	O
Jun-D	B
,	O
and	O
Fra-1	B
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B
and	O
c-Fos	B
.	O

2,3,7,8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism.	O

In	O
addition,	O
the	O
Ah	B
receptor	O
complex	O
recognized	O
a	O
DNA	B
binding	O
site	O
for	O
B	B
cell	O
lineage-specific	O
activator	O
protein	O
(	O
BSAP	B
)	O
in	O
the	O
promoter	B
region	O
of	O
the	O
human	O
CD19	B
gene	O
which	O
is	O
similar	O
to	O
the	O
consensus	B
Ah	B
receptor	O
DNA	B
binding	O
site	O
.	O

nm23	B
genes	O
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B
cells	O
was	O
inhibited	O
by	O
recombinant	O
human	O
nm23	O
-H1	O
,	O
-H2	O
,	O
mouse	O
nm23	O
-M1	O
,	O
and	O
-M2	O
proteins	O
.	O

Endothelial	B
cells	O
stimulated	O
by	O
LPS	O
express	O
E-selectin	B
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B
adhesion	O
during	O
inflammation	O
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	B
cells	O
,	O
when	O
NF-kappa	B
B	O
was	O
already	O
activated,	O
addition	O
of	O
rBPI21	B
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	B
B	O
detectable	O
at	O
4	O
or	O
6	O
h.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B
cytokines	O
produced	O
by	O
antigen	B
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

The	O
activation	O
of	O
NFAT	B
by	O
TCR	B
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	B
transactivator	O
protein	O
,	O
tax	B
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

This	O
observation,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B
and	O
IL-2	B
respond	O
to	O
TCR	B
signals	O
via	O
NFAT	B
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B
gene	O
expression	O
in	O
T	B
cells	O
.	O

3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B
gene	O
to	O
approximately	O
50%	O
in	O
monocytes	B
in	O
a	O
run-on	O
assay	O
.	O

Formation	O
of	O
the	O
NFAT	B
-1	O
transcriptional	O
complex	O
on	O
the	O
IL-2	B
promoter	O
is	O
essential	O
for	O
IL-2	B
transcription	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B
line	O
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT	B
-1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	B
gene	O
for	O
sCD8	O
.	O

Conversely,	O
calcium-independent	B
anti-CD28	O
Ab	O
and	O
PMA-induced	O
IL-2	B
production	O
was	O
resistant.	O

Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B
vacuolar	O
H(+)-ATPase	O
(	O
V-ATPase	B
).	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	B
exon	O
and	O
5'-flanking	B
region	O
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	B
promoter	O
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

DNase	B
I	O
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	O
and	O
Sp1	O
binding	O
sites	O
in	O
the	O
5'-untranslated	O
and	O
proximal	O
coding	O
regions	O
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt's	B
lymphoma	O
cells	O
(	O
Ramos	B
and	O
Daudi	B
)	O
as	O
well	O
as	O
a	O
T	B
lymphocytic	O
cell	O
line	O
(	O
Jurkat	B
).	O

Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium-	O
mediated	O
activation	O
of	O
c-fos	B
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B
C	O
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	B
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	B
well.	O

The	O
human	B
granulocyte-macrophage	O
CSF	O
(	O
GM-CSF	B
)	O
gene	O
is	O
expressed	O
in	O
T	B
cells	O
in	O
response	O
to	O
TCR	B
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2+	O
ionophore	O
.	O

The	O
major	O
inducible	B
protein	O
complex	O
that	O
binds	O
to	O
the	O
human	B
CLEO	B
(	O
hCLEO	B
)	O
element	O
is	O
an	O
AP-1	B
-like	O
complex	O
that	O
is	O
inducible	O
by	O
PMA	O
alone,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2+	O
ionophore	O
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B
promoter	O
,	O
and	O
conversely	O
that	O
mutant-activated	B
Ras	O
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

IL-10	B
affects	O
monocytes	B
and	O
T	B
cells	O
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte-mediated	O
effects	O
predominate.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B
in	O
cells	O
such	O
as	O
monocytes	B
and	O
T	B
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B
protein	O
pairs	O
.	O

To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	B
Factor	O
IV	O
(as	O
indicator	O
of	O
Platelet	O
Aggregation	O
),	O
Type	B
II	O
estrogenic	O
receptors	O
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation.	O

The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	B
(Ipr)	O
peripheral	O
CD4-CD8-	O
(CD4-8-)	O
T	B
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B
in	O
response	O
to	O
TCR	B
or	O
mitogenic	O
stimulation	O
.	O

We,	O
therefore,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	B
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	B
CD4-8-	O
T	B
cells	O
with	O
that	O
of	O
normal	B
T	O
lymphocytes	O
.	O

Furthermore,	O
nuclear	O
extracts	O
from	O
Ipr	B
CD4-8-	O
T	B
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B
T	O
lymphocytes	O
.	O

CD30	B
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(TNF)	O
receptor	O
family,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)-1.	O

Thus,	O
CD30	B
-CD30L	B
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified.	O

The	O
specificity	O
of	O
CIITA	B
for	O
three	O
major	O
MHC	B
class	O
II	O
genes	O
,	O
DR	B
,	O
DQ	B
and	O
DP	B
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	B
residues	O
(	O
amino	B
acids	O
317-1130	O
).	O

Signal	O
integration	O
and	O
NF-kappa	B
B	O
translocation	O
[see	O
comments]	O

Moreover,	O
tethering	O
by	O
P-selectin	B
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B
factor-kappa	O
B	O
(	O
NF-kappa	B
B	O
),	O
a	O
transcription	B
factor	O
required	O
for	O
expression	O
of	O
MCP-1	B
,	O
TNF-alpha	B
,	O
and	O
other	O
immediate-early	B
genes	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	B
alpha-like	O
globin	O
genes	O
,	O
embryonic	B
zeta	O
2	O
and	O
adult	B
alpha	O
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	B
enhancer	O
,	O
HS-40	B
.	O

On	O
the	O
other	O
hand,	O
the	O
3'NF-E2/AP1	B
motif	O
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B
2-globin	O
promoter	O
activity	O
in	O
K562	B
cells	O
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B
AP1	O
factors	O
and	O
the	O
erythroid-enriched	B
NF-E2	O
factor	O
.	O

Nitric	O
oxide	O
-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B
in	O
association	O
with	O
GDP	O
/GTP	O
exchange	O
.	O

These	O
studies	O
identify	O
p21ras	B
as	O
a	O
target	O
of	O
NO	O
in	O
T	B
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B
nucleotide	O
exchange	O
factors	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	B
promoter	O
activity	O
in	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)-transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

In	O
seven	O
EBV-B	B
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	B
,	O
the	O
activity	O
of	O
the	O
IL-2	B
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	B
secretion	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	B
NF-chi	B
B	O
site	O
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	B
promoter	O
in	O
EBV-transformed	B
B	B
cells	O
,	O
whereas	O
other	O
transcription	B
factors	O
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	B
expression	O
in	O
these	O
cells.	O

Here,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild-type	O
EBV	O
or	O
its	O
transforming	B
latent	O
membrane	O
protein-1	O
(	O
LMP-1	B
)	O
results	O
in	O
the	O
loss	O
of	O
TGF-beta	B
1	O
-mediated	O
growth	O
inhibition	O
in	O
human	B
B	B
cells	O
.	O

Taken	O
together,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV	O
-mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	B
cell	O
cycle	O
regulators	O
by	O
LMP-1	B
can	O
lead	O
to	O
pRb	B
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

In	O
GD	O
patients	O
,	O
the	O
responses	O
of	O
peripheral	B
blood	O
mononuclear	O
cells	O
(	O
PBMC	B
)	O
and	O
TSH	B
receptor	O
(	O
TSHR	B
)-specific	O
T	O
cell	O
lines	O
to	O
recombinant	B
human	O
TSHR	B
extracellular	O
domain	O
,	O
thyroglobulin	B
,	O
and	O
TSHR	B
peptides	O
were	O
examined	O
on	O
the	O
day	O
of	O
surgery	O
or	O
RAI	O
therapy	O
(day	O
0)	O
and	O
also	O
6-8	O
weeks	O
and	O
3-6	O
months	O
thereafter.	O

The	O
responses	O
of	O
PBMC	B
from	O
Graves'	O
patients	O
before	O
RAI	O
therapy	O
were	O
less	O
than	O
those	O
in	O
the	O
presurgical	O
group.	O

The	O
reactivity	O
of	O
T	B
cell	O
lines	O
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	B
after	O
treatment.	O

The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B
molecule.	O

A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B
differentiation	O
,	O
T	B
cell	O
factor-1	O
(	O
TCF-1	B
)*	O
encodes	O
a	O
DNA-binding	B
protein	O
.	O

We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti-	B
TCF-1	B
antibodies	O
.	O

This	O
study	O
illustrates	O
the	O
almost	O
complete	O
tolerance	O
of	O
mice	O
for	O
human	B
TCF-1	B
and	O
demonstrates	O
that	O
this	O
tolerance	O
is	O
readily	O
broken	O
by	O
gene	O
knock-out	O
.	O

The	O
PuF	B
site	O
on	O
the	O
silent	B
normal	O
c-myc	B
allele	O
was	O
unoccupied.	O

Identification	O
of	O
two	O
novel	O
regulatory	B
elements	O
within	O
the	O
5'-untranslated	B
region	O
of	O
the	O
human	B
A	O
gamma-globin	O
gene	O
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	B
5'-untranslated	O
region	O
(	O
UTR	B
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	B
activity	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	O
and	O
erythroid	O
-specific	O
protein	O
.	O

The	O
eukaryotic	B
transcription	O
factor	O
NF-kappa	B
B	O
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T-cell	O
activation	O
and	O
growth	O
.	O

Specifically,	O
removal	O
of	O
the	O
N-terminal	B
36	O
amino	O
acids	O
of	O
I	B
kappa	O
B	O
alpha	O
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF-kappa	B
B	O
in	O
the	O
cytoplasm	O
.	O

Together,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B
kappa	O
B	O
alpha	O
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B
kappa	O
B	O
alpha	O
and	O
NF-kappa	B
B	O
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	B
cell	O
characteristics	O
.	O

Activated	O
T	B
cells	O
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity.	O

Platelet-activating	B
factor	O
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B
epidermal	O
growth	O
factor-like	O
growth	O
factor	O
in	O
monocytes	B
.	O

The	O
PAF	B
-induced	O
up-regulation	O
of	O
HB-EGF	B
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	B
B	O
activation	O
,	O
markedly	O
reduced	O
PAF	B
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	B
mRNA	O
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B
transcription	O
factor	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	B
,	O
or	O
only	O
the	O
X1-	O
or	O
X2-	O
boxes	O
of	O
HLA-DRA	B
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	B
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	B
X2-box	O
of	O
the	O
class	B
II	O
major	O
histocompatibility	O
complex	O
promoters	O
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	B
class	O
II	O
isotypes	O
.	O

ZEBRA	B
is	O
a	O
bZIP	B
transcriptional	O
activator	O
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	B
response	O
elements	O
within	O
EBV	B
promoters	O
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B
lytic	O
origin	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B
kinase	O
3	O
and	O
interleukin-4	B
Stat	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
(Stat)	O
protein	O
,	O
we	O
determined	O
whether	O
antibodies	B
to	O
Stat	O
proteins	O
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B
to	O
IL-4	B
Stat	O
,	O
also	O
known	O
as	O
Stat6	B
,	O
but	O
not	O
antibodies	B
to	O
other	O
Stat	B
proteins	O
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B
NAF	O
complex	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B
gene	O
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O

In	O
this	O
report,	O
we	O
show	O
that	O
TAL1	B
is	O
expressed	O
in	O
the	O
leukemic	B
cells	O
of	O
most	O
patients	O
with	O
T-ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B
gene	O
alteration.	O

Thus,	O
TAL1	B
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis-acting	B
regulatory	O
sequences	O
(affecting	O
expression	O
of	O
a	O
single	B
TAL1	B
allele	O
)	O
or	O
changes	O
in	O
trans-acting	O
factors	O
that	O
control	O
TAL1	B
transcription	O
(affecting	O
expression	O
of	O
both	O
TAL1	B
alleles	O
).	O

Erythroid-specific	B
mRNAs	O
encoding	O
gamma-globin	B
and	O
erythroid	B
delta-aminolevulinate	O
synthase	O
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	B
from	O
most	O
of	O
these	O
cases,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	B
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B
Ah	B
receptor	O
(	O
TCDD	B
receptor	O
)	O
mRNA	O
in	O
peripheral	B
blood	O
cells	O
of	O
individuals	O
.	O

However,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	B
cells	O
MOLT4	B
(	O
T	B
cell	O
)	O
and	O
BALL1	B
(	O
B	B
cell	O
),	O
nor	O
in	O
K562	B
erythroblasts	O
.	O

The	O
HEL	B
cells	O
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B
mRNA	O
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B
cells	O
by	O
these	O
combined	O
inducers,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types.	O

Neutrophils	B
and	O
monocytes	B
express	O
high	O
levels	O
of	O
PU.1	B
(	O
Spi-1	B
)	O
but	O
not	O
Spi-B	B
.	O

PU.1	B
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	B
cell	O
lines	O
U937	B
and	O
HL-60	B
to	O
monocytic	O
and	O
neutrophilic	O
cells	O
.	O

Therefore,	O
although	O
PU.1	B
and	O
Spi-B	B
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi-B	B
in	O
myeloid	B
cells	O
makes	O
it	O
unlikely	O
that	O
Spi-B	B
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O

The	O
promoters	B
were	O
used	O
without	O
enhancers	B
,	O
or	O
with	O
enhancers	B
derived	O
from	O
the	O
beta-globin	B
locus	O
control	O
region	O
and	O
the	O
alpha-globin	B
HS-40	O
enhancer	O
.	O

Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-	B
luciferase	B
constructs	O
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O

These	O
experiments	O
show	O
the	O
presence	O
of	O
a	O
strong	O
positive-acting	B
element	O
,	O
located	O
between	O
-417	B
and	O
-207	O
bp	O
5'	O
to	O
the	O
zeta-globin	B
mRNA	O
cap	O
site	O
,	O
is	O
necessary	O
for	O
high-level	O
promoter	O
activity	O
in	O
K562	B
cells	O
.	O

To	O
address	O
this	O
issue,	O
mutationally	O
active	O
PKC	O
-alpha	O
,	O
-epsilon	O
,	O
or	O
-zeta	O
have	O
been	O
transfected	O
into	O
T	B
cells	O
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined.	O

The	O
ability	O
of	O
PKC-epsilon	B
to	O
induce	O
transactivation	O
of	O
NF-AT-1	B
and	O
AP-1	B
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B
activated	O
p21ras	B
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B
isotypes	O
in	O
T	B
cells	O
.	O

The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear.	O

Dexamethasone	O
induced	O
a	O
significant	O
rapid	O
and	O
sustained	O
twofold	O
increase	O
in	O
GRE	B
binding	O
in	O
PBMCs	B
from	O
steroid-sensitive	O
asthmatic	O
patients	O
and	O
nonasthmatic	O
individuals	O
,	O
but	O
this	O
was	O
markedly	O
reduced	O
in	O
steroid-resistant	O
asthmatic	O
patients	O
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B
,	O
including	O
interferons	B
,	O
interleukins	B
,	O
and	O
growth	B
factors	O
,	O
involves	O
activation	O
of	O
JAK	B
kinases	O
and	O
Stat	B
(	O
Signal	B
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Moreover,	O
IL-5	B
induced	O
at	O
least	O
two	O
DNA-binding	B
complexes	O
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B
eosinophils	O
and	O
the	O
IL-6/interferon-gamma	B
response	O
element	O
of	O
the	O
ICAM-1	B
promoter	O
(	O
ICAM-1	B
pIRE	O
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	B
signaling	O
in	O
human	B
eosinophils	O
involve	O
members	O
of	O
the	O
JAK	B
kinase	O
family	O
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B
family	O
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B
releases	O
an	O
elongation	B
block	O
to	O
the	O
transcription	O
of	O
HIV	B
long	O
terminal	O
repeat	O
(	O
LTR	B
);	O
however,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	B
T	O
cells	O
when	O
Tat	B
is	O
absent.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B
mutants	O
containing	O
wild-type	B
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	B
Tat	B
mutants	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B
-virus	O
.	O

In	O
addition,	O
HLA-DRA	B
gene	O
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B
(	O
IFN-gamma	B
).	O

By	O
contrast,	O
Oct-2A	B
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B
induction	O
of	O
the	O
HLA-DRA	B
gene	O
in	O
HeLa	B
cells	O
,	O
but	O
antisense	B
HMG	B
I/Y	B
dramatically	O
decreases	O
the	O
level	O
of	O
induction.	O

In	O
lymphoblastoid	B
cell	O
lines	O
,	O
six	O
EBV-encoded	B
nuclear	O
antigens	O
(	O
EBNA	O
1	O
,	O
2	O
,	O
3A	O
,	O
3B	O
,	O
3C	O
,	O
-LP	O
),	O
three	O
latent	B
membrane	O
proteins	O
(	O
LMP1	B
,	O
2A	B
,	O
2B	B
),	O
and	O
two	O
nuclear	B
RNAs	O
(	O
EBERs	B
)	O
are	O
expressed.	O

Expression	O
of	O
LMP1	B
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B
cells	O
in	O
two	O
cases	O
and	O
EBNA2	B
was	O
detected	O
in	O
some	O
tumor	B
cells	O
in	O
three	O
other	O
cases.	O

The	O
activation	O
of	O
the	O
Jak	B
-STAT	B
1	O
signaling	O
pathway	O
by	O
IL-5	B
in	O
eosinophils	B
.	O

The	O
involvement	O
of	O
Jak	B
2	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

Jak	B
2	O
coprecipitated	O
with	O
the	O
beta-subunit	O
of	O
the	O
IL-5	B
receptor	O
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B
with	O
the	O
receptor.	O

IL-5	B
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma-activating	B
sequence	O
.	O

Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B
blood	O
mononuclear	O
cells	O
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

PHA	B
-induced	O
proliferation	O
of	O
PBMCs	B
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(P	O
<	O
0.01),	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only.	O

We	O
thus	O
conclude	O
that	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	B
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	B
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	O
beta	O
,	O
DP	O
alpha	O
and	O
-beta	O
,	O
and	O
DQ	O
alpha	O
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	B
start	O
site	O
.	O

Transcriptional	O
activity	O
of	O
core	O
binding	O
factor-	O
alpha	O
(AML1)	O
and	O
beta	O
subunits	O
on	O
murine	B
leukemia	O
virus	O
enhancer	O
cores	O
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B
alpha	O
subunit	O
is	O
AML1	B
,	O
also	O
called	O
Cbf	B
alpha	O
2	O
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B
beta	O
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B
enhancer	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B
is	O
a	O
factor	O
in	O
T	B
lymphocytes	O
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	B
cores	O
.	O

Thus,	O
a	O
complete	O
understanding	O
of	O
how	O
T	B
cells	O
recognize	O
the	O
SL3	B
core	O
remains	O
to	O
be	O
elucidated.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
),	O
we	O
now	O
show	O
that,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B
alpha	O
,	O
IL-10	B
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF	B
kappa	O
B	O
),	O
a	O
transcription	B
factor	O
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B
cytokine	O
genes	O
.	O
Several	O
other	O
transcription	B
factors	O
including	O
NF-	O
IL-6	B
,	O
AP-1	B
,	O
AP-2	B
,	O
GR	B
,	O
CREB	B
,	O
Oct-1	B
,	O
and	O
Sp-1	B
are	O
not	O
affected	O
by	O
IL-10	B
.	O

IL-4	B
,	O
another	O
cytokine	B
that	O
inhibits	O
cytokine	B
mRNA	O
accumulation	O
in	O
monocytes	B
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS	O
-induced	O
NF	B
kappa	O
B	O
activation	O
.	O

LMP-1	B
,	O
an	O
Epstein-Barr	B
virus	O
membrane	O
protein	O
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	B
and	O
rodent	B
fibroblasts	O
.	O

The	O
mechanism(s)	O
regulating	O
this	O
activation	O
remains	O
unknown.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF-kappa	B
B	O
-dependent-genes	O
,	O
including	O
those	O
encoding	O
p105	B
and	O
I	B
kappa	O
B	O
alpha	O
(	O
MAD3	B
).	O

A	O
DNA	B
response	O
element	O
(	O
TR2RE-SV40	B
)	O
for	O
the	O
TR2	B
orphan	O
receptor	O
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	B
hormone	O
receptor	O
superfamily	O
,	O
has	O
been	O
identified	O
in	O
the	O
simian	B
virus	O
40	O
(	O
SV40	O
)	O
+55	O
region	O
(	O
nucleotide	B
numbers	O
368-389	O
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3'	O
).	O

Together,	O
these	O
data	O
suggest	O
the	O
TR2RE-	B
SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	B
response	O
element	O
for	O
the	O
TR2	B
orphan	O
receptor	O
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

We	O
have	O
analyzed	O
CBF	B
beta	O
-MYH11	B
fusion	O
transcripts	O
by	O
RT-PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology.	O

Three	O
of	O
29	O
(10%)	O
AML	O
M4	O
without	O
abnormal	B
eosinophils	O
were	O
CBF	B
beta	O
-MYH11	B
positive,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	B
16	O
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(2	O
not	O
tested).	O

These	O
data	O
show	O
that	O
CBF	B
beta	O
-MYH11	B
fusion	O
transcripts	O
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	B
16	O
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest.	O

In	O
HeLa	B
cells	O
stably	O
transfected	O
with	O
the	O
HIV-1	B
tat	O
gene	O
(	O
HeLa-tat	B
cells	O
),	O
expression	O
of	O
the	O
Tat	B
protein	O
enhanced	O
both	O
TNF	B
-induced	O
activation	O
of	O
NF-kappa	B
B	O
and	O
TNF	B
-mediated	O
cytotoxicity	O
.	O

In	O
both	O
T	B
cells	O
and	O
HeLa	B
cells	O
HIV-1	B
Tat	O
suppressed	O
the	O
expression	O
of	O
Mn-dependent	B
superoxide	O
dismutase	O
(	O
Mn-SOD	B
),	O
a	O
mitochondrial	B
enzyme	O
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B
region	O
of	O
HIV-1	B
Tat	B
is	O
required	O
to	O
suppress	O
Mn-SOD	B
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B
)	O
and	O
the	O
GSH:oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades.	O

Dexamethasone	O
may	O
be	O
superior	O
to	O
prednisone	O
in	O
conventional	O
equi-effective	O
doses.	O

Expression	O
of	O
the	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
latent	B
membrane	O
protein	O
1	O
(	O
LMP-1	B
)	O
oncogene	O
is	O
regulated	O
by	O
the	O
EBV	B
nuclear	O
protein	O
2	O
(	O
EBNA-2	B
)	O
transactivator	O
.	O

The	O
previously	O
characterized	O
factors	O
J	B
kappa	O
,	O
PU.1	B
,	O
and	O
AML1	B
bind	O
to	O
the	O
LMP-1	B
E2RE	O
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B
to	O
LBF7	B
).	O

LBF2	B
was	O
found	O
only	O
in	O
epithelial	B
cell	O
lines	O
,	O
whereas	O
LBF3	B
,	O
LBF5	B
,	O
LBF6	B
,	O
and	O
LBF7	B
were	O
not	O
cell	O
type	O
specific.	O

LBF3	B
,	O
LBF5	B
,	O
LBF6	B
,	O
or	O
LBF7	B
may	O
also	O
be	O
involved,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B
responsiveness	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic-hippocampal	B
glucocorticoid	O
type	O
II	O
receptor	O
(	O
GCII	B
).	O

GCII	B
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders.	O

Maximal	O
induction	O
of	O
TNF	B
alpha	O
mRNA	O
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	B
cells	O
with	O
calcium	O
ionophores	O
alone,	O
via	O
a	O
calcineurin	B
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

Thus,	O
although	O
the	O
kappa	B
3	O
element	O
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp	B
-binding	O
sites	O
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B
promoter	B
element	O
in	O
T	B
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B
.	O

The	O
specificity	O
of	O
MNDA	B
expression	O
for	O
cells	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	B
lines	O
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

As	O
we	O
reported	O
previously,	O
MNDA	B
mRNA	O
level	O
in	O
adherent	O
monocytes	B
is	O
elevated	O
by	O
IFN-alpha	B
;	O
in	O
this	O
study,	O
we	O
further	O
assessed	O
MNDA	B
expression	O
in	O
in	O
vitro	O
monocyte-derived	O
macrophages	B
.	O

The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	B
positive	O
cells	O
between	O
steady-state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	B
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B
expression	O
occurs	O
at	O
more	O
than	O
one	O
point.	O

EBNA-2	B
trans-activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	B
,	O
c-fgr	B
,	O
latent	B
membrane	O
protein	O
1	O
(	O
LMP1	B
)	O
and	O
terminal	B
protein	O
1	O
(	O
TP1	B
).	O

To	O
determine	O
whether	O
EBNA-2	B
also	O
trans-activates	O
the	O
LMP	B
promoter	O
by	O
protein-protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	B
promoter	O
fragments	O
of	O
different	O
sizes.	O

However,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B
promoter	O
-binding	O
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M(r)	O
in	O
EBNA-2	B
-positive	O
cell	O
extracts	O
.	O

Terminal	O
differentiation	O
of	O
B	B
cells	O
to	O
plasma	B
cells	O
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	B
and	O
extinction	O
of	O
MHC	B
class	O
II	O
expression	O
on	O
the	O
cell	O
surface.	O

It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL-6	B
stimulation	O
is	O
prolonged.	O

The	O
human	B
interleukin-3	O
(	O
IL-3	B
)	O
gene	O
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	B
cells	O
.	O

Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	B
5'	O
flanking	O
region	O
of	O
the	O
IL-3	B
gene	O
.	O

Expression	O
of	O
the	O
Runt	B
domain	O
-encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	B
cells	O
during	O
thymic	O
development	O
.	O

Northern	O
(RNA)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	B
cells	O
throughout	O
their	O
development,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B
is	O
a	O
T-cell-specific	B
transcription	O
factor	O
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B
factor	O
binding	O
to	O
DNA.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	B
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	B
factors	O
.	O

Stimulation	O
of	O
human	B
CD4+	O
T-cell	O
clones	O
through	O
the	O
T-cell	B
receptor	O
(	O
TcR	B
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long-lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

In	O
this	O
study,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA.	O

The	O
inducible	B
factors	O
NK-kappa	B
B	O
,	O
beta	B
E2	O
,	O
CD28RC	B
,	O
and	O
AP-1	B
are	O
not	O
expressed	O
in	O
resting	B
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells.	O

A	O
trace	O
element	O
preparation	O
(	O
Beres	O
Drops	O
Plus	O
,	O
BDP	O
)	O
elevates	O
the	O
number	O
of	O
glucocorticoid	B
receptors	O
(	O
gcR	B
)	O
in	O
peripheral	B
lymphocytes	O
isolated	O
both	O
from	O
healthy	O
blood	O
donors	O
and	O
rheumatoid	O
arthritis	O
patients	O
.	O

The	O
DNA	O
and	O
steroid	B
binding	O
domains	O
of	O
the	O
glucocorticoid	B
receptor	O
are	O
not	O
altered	O
in	O
mononuclear	B
cells	O
of	O
treated	O
CLL	O
patients	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA-	O
and	O
the	O
steroid	O
-binding	O
region	O
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation,	O
suggesting	O
that	O
the	O
glucocorticoid	B
receptor	O
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains.	O

An	O
AP1	B
binding	O
site	O
upstream	O
of	O
the	O
kappa	B
immunoglobulin	O
intron	O
enhancer	O
binds	O
inducible	B
factors	O
and	O
contributes	O
to	O
expression.	O

The	O
footprinted	B
binding	O
site	O
is	O
homologous	O
to	O
the	O
consensus	B
AP1	O
motif	O
.	O

The	O
tal-1	B
gene	O
,	O
frequently	O
activated	O
in	O
human	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
),	O
is	O
expressed	O
in	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mast	O
cell	O
lineages	O
during	O
normal	O
hematopoiesis	O
.	O

Five	O
major	O
DNase-I	B
hypersensitive	O
sites	O
(	O
HS	B
)	O
were	O
mapped	O
in	O
the	O
tal-1	B
locus.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	B
elements	O
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	B
promoters	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M-TAT/EPO	O
,	O
M-TAT/GM-CSF	O
,	O
and	O
M-TAT/SCF	O
cells	O
,	O
respectively.	O

Thus,	O
erythroid	O
development	O
of	O
M-TAT	B
cells	O
is	O
promoted	O
by	O
EPO	B
and	O
suppressed	O
by	O
GM-CSF	B
.	O

Peripheral	B
blood	O
resting	B
cells	O
did	O
not	O
express	O
cdc2	B
mRNA	O
,	O
but	O
it	O
was	O
induced	O
in	O
T-lymphocytes	B
when	O
the	O
cells	O
reentered	O
the	O
cell	O
cycle	O
in	O
response	O
to	O
specific	O
mitogens	O
.	O

E2F	B
binding	O
was	O
not	O
observed	O
in	O
both	O
granulocytes	B
and	O
monocytes	B
.	O

These	O
results	O
suggest	O
that	O
cdc2	B
mRNA	O
expression	O
is	O
related	O
to	O
the	O
cell	O
cycling	O
of	O
normal	B
human	O
hematopoietic	B
cells	O
and	O
that	O
E2F	B
plays	O
some	O
roles	O
in	O
the	O
regulation	O
of	O
its	O
expression.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types.	O

As	O
such,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	B
cells	O
of	O
the	O
Jurkat	B
line	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	B
/macrophages	B
are	O
partially	O
understood.	O

First,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	B
.	O

Transcriptional	O
activity	O
of	O
p105	B
is	O
also	O
increased	O
in	O
infected	B
cells	O
and	O
is	O
also	O
mediated	O
by	O
NF-kappa	B
B	O
through	O
a	O
specific	O
kappa	B
B	O
motif	O
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B
receptor	O
.	O

Furthermore,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	B
acid	O
receptor	O
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B
receptor	O
.	O

It	O
has	O
been	O
reported	O
that	O
HIV-1	B
protease	O
may	O
cleave	O
the	O
NF-kappa	B
B	O
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro.	O

The	O
limited	O
activation	O
of	O
NF-kappa	B
B	O
by	O
HIV	B
protease	O
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

Deletion	O
of	O
the	O
NF-kappa	B
B	O
elements	O
of	O
the	O
HIV-1	B
LTR	O
significantly	O
inhibited	O
Tat	B
-mediated	O
transactivation	O
in	O
T-cell	B
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B
line	O
,	O
U937	B
.	O

Selected	O
transfected	B
clones	O
produced	O
low	O
levels	O
of	O
IFN	B
A	O
(	O
IFNA	B
)	O
constitutively,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B
and	O
interleukin-2	B
receptor	O
upon	O
stimulation	O
with	O
phytohemagglutinin	B
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained.	O

Chromosomal	O
localization	O
of	O
two	O
KOX	B
zinc	O
finger	O
genes	O
on	O
chromosome	B
bands	O
7q21-q22	B
.	O

The	O
genes	O
KOX	B
4	O
and	O
KOX	B
9	O
,	O
mapped	O
on	O
chromosome	B
8q24	O
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	B
fragment	O
of	O
450	O
kb	O
.	O

Mononuclear	B
leukocytes	O
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham-exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1,	O
24,	O
and	O
72	O
h.	O

Thus,	O
failure	O
of	O
virus-exposed	B
T	B
cells	O
to	O
produce	O
Fos	B
and	O
Jun	B
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O

The	O
expression	O
levels	O
of	O
human	B
RAR	O
alpha	O
(	O
hRAR	B
alpha,	O
receptor	O
for	O
all-trans	O
RA	O
)	O
and	O
the	O
human	B
retinoid-X	O
receptor	O
alpha	O
(	O
hRXR	B
alpha	O
receptor	O
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all-trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B
and	O
CEM	B
cells	O
,	O
and	O
elevated	O
in	O
U937	B
cells	O
,	O
after	O
PMA	O
stimulation.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	B
in	O
vitro.	O

These	O
redox-regulated	B
enzymes	O
trigger	O
signal	O
cascades	O
for	O
NF	B
kappa	O
B	O
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	B
cell	O
antigen	O
receptor	O
,	O
from	O
CD4	B
and	O
CD8	B
molecules	O
,	O
and	O
from	O
the	O
IL-2	B
receptor	O
beta-chain	O
.	O

T	B
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B
patient	O
T	B
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro.	O

The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	B
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli.	O

We	O
further	O
found	O
that	O
high	O
activities	O
of	O
the	O
transcriptional	B
activators	O
,	O
GATA-1	B
and	O
SP1	B
,	O
are	O
associated	O
with	O
normal	O
adult	O
erythroid	O
differentiation	O
.	O

Cord	O
blood	O
cultures	O
showed	O
an	O
additive	O
combination	O
of	O
"adult"	O
and	O
"fetal"	O
patterns.	O

Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	B
progenitors	O
may	O
occur	O
in	O
adulthood	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B
kappa	O
B	O
alpha	O
protein	O
is	O
simultaneous	O
translocation	O
of	O
NF-kappa	B
B-related	O
transcription	B
factors	O
to	O
nuclei	O
of	O
adhered	O
monocytes.	O

Interestingly,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	B
monocytes	O
,	O
cytoplasmic	O
levels	O
of	O
IL-1	B
beta	O
mRNA	O
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	B
kappa	O
B	O
alpha	O
/MAD-3	O
mRNA	O
did	O
not.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	B
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix-loop-helix	B
and	O
PAS	B
domains	O
.	O

We	O
have	O
reconstituted	O
ligand-dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA-binding	B
form	O
by	O
using	O
the	O
dioxin	B
receptor	O
and	O
its	O
bHLH-PAS	B
partner	O
factor	O
Arnt	B
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate.	O

In	O
line	O
with	O
these	O
observations,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B
receptor	O
with	O
hsp90	B
.	O

Thus,	O
the	O
dioxin	B
receptor	O
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	B
factors	O
by	O
hsp90	B
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	B
kinase	O
(	O
PKC	B
)	O
but	O
have	O
no	O
effect	O
(in	O
comparison	O
to	O
anti-CD3	B
antibodies	O
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	O
.	O

The	O
expression	O
of	O
AP-1	B
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	B
activation	O
.	O

Protein	B
kinase	O
C	O
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B
in	O
activated	B
T	O
cells	O
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF-kappa	B
B	O
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	B
.	O

We	O
expressed	O
these	O
factors	O
in	O
S.	O
cerevisiae	O
and	O
observed	O
greater	O
than	O
5-fold	O
stimulation	O
of	O
a	O
lacZ	B
reporter	O
gene	O
only	O
with	O
Oct-2	B
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	B
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Interleukin-2	B
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B
in	O
human	B
T	O
lymphocytes	B
.	O

In	O
contrast,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL-2	B
ligation	O
,	O
whereas	O
tyrosine	B
-phosphorylated	O
stat1	O
proteins	O
(	O
91	O
and	O
84	O
kDa	O
proteins	O
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon-gamma	B
treatment	O
of	O
HeLa	B
cells	O
.	O

Taken	O
together,	O
we	O
report	O
that	O
IL-2	B
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B
protein	O
in	O
antigen-specific	B
human	O
T	O
cell	O
lines	O
.	O

In	O
resting	B
T	O
cells	O
,	O
many	O
of	O
these	O
NF-kappa	B
B	O
/Rel	O
factors	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin-rich	B
inhibitory	O
proteins	O
,	O
including	O
I	B
kappa	O
B	O
alpha	O
.	O

We	O
further	O
demonstrate	O
that	O
Tax	B
induction	O
of	O
nuclear	O
c-Rel	B
expression	O
is	O
activated	O
by	O
the	O
RelA	B
(	O
p65	B
)	O
subunit	O
of	O
NF-kappa	B
B	O
,	O
which	O
activates	O
transcription	O
of	O
the	O
c-rel	B
gene	O
through	O
an	O
intrinsic	O
kappa	B
B	O
enhancer	O
element	O
.	O

The	O
activation	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation,	O
B	B
lymphocytes	B
containing	O
constitutive	O
nuclear	O
NF-kappa	B
B	O
revealed	O
constitutively	O
phosphorylated	O
p65	B
and	O
I	B
kappa	O
B	O
alpha	O
.	O

In	O
fact,	O
cellular	O
NF-kappa	B
B	O
activity	O
was	O
phosphorylation-dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B
-containing	O
NF-kappa	B
B	O
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro.	O

It	O
is	O
well	O
documented	O
that	O
treatment	O
of	O
serum-grown	B
HL60	B
cells	O
with	O
10(-7)	O
M	O
all-trans	O
retinoic	O
acid	O
(	O
all-trans	O
RA	O
)	O
induces	O
neutrophil	B
differentiation	O
,	O
whereas	O
treatment	O
with	O
10(-7)	O
M	O
1	O
alpha,25	O
dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induces	O
differentiation	O
towards	O
monocytes	B
.	O

As	O
shown	O
for	O
all-trans	O
RA	O
,	O
9-cis	O
RA	O
cooperated	O
with	O
D3	O
to	O
promote	O
monocyte	O
differentiation	O
.	O

The	O
observed	O
cooperativities	O
between	O
either	O
9-cis	O
RA	O
or	O
all-trans	O
RA	O
and	O
D3	O
have	O
important	O
implications	O
for	O
the	O
use	O
of	O
combinations	O
of	O
these	O
agents	O
in	O
differentiation	O
therapy	O
.	O

In	O
this	O
paper	O
we	O
describe	O
results	O
using	O
mRNA	B
differential	O
display	O
reverse	B
transcriptase	O
PCR	O
(	O
DDPCR	O
)	O
to	O
identify	O
and	O
isolate	O
short	O
cDNA	O
sequence	O
tags	O
from	O
thymocyte	B
and	O
prostate	B
cells	O
under	O
various	O
hormone	O
conditions	O
.	O

We	O
also	O
used	O
DDPCR	O
to	O
isolate	O
DESTs	B
from	O
androgen-modulated	O
rat	O
ventral	O
prostate	O
tissue	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
found	O
to	O
correspond	O
to	O
the	O
3'	B
end	O
of	O
prostatic	B
spermine	O
binding	O
protein	O
mRNA	O
,	O
a	O
known	O
androgen-regulated	B
gene	O
.	O

We	O
have	O
shown	O
that,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large,	B
immature	O
cells	O
expresses	O
CD21	B
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor,	O
CD21	B
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling,	O
because	O
neither	O
specific	B
mAb	O
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95-8.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	B
,	O
an	O
early	B
gene	O
that	O
characterizes	O
EBV	B
-infected	O
B	O
cells	O
after	O
disruption	O
of	O
latency.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O

Serum	O
cortisol	O
,	O
osteocalcin	O
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined.	O

Serum	O
osteocalcin	B
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O

Finally,	O
these	O
short-term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side-effects	O
usually	O
observed	O
during	O
long-term	O
treatment	O
with	O
glucocorticoids	O
.	O

However,	O
immediately	O
after	O
TcR/CD3	B
cross-linking	O
(after	O
approximately	O
1	O
h;	O
immediate)	O
binding	O
of	O
p50.p65	B
heterodimers	O
was	O
observed.	O

Interestingly,	O
all	O
those	O
early	O
and	O
late	O
events,	O
but	O
not	O
the	O
immediate	O
ones,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti-	B
tumor	B
necrosis	O
factor	O
alpha	O
(TNF-alpha)	O
monoclonal	O
antibody	O
.	O

TNF-alpha	B
,	O
therefore,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF-kappa	B
B	O
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	B
and	O
c-rel	B
,	O
and	O
new	O
mRNA	B
synthesis	O
for	O
c-rel	B
and	O
p105/p50	B
.	O

We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC-box	B
can	O
functionally	O
compensate	O
for	O
the	O
GM-kappa	B
B/	O
GC-box	B
region	O
,	O
suggesting	O
that	O
the	O
GC-motif	B
can	O
function	O
independently	O
of	O
the	O
GM-kappa	B
B	O
motif	O
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	B
II	O
major	O
histocompatibility	O
complex	O
gene	O
DPA	B
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B
finger	O
proteins	O
that	O
includes	O
a	O
Drosophila	B
developmental	O
control	O
protein	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B
finger	O
motifs	O
of	O
the	O
C2H2	B
type	O
in	O
the	O
C-terminal	B
region	O
,	O
that	O
are	O
Kruppel-like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	B
link	O
sequence	O
connecting	O
them.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	O
and	O
J	O
elements	O
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF-kappa	B
B	O
activation	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	B
-stimulated	O
activation	O
of	O
NF-kappa	B
B	O
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF-kappa	B
B	O
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event(s)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF-kappa	B
B	O
signal	O
transduction	O
pathway	O
.	O

This	O
hybrid	O
clone,	O
designated	O
NR2	B
,	O
was	O
characterized	O
by	O
several	O
methods,	O
including	O
PCR	O
,	O
with	O
eight	O
pairs	O
of	O
oligonucleotides	O
mapped	O
to	O
Chr	B
20	O
:	O
D20S5	B
,	O
D20S41	B
,	O
D20S42	B
,	O
D20S56	B
,	O
D20S57	B
,	O
D20S58	B
,	O
adenosine	B
deaminase	O
(	O
ADA	B
),	O
and	O
Prion	B
protein	O
(	O
PRIP	B
);	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	B
)	O
analyses	O
with	O
four	O
genomic	B
anonymous	O
probes	O
(	O
D20S5	B
,	O
cD3H12	B
,	O
D20S17	B
,	O
D20S18	B
);	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
total	B
human	O
DNA	O
and	O
D20Z1	B
,	O
a	O
sequence	O
specific	O
to	O
the	O
human	B
Chr	B
20	O
centromere	O
,	O
as	O
probes.	O

Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	B
octamer	O
motif	O
of	O
the	O
interleukin	B
2	O
enhancer	O
by	O
AP-1	B
,	O
Oct-2	B
,	O
and	O
retinoic	B
acid	O
receptor	O
.	O

This	O
Oct-2	B
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

Mutations	O
of	O
the	O
genuine	B
octamer-binding	O
site	O
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	B
and	O
Oct-2	B
and	O
the	O
TPA	O
/	O
Ca(2+)	O
-induced	O
transactivation	O
of	O
the	O
OAP	B
/octamer	O
motif	O
.	O

Missense	O
mutation	O
in	O
exon	B
7	O
of	O
the	O
common	B
gamma	O
chain	O
gene	O
causes	O
a	O
moderate	O
form	O
of	O
X-linked	O
combined	O
immunodeficiency	O
.	O

As	O
in	O
XSCID,	O
X-chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	O
and	O
B	O
lymphocytes	O
.	O

Therefore,	O
this	O
point	O
mutation	O
in	O
the	O
gamma	B
c	O
gene	O
leads	O
to	O
a	O
less	O
severe	O
degree	O
of	O
deficiency	O
in	O
cellular	O
and	O
humoral	O
immunity	O
than	O
that	O
seen	O
in	O
XSCID	O
.	O

The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)-induced	O
TF	B
expression	O
was	O
examined	O
in	O
murine	B
peritoneal	O
macrophages	O
and	O
human	B
monocytes	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl-cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	B
mature	O
glycoprotein	O
in	O
LPS	B
-treated	O
cells	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	B
/macrophage	B
activation	O
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV	B
-negative	O
B-cell	O
lines	O
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	B
phenotype	O
.	O

Thapsigargin	O
induces	O
IL-2	B
receptor	O
alpha-chain	O
in	O
human	B
peripheral	O
and	O
Jurkat	B
T	O
cells	O
via	O
a	O
protein	B
kinase	O
C	O
-independent	O
mechanism	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	B
alpha	O
by	O
TG	O
was	O
also	O
observed	O
in	O
human	B
peripheral	O
T	O
cells	O
.	O

In	O
toto,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B
alpha	O
in	O
human	B
T	O
cells	O
through	O
a	O
PKC	B
-independent	O
pathway	O
.	O

We	O
investigated	O
the	O
possible	O
mechanisms	O
of	O
estradiol	O
acting	O
via	O
the	O
polymorphonuclear	B
leukocytes	O
(	O
PMNs	B
),	O
which	O
are	O
important	O
in	O
the	O
immune	O
response	O
.	O

These	O
observations	O
suggest	O
that	O
17	O
beta-	O
estradiol	O
suppressed	O
the	O
chemotaxis	O
of	O
PMNs	B
by	O
a	O
receptor-dependent	O
mechanism	O
.	O

The	O
TCL1	B
locus	O
on	O
chromosome	B
14q32.1	O
is	O
frequently	O
involved	O
in	O
chromosomal	O
translocations	O
and	O
inversions	O
with	O
one	O
of	O
the	O
T-cell	B
receptor	O
loci	O
in	O
human	O
T-cell	O
leukemias	O
and	O
lymphomas	O
.	O

The	O
TCL1	B
gene	O
sequence,	O
which,	O
to	O
our	O
knowledge,	O
shows	O
no	O
sequence	O
homology	O
with	O
other	O
human	B
genes	O
,	O
is	O
preferentially	O
expressed	O
early	O
in	O
T-	O
and	O
B-	O
lymphocyte	O
differentiation.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	B
II	O
(bp	O
-88	O
to	O
-	O
59),	O
which	O
lies	O
10	B
bp	O
upstream	O
from	O
the	O
PU.1	B
-binding	O
site	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B
B	O
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B
enhancer-binding	O
protein	O
2/core-binding	O
factor	O
(	O
PEBP2/CBF	B
)	O
family,	O
which	O
includes	O
the	O
AML1	O
gene	O
product,	O
while	O
Mono	B
A	O
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B
cells	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
activation,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	B
leukemia	O
HL-60	O
cells	O
and	O
thymocytes	B
.	O

However,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B
B	O
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B
hematopoietic	O
cells	O
.	O

PKC-zeta	B
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology,	O
surface	O
antigen	O
expression,	O
and	O
lysosomal	B
enzyme	O
activities	O
and	O
were	O
distinct	O
from	O
parental	B
U937	B
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

A	O
family	O
of	O
serine	B
proteases	O
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	B
cells	O
specifically	O
processes	O
the	O
nuclear	B
factor-kappa	O
B	O
subunit	O
p65	O
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells.	O

Stimulation	O
of	O
plus	B
clones	O
liberated	O
the	O
classical	O
p50-p65	B
complex	O
from	O
cytoplasmic	O
pools,	O
whereas	O
minus	B
clones	O
produced	O
an	O
apparently	O
novel,	O
faster-migrating	B
complex	O
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	B
U937	O
clones	O
,	O
but	O
not	O
in	O
the	O
plus	B
clones	O
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B
G	O
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo-	B
monocytic	B
cells	O
.	O

Southern	O
analysis	O
using	O
a	O
human	B
progesterone	B
receptor	O
(	O
hPR	B
)	O
cDNA	O
probe	O
identified	O
a	O
germline	B
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	B
)	O
defined	O
by	O
two	O
alleles	B
:	O
T1	B
,	O
represented	O
by	O
a	O
2.7	B
kb	O
fragment	O
;	O
and	O
T2	B
,	O
represented	O
by	O
a	O
1.9	B
kb	O
fragment	O
and	O
characterised	O
by	O
an	O
additional	O
TaqI	B
restriction	O
site	O
with	O
respect	O
to	O
T1	B
.	O

Using	O
hPR	B
cDNA	O
region-specific	O
probes	O
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	B
G	O
of	O
the	O
hPR	B
gene	O
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	B
has	O
no	O
intrinsic	O
DNA-binding	O
activity	O
and	O
recognizes	O
the	O
POU	B
domains	O
of	O
Oct-1	B
and	O
Oct-2	B
,	O
but	O
not	O
those	O
of	O
Oct-4	B
and	O
Oct-6	B
.	O

Modulation	O
of	O
transcription	B
factor	O
NF	B
kappa	O
B	O
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

NF	B
kappa	O
B	O
controls	O
many	O
immunologically	B
important	O
genes	O
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

The	O
first	O
early-induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B
mRNA	O
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B
factors	O
,	O
including	O
IL-6	B
.	O

Furthermore,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	B
-induced	O
junB	B
transcription	O
waves	O
.	O

Altogether	O
these	O
data	O
indicate	O
that,	O
in	O
7TD1	B
cells	O
,	O
IL-6	B
controls	O
junB	B
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

Ultrastructurally,	O
the	O
cells	O
had	O
alpha-granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	B
peroxidase	O
activity	O
.	O

Ten-day	O
exposure	O
to	O
Epo	B
induced	O
mature	B
erythroblasts	O
and	O
red	B
cells	O
.	O

This	O
cell	B
line	O
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O

In	O
addition	O
to	O
activation	O
of	O
phospholipase	B
C	O
gamma	O
1	O
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium	O
-independent	O
,	O
CD28	B
-specific	O
pathway	O
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c-jun	B
and	O
junB	B
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	B
family	O
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	B
cells	O
caused	O
by	O
ligation	O
of	O
CD28	B
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

LTR	B
-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	B
reporter	O
constructs	O
that	O
were	O
transiently	O
transfected	O
into	O
cultured	B
cells	O
.	O

Mutagenesis	O
studies,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	B
sequence	O
duplication	O
and	O
the	O
NF	B
kappa	O
B	O
site	O
contained	O
within	O
it.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	B
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

In	O
our	O
studies,	O
cells	O
of	O
the	O
human	B
monocytic	O
line	O
Mono	B
Mac	O
6	O
,	O
cultured	O
in	O
medium	O
containing	O
fetal-calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
),	O
also	O
exhibit	O
such	O
'constitutive'	O
NF-kappa	B
B	O
,	O
as	O
demonstrated	O
by	O
mobility-shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

Using	O
LPS-free	O
and	O
serum-free	O
conditions	O
,	O
constitutive	O
NF-kappa	B
B	O
can	O
be	O
detected	O
in	O
different	O
cell	B
lines	O
of	O
the	O
monocytic	B
lineage	O
(	O
HL60	B
,	O
U937	B
,	O
THP-1	B
,	O
Mono	B
Mac	O
1	O
and	O
Mono	B
Mac	O
6	O
),	O
but	O
not	O
in	O
Molt	B
4	O
T	O
cells	O
or	O
K562	B
stem	O
cells	O
.	O

The	O
constitutive	O
NF-kappa	B
B	O
appears	O
to	O
be	O
functionally	O
active,	O
since	O
a	O
low	O
level	O
of	O
tumour	B
necrosis	O
factor	O
(TNF)	O
transcript	O
is	O
detectable	O
in	O
monocytes	B
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS)	O

BFU-E	B
-derived	O
colonies	O
increase	O
progressively	O
in	O
size,	O
as	O
determined	O
by	O
cell	O
number,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(10-fold	O
expansion)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10.	O

In	O
BFU-E	B
-derived	O
colonies	O
cultured	O
with	O
Steel	B
factor	O
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control.	O

C/EBP	B
beta	O
regulation	O
of	O
the	O
tumor	B
necrosis	O
factor	O
alpha	O
gene	O
.	O

We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	B
alpha	O
is	O
regulated	O
by	O
the	O
transcription	B
factor	O
C/EBP	B
beta	O
(	O
NF-IL6	B
).	O

Calcium/calmodulin-dependent	B
protein	O
kinase	O
II	O
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
-mediated	O
pathways	O
for	O
cytokine	B
gene	O
transcription	O
in	O
human	B
T	O
cells	O
.	O

However,	O
the	O
role	O
of	O
CaM-K	B
II	O
remains	O
unknown.	O

The	O
inhibitory	O
effect	O
of	O
CaM-K	B
II	O
on	O
IL-2	B
promoter	O
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF-AT	O
transactivating	O
pathways	O
.	O

gamma	B
B*CaM-K	O
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B
or	O
stimulation	O
with	O
PMA	O
.	O

Induction	O
of	O
TaxI	B
in	O
a	O
human	B
T-cell	O
line	O
Jurkat	O
carrying	O
the	O
TaxI	B
gene	O
under	O
the	O
metallothionein	B
promoter	O
led	O
to	O
increases	O
in	O
mRNA	B
and	O
surface	O
expression	O
of	O
ICAM-I	B
.	O

ICAM-I	B
mRNA	O
was	O
quite	O
low	O
in	O
MT-I	B
,	O
but	O
no	O
genomic	O
changes	O
were	O
found.	O

Three	O
other	O
ATL	B
cell	O
lines	O
(	O
TL-OmI	B
,	O
H582	B
,	O
HuT102	B
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	B
for	O
the	O
LFA-I	B
beta	O
chain	O
(	O
CD18	B
).	O

Theileria	O
annulata	O
infects	O
bovine	B
leucocytes	O
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic.	O

An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	B
clone	O
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	B
encoding	O
c-Fos	B
,	O
a	O
common	O
component	O
of	O
AP-1	B
and	O
observed	O
that	O
it	O
was	O
indeed	O
up-regulated	O
in	O
infected	B
cells	O
.	O

EBV	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	B
),	O
one	O
of	O
the	O
first	O
genes	O
expressed	O
after	O
EBV	O
infection	O
of	O
B-cells	B
,	O
is	O
a	O
transcriptional	O
activator	O
of	O
viral	B
and	O
cellular	B
genes	O
and	O
is	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
virus	O
.	O

EBNA2	B
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation.	O

These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B-cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen,	O
T-cell	O
signals	O
and	O
growth	B
factors	O
.	O

The	O
synergistic	O
antigen	B
receptor	O
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B
kinase	O
C	O
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester,	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	B
induces	O
both	O
NF-kappa	B
B	O
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein(s)	O
responsible	O
for	O
terminating	O
NF-kappa	B
B	O
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near-perfect	O
direct	B
repeats	O
(	O
DR	B
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	B
insert	O
was	O
proven	O
to	O
be	O
the	O
main	O
transcription-activation	B
element	O
,	O
with	O
enhancer-like	O
characteristics	O
.	O

A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	B
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	B
insert	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	B
protein	O
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O

Epstein-Barr	B
virus	O
SM	O
protein	O
.	O

Computer	O
analysis	O
of	O
the	O
SM	B
protein	O
sequence	O
showed	O
a	O
C	B
terminal	O
section	O
of	O
SM	B
to	O
be	O
related	O
to	O
genome	B
positional	O
homologues	O
of	O
four	O
other	O
herpesviruses	O
and	O
revealed	O
consensus	B
CKII	B
sites	O
near	O
the	O
N	B
termini	O
of	O
the	O
EBV	B
SM	B
protein	O
,	O
the	O
herpes	B
simplex	O
virus	O
(	O
HSV	O
)	O
ICP27	O
protein	O
and	O
the	O
herpesvirus	B
saimiri	O
(	O
HVS	O
)	O
open	O
reading	O
frame	O
57	O
protein	O
.	O

Inducible	O
binding	O
to	O
the	O
c-fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine-containing	B
protein	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	B
complex	O
(	O
Band	B
A	O
)	O
binds	O
to	O
SRE	B
DNA	O
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	B
PBL-T	O
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein-protein	O
interaction	O
.	O

Here	O
we	O
show,	O
by	O
in	O
vivo	O
DNase	B
I	O
footprinting	O
,	O
that	O
the	O
AIR-1	B
locus	O
defect	O
correlates	O
with	O
changes	O
in	O
the	O
DRA	B
promoter	O
occupancy	O
.	O

Thus,	O
the	O
use	O
of	O
DNase	B
I	O
allowed	O
us,	O
for	O
the	O
first	O
time,	O
to	O
correlate	O
the	O
AIR-1	B
locus	O
defect	O
with	O
class	B
II	O
promoter	O
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	B
class	O
II-negative	O
cells	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	B
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	B
-137	O
and	O
-64	O
that	O
binds	O
Elf-1	B
and	O
HMG-I(Y)	B
.	O

Elf-1	B
physically	O
associated	O
with	O
HMG-I	B
and	O
with	O
NF-kappa	B
B	O
p50	B
and	O
c-Rel	B
in	O
vitro,	O
suggesting	O
that	O
protein-protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	B
finger	O
proteins	O
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	B
zinc	O
finger	O
peptide	O
domain	O
was	O
used	O
to	O
isolate	O
63	O
cDNA	B
clones	O
for	O
Kruppel-related	B
zinc	O
finger	O
genes	O
from	O
the	O
human	B
monoblast	O
cell	O
line	O
U-937	O
.	O

In	O
contrast,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Using	O
a	O
modified	O
sperm	B
typing	O
protocol	O
,	O
the	O
mutation	O
frequency	O
of	O
the	O
CAG	B
repeat	O
region	O
at	O
the	O
androgen	B
receptor	O
locus	O
has	O
been	O
measured	O
using	O
a	O
rare	O
semen	O
sample	O
from	O
an	O
individual	O
with	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
).	O

68%	O
of	O
the	O
contractions	O
were	O
also	O
one	O
or	O
two	O
repeats	O
but	O
six	O
(16%)	O
were	O
very	O
large	O
(12-25	O
repeats).	O

Aspirin-like	O
drugs	O
can	O
protect	O
human	B
T	O
lymphocytes	O
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD(P)H:quinone	B
reductase	O
-dependent	O
mechanism	O
.	O

We	O
had	O
previously	O
found	O
that	O
aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
AP-1	B
in	O
human	B
T	O
lymphocytes	B
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose-dependent	O
manner	O
,	O
e.g.,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ	O
-treated	O
dead	O
cells	O
by	O
70%.	O

Correlation	O
of	O
differentiation-inducing	O
activity	O
of	O
retinoids	O
on	O
human	B
leukemia	O
cell	O
lines	O
HL-60	B
and	O
NB4	B
.	O

The	O
human	B
platelet-activating	O
factor	O
receptor	O
(	O
PAFR	B
)	O
gene	O
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	B
(	O
promoter	B
1	O
and	O
promoter	B
2	O
)	O
to	O
generate	O
two	O
transcripts	O
(designated	O
as	O
PAFR	B
transcript	O
1	O
and	O
PAFR	B
transcript	O
2	O
),	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical.	O

One	O
gene,	O
two	O
transcripts	B
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B
La/SS-B	O
from	O
a	O
cDNA	B
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens'	O
syndrome	O
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	B
5'-end	O
is	O
a	O
part	O
of	O
the	O
intron	B
.	O

Cross-linking	O
CD40	B
on	O
B	B
cells	O
rapidly	O
activates	O
nuclear	B
factor-kappa	O
B	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	B
cross-linking	O
link	O
to	O
cellular	O
responses.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross-linking	O
CD40	B
supports	O
NF-kappa	B
B	O
-dependent	O
gene	O
expression	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel	B
/p65	B
heterodimers	O
to	O
a	O
kappa	B
B-like	O
site	O
in	O
the	O
TF	B
promoter	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B
protein	O
,	O
TF	B
mRNA	O
and	O
TF	B
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

1,25-Dihydroxyvitamin	B
D3	O
receptors	O
in	O
peripheral	B
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
.	O

The	O
median	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
all	O
three	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(mean	O
+/-	O
S.D.	O
(range):	O
PHP	O
,	O
1.2	O
+/-	O
1.0	O
(0.2-4)	O
x	O
10(-10)	O
M;	O
SH	O
,	O
0.6	O
+/-	O
0.4	O
(0.2-1.2)	O
x	O
10(-10)	O
M;	O
RT	O
,	O
1.1	O
+/-	O
0.5	O
(0.4-1.9)	O
x	O
10(-10)	O
M;	O
controls	O
,	O
1.0	O
+/-	O
0.6	O
(0.3-2.6)	O
x	O
10(-10)	O
M).	O
However,	O
the	O
maximal	O
binding	O
capacity	O
(	O
Nmax	O
)	O
was	O
significantly	O
enhanced	O
in	O
PHP	O
(3.9	O
+/-	O
1.9	O
(1.3-7.6)	O
fmol/10(7)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(1.1-4.4)	O
fmol/10(7)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0006)	O
and	O
decreased	O
in	O
SH	O
(0.8	O
+/-	O
0.5	O
(0.2-1.6)	O
fmol/10(7)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(1.1-4.4)	O
fmol/10(7)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0001),	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
RT	O
(2.3	O
+/-	O
0.7	O
(1.2-3.3)	O
fmol/10(7)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(1.1-4.4)	O
fmol/10(7)	O
cells	O
in	O
controls	O
).	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	B
45,X/46,X,r(X)	O
karyotype	O
.	O

The	O
two	O
tiny	O
ring	O
X	B
chromosomes	O
studied	O
with	O
an	O
antibody	B
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B
H4	O
marking	O
transcribed	B
chromatin	O
domains	O
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

Stimulation	O
of	O
T-cells	B
by	O
agonistic	O
anti-	B
CD28	B
antibodies	O
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)-	O
or	O
TcR	B
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B
factor	O
NF-kappa	B
B	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	B
factors	O
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T-cell	O
activation	O
.	O

To	O
reconcile	O
these	O
observations,	O
we	O
expressed	O
a	O
hybrid	B
CD8-	O
Nef	B
protein	O
in	O
Jurkat	B
cells	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	B
4	O
expression	O
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region,	O
we	O
found	O
that	O
the	O
3'-most	B
site	O
alone	O
was	O
sufficient	O
for	O
binding	O
GA-binding	B
protein	O
alpha	O
(	O
GABP	B
alpha	O
)/	O
GABP	B
beta	O
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a,	O
a	O
new	B
Ets-1-containing	O
complex	O
"	O
c	B
"	O
appeared.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor.	O

Several	O
antiandrogens	O
show	O
agonistic	O
properties	O
for	O
a	O
mutated	B
androgen	O
receptor	O
(	O
LNCaP	B
cell	O
variant	O
);	O
trypsin	B
digestion	O
of	O
antiandrogen	B
-bound	O
mutated	O
receptor	O
also	O
resulted	O
in	O
a	O
29-kDa	B
fragment	O
.	O

Activation	O
of	O
nuclear	B
factor	O
kappa	O
B	O
in	O
human	B
neuroblastoma	B
cell	O
lines	O
.	O

The	O
TNF	B
alpha	O
-activated	O
NF-kappa	B
B	O
was	O
transcriptionally	O
functional.	O

In	O
other	O
neuroblastoma	B
cell	O
lines	O
,	O
such	O
as	O
SK-N-Be(2)	B
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF-kappa	B
B	O
activation	O
.	O

Furthermore,	O
the	O
results	O
obtained	O
with	O
TNF	B
alpha	O
proved	O
that	O
NF-kappa	B
B	O
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	B
differentiation	O
.	O

To	O
identify	O
ets-related	B
transcriptional	O
regulators	O
expressed	O
in	O
pre-B	B
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	B
or	O
the	O
microB	B
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	B
family	O
.	O

Full-length	O
ERP	B
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself.	O

These	O
data	O
suggest	O
that	O
ERP	B
might	O
play	O
a	O
role	O
in	O
B-cell	B
development	O
and	O
in	O
IgH	B
gene	O
regulation	O
.	O

As	O
a	O
first	O
step	O
towards	O
identifying	O
a	O
human	O
genetic	O
disorder	O
or	O
mouse	O
mutation	O
for	O
which	O
EBF	B
could	O
be	O
a	O
candidate	O
gene,	O
we	O
have	O
chromosomally	O
mapped	O
the	O
corresponding	O
locus	O
in	O
both	O
species.	O

The	O
GM-kappa	B
B	O
sequence	O
is	O
recognized	O
by	O
NF-kappa	B
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

In	O
contrast,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF-kappa	B
B	O
and	O
AP-1	B
significantly	O
augmented	O
transcription	O
from	O
the	O
GM-CSF	B
promoter	O
containing	O
the	O
GM-kappa	B
B/GC-box	O
and	O
the	O
CLE0	B
(	O
AP-1	B
/NF-AT	O
).	O

Nonpituitary	B
human	O
prolactin	O
gene	O
transcription	O
is	O
independent	O
of	O
Pit-1	B
and	O
differentially	O
controlled	O
in	O
lymphocytes	B
and	O
in	O
endometrial	O
stroma	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit-1	B
and	O
of	O
PR	B
as	O
potential	O
transcriptional	B
regulators	O
,	O
since	O
the	O
POU	B
domain	O
protein	O
Pit-1	B
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	B
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	B
gene	O
is	O
activated.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	B
promoter	O
in	O
decidualized	O
endometrial	B
stromal	O
cells	O
actively	O
secreting	O
PRL	B
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non-PRL-secreting	B
endometrial	O
stromal	O
cells	O
.	O

EL-4	B
cells	O
also	O
produce	O
low	O
levels	O
of	O
IL-5	B
when	O
stimulated	O
by	O
PMA	O
alone;	O
however,	O
cAMP	O
greatly	O
augments	O
PMA	O
-dependent	O
IL-5	B
production	O
.	O

One	O
of	O
the	O
nuclear	B
factors	O
(	O
NFs	B
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B
promoter	O
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B
for	O
activated	B
t	O
cell	O
.	O

However,	O
sequence	O
specificity	O
of	O
NF-AT	B
was	O
more	O
similar	O
to	O
that	O
of	O
NF(P)	B
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B
was	O
detected	O
in	O
NF(P)	B
.	O

The	O
POU	B
DNA-binding	O
motif	O
defines	O
a	O
conserved	O
family	O
of	O
eukaryotic	B
transcription	O
factors	O
involved	O
in	O
regulation	O
of	O
gene	O
expression	O
.	O

A	O
fragment	O
of	O
Oct-2	B
containing	O
POUHD	B
and	O
an	O
adjoining	O
linker	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
characterized	O
by	O
three-dimensional	O
nuclear	O
magnetic	O
resonance	O
(	O
3D-NMR	O
)	O
spectroscopy	O
.	O

Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	B
in	O
the	O
absence	O
of	O
POUs	B
.	O

HIV-1	O
expression	O
was	O
activated	O
from	O
J	B
delta	O
K	O
cells	O
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
),	O
sodium	O
butyrate	O
(	O
NaB	O
),	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
),	O
but	O
not	O
tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
),	O
confirming	O
the	O
role	O
of	O
NF-kappa	B
B	O
in	O
mediating	O
TNF-alpha	B
induction	O
of	O
HIV	O
transcription	O
.	O

T	B
lymphocyte	O
activation	O
and	O
interleukin-2	B
(	O
IL-2	B
)	O
production	O
require	O
at	O
least	O
two	O
signals,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B
cell	O
receptor	O
(	O
TCR	B
)	O
and	O
the	O
CD28	B
auxiliary	O
receptor	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B
induction	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
JNK	B
,	O
and	O
a	O
competitive	O
inhibitor	O
of	O
Jun	B
phosphorylation	O
by	O
JNK	B
inhibited	O
IL-2	B
promoter	O
activation	O
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	B
cells	O
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Animals	O
were	O
sacrificed	O
at	O
various	O
times	O
post-dosing	O
until	O
120	O
h,	O
spleen	O
was	O
excised	O
and,	O
after	O
incubation	O
of	O
lymphocytes	B
with	O
PHA	B
,	O
splenocyte	O
blastogenic	O
responses	O
were	O
assessed	O
by	O
measuring	O
cellular	O
incorporation	O
of	O
3H-thymidine	O
.	O

Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O

The	O
promoter	B
of	O
the	O
human	O
major	O
histocompatibility	B
complex	O
class	O
II-associated	O
invariant-chain	O
gene	O
(	O
Ii	B
)	O
contains	O
two	O
NF-kappa	B
B	O
/Rel	O
binding	O
sites	O
located	O
at	O
-109	B
to	O
-118	O
(	O
Ii	B
kappa	O
B-1	O
)	O
and	O
-163	B
to	O
-172	O
(	O
Ii	B
kappa	O
B-2	O
)	O
from	O
the	O
transcription	O
start	O
site.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF-kappa	B
B	O
/Rel	O
family	O
of	O
transcription	B
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA-binding	B
complexes	O
that	O
contain	O
p50	B
,	O
p52	B
,	O
p65	B
,	O
and	O
cRel	B
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B
correlates	O
with	O
negative	O
regulation	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF-kappa	B
B	O
/Rel	O
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF-kappa	B
B	O
/Rel	O
binding	O
sites	O
.	O

METHODS:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein-Barr	O
early	O
region	O
(EBER)	O
RNA-positive	O
].	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4+	B
cell	O
counts	O
(P	O
>	O
0.05)	O
or	O
anti-	O
EBV	O
antibody	O
titres	O
(P	O
>	O
0.05).	O

Effects	O
of	O
prostaglandin	B
E2	O
on	O
Th0-type	B
human	O
T	O
cell	O
clones	O
:	O
modulation	O
of	O
functions	O
of	O
nuclear	B
proteins	O
involved	O
in	O
cytokine	B
production	O
.	O

In	O
contrast,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)/	O
A23187	O
,	O
PGE2	B
enhanced	O
the	O
production	O
of	O
IL-4	B
and	O
IL-5	B
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	B
.	O

Interestingly,	O
PGE2	B
or	O
di-butyryl	O
(Bt2)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF-kappa	B
B	O
(	O
p50	B
/p65	B
)	O
heterodimer	O
to	O
the	O
kappa	B
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti-CD3	B
mAb	O
but	O
not	O
with	O
PMA	O
/A23187	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	B
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF-kappa	B
B	O
but	O
not	O
for	O
NF-AT	B
,	O
AP-1	B
or	O
CLE0	B
binding	O
protein	O
.	O

NF-kappa	B
B	O
(	O
P65	B
or	O
P65/P50	B
heterodimer	O
)	O
bound	O
to	O
the	O
P	B
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	B
sequence	O
when	O
expression	B
plasmids	O
were	O
cotransfected	O
with	O
P	B
sequence	O
-driven	O
reporter	O
plasmids	O
in	O
Jurkat	B
T	O
cells	O
.	O

Unlike	O
NF-AT	B
,	O
NF(P)	B
does	O
not	O
contain	O
AP1	B
as	O
its	O
DNA	B
binding	O
component	O
.	O

The	O
EGR-1	B
promoter	O
contains	O
six	O
CC(A/T)6GG	B
(CArG)	O
motifs	O
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine	O
/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	B
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B
ribosomal	O
protein	O
S6	O
serine	O
/threonine	O
kinases	O
,	O
pp70S6K	B
and	O
pp90rsk	B
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	B
.	O

Since	O
kappa	B
B	O
motifs	O
are	O
present	O
in	O
VCAM-1	B
and	O
intercellular	B
adhesion	O
molecule-1	O
(	O
ICAM-1	B
)	O
promoters	O
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	B
and	O
ICAM-1	B
induction	O
and	O
subsequent	O
monocyte	B
adhesion	O
in	O
TNF-treated	B
human	O
umbilical	O
vein	O
endothelial	B
cells	O
(	O
HUVECs	B
).	O

Although	O
ICAM-1	B
induction	O
was	O
unaffected,	O
inhibitors	O
of	O
NADPH	B
oxidase	O
(	O
apocynin	O
)	O
or	O
cytochrome	B
P-450	O
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B
induction	O
by	O
TNF,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation.	O

Displacement	O
of	O
an	O
E-box-binding	B
repressor	O
by	O
basic	B
helix-loop-helix	O
proteins	O
:	O
implications	O
for	O
B-cell	O
specificity	O
of	O
the	O
immunoglobulin	B
heavy-chain	O
enhancer	O
.	O

By	O
employing	O
a	O
derivative	O
E	B
box	O
that	O
binds	O
ZEB	B
but	O
not	O
E2A	B
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B
is	O
active	O
in	O
B	B
cells	O
and	O
the	O
IgH	B
enhancer	O
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B
proteins	O
.	O

The	O
anti-inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF-kappa	B
B	O
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c-myb	B
gene	O
in	O
erythroid	O
differentiation	O
of	O
K562	B
cell	O
induced	O
by	O
hemin	B
(	O
Hm	B
)	O
and	O
erythropoietin	B
(	O
Epo	B
),	O
we	O
constructed	O
recombinant	B
plasmid	O
that	O
could	O
produce	O
antisense	B
myb	O
RNA	O
after	O
induction	O
with	O
dexamethasone	O
.	O

It	O
is	O
suggested	O
that	O
constitutive	O
expression	O
of	O
c-myb	B
mRNA	O
is	O
necessary	O
for	O
Hm	B
-induced	O
differentiation	O
,	O
and	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
c-myb	B
mRNA	O
induced	O
by	O
antisense	B
myb	O
RNA	O
expression	O
suppresses	O
Hm	B
-induced	O
differentiation	O
.	O

Prenatal	O
immune	O
challenge	O
alters	O
the	O
hypothalamic-pituitary-adrenocortical	O
axis	O
in	O
adult	O
rats	O
.	O

In	O
addition,	O
after	O
novelty	O
stress	O
the	O
HRBC	B
group,	O
but	O
not	O
the	O
LPS	B
group	O
,	O
showed	O
increased	O
ACTH	O
and	O
corticosterone	O
levels	O
.	O

Clinically,	O
it	O
may	O
be	O
postulated	O
that	O
disturbed	O
fetal	O
brain	O
development	O
due	O
to	O
prenatal	O
immune	O
challenge	O
increases	O
the	O
vulnerability	O
to	O
develop	O
mental	O
illness	O
involving	O
inadequate	O
responses	O
to	O
stress	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	B
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

Activation	O
of	O
a	O
novel	O
serine	B
/threonine	O
kinase	O
that	O
phosphorylates	O
c-Fos	B
upon	O
stimulation	O
of	O
T	O
and	O
B	O
lymphocytes	O
via	O
antigen	O
and	O
cytokine	B
receptors	O
.	O

Fos	B
kinase	O
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	O
and	O
CD2	O
receptors	O
in	O
Jurkat	B
and	O
normal	B
human	O
T	O
lymphocytes	O
and	O
in	O
response	O
to	O
IL-6	B
and	O
anti-IgM	B
in	O
the	O
human	B
B	O
cell	B
lines	O
AF10	B
and	O
Ramos	B
,	O
respectively.	O

Fos	B
kinase	O
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M(r)	O
=	O
65,000	O
and	O
isoelectric	O
point	O
=	O
6.1.	O

Lesions	O
resulting	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infection	O
are	O
characterized	O
by	O
infiltration	O
of	O
CD4+	B
lymphocytes	O
.	O

The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B
antigens	O
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O

Human	B
T-cell	O
clones	O
reactive	O
with	O
gC	B
and	O
VP16	B
are	O
reported	O
here	O
for	O
the	O
first	O
time.	O

The	O
RAR	B
alpha	O
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B
product	O
of	O
PML-RAR	B
alpha	O
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished.	O

Cytokines	B
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette-Guerin	O
(BCG)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	B
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins.	O

Both	O
LAM	B
-and	O
LPS	B
-inducible	O
IL-6	B
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	B
fragment	O
,	O
positions	O
-158	B
to	O
-49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B
acetyltransferase	O
assay	O
.	O

We	O
conclude	O
that	O
the	O
NF-IL6	O
and	O
NF-kappa	O
B	O
sites	O
mediate	O
IL-6	B
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up-regulation	O
of	O
CD14	B
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B
induction	O
.	O

A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	B
site	O
not	O
only	O
eliminates	O
Sp1	B
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B
expression	O
.	O

The	O
t(17;19)	B
translocation	O
in	O
acute	O
lymphoblastic	O
leukemias	O
results	O
in	O
creation	O
of	O
E2A-	B
hepatic	B
leukemia	O
factor	O
(	O
HLF	B
)	O
chimeric	B
proteins	O
that	O
contain	O
the	O
DNA-binding	B
and	O
protein	O
dimerization	O
domains	O
of	O
the	O
basic	B
leucine	O
zipper	O
(bZIP)	O
protein	O
HLF	B
fused	O
to	O
a	O
portion	O
of	O
E2A	B
proteins	O
with	O
transcriptional	O
activation	O
properties	O
.	O

These	O
differences	O
were	O
directly	O
attributable	O
to	O
loss	O
of	O
an	O
HLF	B
ancillary	O
DNA-binding	O
domain	O
in	O
all	O
E2A-	B
HLF	B
chimeras	O
and	O
were	O
further	O
exacerbated	O
by	O
a	O
zipper	O
mutation	O
in	O
one	O
isolate.	O

ZAP-70	B
tyrosine	O
kinase	O
,	O
CD45	B
,	O
and	O
T	B
cell	O
receptor	O
involvement	O
in	O
UV-	O
and	O
H2O2-	O
induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Normal	O
T	B
lymphocytes	O
whose	O
surface	O
expression	O
of	O
CD3	B
was	O
depleted	O
showed	O
impaired	O
UV-induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

ZAP-70	B
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	B
and	O
CD45	B
,	O
whereas	O
only	O
CD3	B
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	B
myeloid	O
cell	O
lines	O
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	B
factor	O
gene	O
expression	O
in	O
monocytic	B
cells	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B
heterodimers	O
to	O
a	O
kappa	B
B-like	O
site	O
.	O

This	O
nuclear	B
complex	O
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B
gene	O
.	O

Antibodies	O
against	O
the	O
NF-kappa	B
B	O
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	B
and	O
p65	B
and	O
the	O
absence	O
of	O
p50	B
in	O
the	O
TF	B
complex	O
and	O
further	O
showed	O
that	O
c-Rel/	B
p65	B
heterodimers	O
selectively	O
bound	O
to	O
the	O
TF	B
kappa	O
B-like	O
site	O
.	O

Tenascin	B
(	O
TN	B
)	O
is	O
an	O
extracellular	B
matrix	O
protein	O
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	B
as	O
a	O
natural	O
antagonist	O
to	O
FN	B
action,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	B
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence.	O

Stimulation	O
of	O
T	B
cells	O
with	O
tumor	O
necrosis	O
factor,	O
interleukin-1,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene.	O

The	O
transcription	B
factor	O
AP-1	B
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	B
factors	O
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol-13	O
acetate	O
(	O
TPA	O
).	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(0.2	O
mM)	O
the	O
expression	O
of	O
c-fos	B
mRNA	O
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(0.5	O
microM)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha-lipoic	O
acid	O
(0.2	O
microM),	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min.	O

To	O
evaluate	O
this	O
possibility,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	B
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	B
proliferation	O
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies.	O

We	O
recently	O
confirmed	O
the	O
existence	O
of	O
gelatinase	O
granules	O
as	O
a	O
subpopulation	O
of	O
peroxidase-negative	O
granules	O
by	O
double-labeling	O
immunogold	O
electron	O
microscopy	O
on	O
intact	O
cells	O
and	O
by	O
subcellular	O
fractionation	O
.	O

We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase-negative	O
granules	O
containing	O
gelatinase	B
but	O
lacking	O
lactoferrin	B
,	O
contain	O
50%	O
of	O
total	O
cell	O
gelatinase	B
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O

Regulation	O
of	O
interleukin-2	B
receptor	O
alpha	O
chain	O
expression	O
and	O
nuclear	B
factor.kappa	O
B	O
activation	O
by	O
protein	B
kinase	O
C	O
in	O
T	B
lymphocytes	O
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	B
and	O
c-Rel	B
NF.kappa	B
B	O
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus,	O
where	O
they	O
bound	O
the	O
kappa	B
B	O
sequence	O
of	O
the	O
IL-2R	B
alpha	O
promoter	O
either	O
as	O
p50.p65	B
or	O
as	O
p50.	B
c-Rel	B
heterodimers.	O

Those	O
results	O
indicate	O
that,	O
in	O
resting	B
T	O
cells	O
,	O
PKC	B
activation	O
has	O
only	O
a	O
triggering	O
role,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B
alpha	O
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B
alpha	O
chain	O
or	O
NF.kappa	B
B	O
activation	O
.	O

Induction	O
of	O
HIV-1	O
-	O
LTR	B
-driven	O
transcription	O
in	O
THP-1	B
cells	O
by	O
superantigens	B
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B
factor-kappa	O
B	O
DNA-binding	O
activity	O
.	O

Mitogen	O
activation	O
of	O
human	B
peripheral	O
T	B
lymphocytes	O
induces	O
the	O
formation	O
of	O
new	O
cyclic	B
AMP	O
response	O
element-binding	O
protein	O
nuclear	O
complexes	O
.	O

Four	O
complexes	O
are	O
identified	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
two	O
of	O
which	O
are	O
induced	O
by	O
mitogen	B
activation	O
.	O

Mitogen	O
induction	O
of	O
the	O
electrophoretic	B
mobility	O
shift	O
assay	O
complexes	O
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti-atherosclerotic	O
agents	O
;	O
however,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood.	O

The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1	B
-induced	O
response	O
was	O
45	O
microM.	O

Activation	O
of	O
the	O
transcription	B
factor	O
NF-kappa	B
B	O
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E-selectin	B
expression	O
in	O
EC	B
.	O

Central	B
nervous	O
system	O
-derived	O
cells	O
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	B
-independent	O
transactivation	O
by	O
Tat	B
.	O

Tat	B
transactivation	O
mediated	O
by	O
the	O
kappa	B
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B
.	O

Moreover,	O
TAR	B
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor-dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B-binding	O
activity	O
.	O

We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	B
lymphocytes	O
both	O
IL-4	B
and	O
IL-13	B
activate	O
the	O
same	O
recently	O
identified	O
transcription	B
factor	O
NF-IL4	B
which	O
binds	O
to	O
the	O
specific	B
responsive	O
element	O
IL-4RE	O
.	O

Encephalomyocarditis	O
virus	O
internal	O
ribosomal	O
entry	O
site	O
RNA-protein	O
interactions	O
.	O

Internal	O
ribosome	O
binding	O
likely	O
requires	O
the	O
interaction	O
of	O
trans-acting	B
factors	O
that	O
recognize	O
both	O
the	O
mRNA	B
and	O
the	O
ribosomal	B
complex	O
.	O

On	O
the	O
basis	O
of	O
cross-linking	O
results	O
with	O
21	O
different	O
EMCV	B
IRES	B
fragments	O
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	B
binding	O
sites	O
for	O
p52	B
,	O
p57	B
,	O
p70	B
,	O
and	O
p100	B
are	O
proposed.	O

Retinoid-like	B
receptors	O
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B
with	O
other	O
nuclear	B
hormone	O
receptors	O
.	O

The	O
critical	O
region	O
of	O
THR	B
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B
box	O
of	O
the	O
DNA	B
binding	O
domain	O
.	O

In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP-1	B
myeloid	O
leukemia	O
cell	O
line	O
acquire	O
macrophage-like	O
characteristics	O
after	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
).	O

Their	O
effects	O
on	O
the	O
src-family	B
tyrosine	O
kinase	O
genes	O
were	O
different:	O
hck	B
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	O
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O

An	O
active	O
v-abl	B
protein	O
tyrosine	O
kinase	O
blocks	O
immunoglobulin	B
light-chain	O
gene	O
rearrangement	O
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v-abl	B
protein	O
tyrosine	O
kinase	O
triggers	O
high-frequency	O
rearrangement	O
of	O
kappa	O
and	O
lambda	O
light-chain	O
genes	O
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	B
protein	O
specifically	O
interferes	O
with	O
light-chain	B
gene	O
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	B
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	B
gene	O
expression	O
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B
B-binding-proteins	O
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	B
,	O
IL-3	B
,	O
M-CSF	B
receptor	O
(	O
C-FMS	B
),	O
early	B
growth	O
response	O
gene-1	O
(	O
EGR-1	B
)	O
and	O
M-CSF	B
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing,	O
in	O
8	O
cases,	O
constitutive	B
DNA	O
from	O
skin	B
fibroblasts	O
with	O
leukemic	B
DNA	O
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied.	O

The	O
HB9	B
gene	O
is	O
composed	O
of	O
3	O
exons	B
spread	O
over	O
6	O
kilobases	O
of	O
DNA.	O

Northern	O
blot	O
analysis	O
of	O
poly(A)	B
RNA	O
purified	O
from	O
the	O
human	B
B	O
cell	O
line	O
RPMI	O
8226	O
and	O
from	O
activated	B
T	O
cells	O
revealed	O
a	O
major	B
mRNA	O
transcript	O
of	O
2.2	O
kilobases	O
.	O

In	O
addition,	O
transcripts	O
were	O
detected	O
in	O
RNA	O
prepared	O
from	O
tonsil	B
B	O
cells	O
and	O
in	O
situ	O
hybridization	O
studies	O
localized	O
them	O
in	O
the	O
germinal	O
center	O
region	O
of	O
adult	O
tonsil	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
Tat	O
on	O
interleukin-2	B
(	O
IL-2	B
)	O
expression	O
,	O
we	O
used	O
IL-2	B
promoter	O
-chloramphenicol	B
acetyltransferase	O
constructs	O
and	O
IL-2	B
-secreting	O
Jurkat	B
T	O
cells	O
as	O
a	O
model	O
system.	O

The	O
NF-kappa	B
B	O
site	O
at	O
positions	O
-206	B
to	O
-195	O
of	O
the	O
IL-2	B
promoter	O
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B
effect	O
.	O

Activation	O
of	O
nuclear	B
factor	O
kappa	O
B	O
in	O
human	B
lymphoblastoid	O
cells	O
by	O
low-dose	O
ionizing	O
radiation	O
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high.	O

The	O
expression	O
of	O
the	O
p50	O
and	O
p65	O
NF-kappa	O
B	O
subunits	O
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

One	O
63-kDa	B
isoform	O
,	O
termed	O
I	B
kappa	O
B	O
gamma-1	O
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C-terminal	O
to	O
ankyrin	B
repeat	O
7	O
,	O
has	O
a	O
novel	O
35-amino	B
acid	O
C	O
terminus	O
encoded	O
by	O
an	O
alternative	B
reading	O
frame	O
of	O
the	O
p105	B
gene	O
.	O

While	O
p70	B
I	B
kappa	O
B	O
gamma	O
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c-Rel-	O
mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	B
kappa	O
B	O
gamma-1	O
and	O
I	B
kappa	O
B	O
gamma-2	O
are	O
specific	O
for	O
p50	B
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit.	O

To	O
understand	O
GATA3	B
gene	O
regulation	O
,	O
we	O
cloned	O
the	O
human	B
gene	O
and	O
the	O
5'	B
end	O
of	O
the	O
mouse	B
GATA3	B
gene	O
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	B
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	B
of	O
housekeeping	B
genes	O
.	O

Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	B
unit	O
spans	O
approximately	O
35	O
kilobases	O
.	O

LBR	B
's	O
nucleoplasmic	B
domain	O
is	O
encoded	O
by	O
exons	B
1-4	O
,	O
and	O
its	O
hydrophobic	B
domain	O
,	O
with	O
eight	O
putative	O
transmembrane	B
segments	O
,	O
is	O
encoded	O
by	O
exons	B
5-13	O
.	O

CD38	B
is	O
a	O
leukocyte	B
differentiation	O
antigen	O
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	O
and	O
B-	O
lymphocytes	O
.	O

Here	O
we	O
report	O
that	O
ATRA	O
-induced	O
expression	O
of	O
CD38	B
antigen	O
in	O
myeloid	B
cells	O
is	O
mediated	O
through	O
retinoic	B
acid-alpha	O
receptor	O
(	O
RAR	B
alpha	O
).	O

Induction	O
of	O
CD38	B
in	O
acute	O
promyelocytic	O
and	O
acute	O
myeloblastic	O
leukemia	O
cells	O
was	O
independent	O
of	O
ATRA	O
-induced	O
cytodifferentiation	O
.	O

Some	O
antioxidants	O
inhibit,	O
in	O
a	O
co-ordinate	O
fashion,	O
the	O
production	O
of	O
tumor	B
necrosis	O
factor-alpha	O
,	O
IL-beta	B
,	O
and	O
IL-6	B
by	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha-tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	B
factors	O
NF-kappa	B
B	O
and	O
AP-1	B
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	B
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

An	O
interleukin-4-induced	B
transcription	O
factor	O
:	O
IL-4	B
Stat	O
.	O

IL-4	B
may	O
mediate	O
its	O
biological	O
effects,	O
at	O
least	O
in	O
part,	O
by	O
activating	O
a	O
tyrosine-phosphorylated	B
DNA	O
binding	O
protein	O
.	O

Such	O
observations	O
indicate	O
that	O
IL-4	B
Stat	O
has	O
the	O
same	O
functional	B
domain	O
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Because	O
there	O
is	O
the	O
theoretical	O
possibility	O
of	O
an	O
E1a-	O
replication-deficient	O
vector	O
replicating	O
as	O
a	O
result	O
of	O
recombination	O
or	O
complementation	O
with	O
Ad	B
2/5	O
E1a	O
sequences	O
present	O
in	O
the	O
target	O
cell,	O
this	O
study	O
is	O
directed	O
toward	O
evaluating	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
for	O
the	O
presence	O
of	O
E1a	O
sequences.	O

These	O
results	O
demonstrate	O
that	O
there	O
are	O
detectable	O
Ad	B
2/5	O
E1a	B
sequences	O
in	O
the	O
respiratory	O
epithelium	O
of	O
a	O
small	O
percentage	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
.	O

Pathological	O
evaluation	O
revealed	O
a	O
high-grade	O
vulvar	O
leiomyosarcoma	O
.	O

Macrophages	B
and	O
T	O
and	O
B	O
lymphocytes	O
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O

LIF	B
induced	O
a	O
dose-dependent	O
increase	O
in	O
p24	B
antigen	O
production	O
in	O
the	O
chronically	B
infected	O
promonocytic	O
cell	O
line	O
U1	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h.	O

Induction	O
of	O
NF-kB	B
and	O
HIV	O
replication	O
by	O
cytokines	B
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

L227	B
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B
mRNA	O
,	O
whereas	O
2.06	B
plus	O
GAM	B
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]i	O
from	O
both	O
the	O
intracellular	O
and,	O
in	O
particular,	O
the	O
extracellular	O
pools	O
.	O

These	O
findings	O
demonstrate	O
that	O
cross-linking	O
of	O
MHC	B
class	O
II	O
molecules	O
transduced	O
the	O
negative	O
signals	O
through	O
intracellular	O
mechanisms	O
different	O
from	O
those	O
present	O
in	O
the	O
cross-linking	O
of	O
surface	O
IgM	B
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	B
mRNA	O
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	B
induced	O
VDR	B
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha,25-(OH)2D3	O
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	B
B	O
lymphocytes	O
can	O
express	O
VDR	B
mRNA	O
and	O
protein	B
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D	O
-dependent	O
gene	O
regulation	O
.	O

Several	O
cis-acting	B
regulatory	O
sites	O
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	B
gene	O
after	O
stimulation.	O

Finally,	O
the	O
AP-1	O
(-186	O
to	O
-176)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-206	B
to	O
-195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	B
cells	O
.	O

CD14	B
is	O
a	O
membrane	B
glycoprotein	O
expressed	O
specifically	O
on	O
monocytes	B
and	O
macrophages	B
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	B
differentiation	O
.	O

A	O
DNA	B
fragment	O
containing	O
128	B
bp	O
of	O
upstream	O
sequence	O
had	O
strong,	O
monocyte-specific	O
promoter	O
activity	O
in	O
the	O
CD14	B
positive	O
monocytic	O
cell	O
line	O
Mono	B
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	B
cell	O
lines	O
HeLa	B
and	O
REX	B
.	O

CD14	B
Sp1	B
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105-kDa	B
Sp1	B
species	O
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	B
than	O
non-monocytic	B
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	B
,	O
such	O
as	O
phosphorylation,	O
may	O
explain	O
how	O
the	O
Sp1	B
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	B
promoters	O
,	O
the	O
AP-1	B
and	O
kappa	B
B-like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

Furthermore,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-induced	O
activation	O
through	O
authentic	O
kappa	B
B	O
site	O
of	O
immunoglobulin	B
(Ig)	O
gene	O
,	O
to	O
which	O
NF-kappa	B
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	B
kappa	O
B-like	O
site	O
and	O
Ig	O
kappa	B
B	O
site	O
are	O
FK506	O
-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B
factors	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[3H]testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
androgen	B
receptors	O
in	O
peripheral	B
mononuclear	O
leukocytes	O
differ	O
from	O
those	O
in	O
genital	B
skin	O
fibroblasts	O
.	O

The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed.	O

Anti-	B
CD28	B
-stimulated	O
T	O
cells	O
produced	O
significant	O
amounts	O
of	O
IL-8	B
;	O
additionally,	O
costimulation	O
with	O
anti-CD3	B
and	O
anti-	B
CD28	B
Abs	O
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	B
secretion	O
.	O

MHC	B
class	O
II	O
signaling	O
in	O
B-cell	B
activation	O
[see	O
comments]	O

In	O
this	O
review,	O
Paul	O
Scholl	O
and	O
Raif	O
Geha	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
mechanisms	O
of	O
MHC	B
class	O
II	O
signaling	O
and	O
analyse	O
their	O
role	O
in	O
human	O
B-cell	B
activation	O
.	O

Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density;	O
thus,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O

RESULTS.	O

Arrested	O
development	O
:	O
understanding	O
v-abl	B
.	O

These	O
observations	O
suggest	O
that	O
v-abl	B
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	B
cells	O
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Type	B
I	O
corticosteroid	B
receptors	O
are	O
down	O
regulated	O
by	O
excess	O
of	O
mineralocorticoids	O
(primary	O
and	O
secondary	O
hyperaldosteronism	O
,	O
pseudohyperaldosteronism	O
)	O
and	O
of	O
glucocorticoids	O
(	O
Cushing's	O
syndrome	O
).	O
Type	B
II	O
corticosteroid	B
receptors	O
are	O
not	O
reduced	O
by	O
excess	O
of	O
endogenous	O
corticosteroids	O
(	O
Cushing's	O
syndrome	O
).	O

After	O
dexamethasone	O
suppression	O
(1	O
mg	O
at	O
11	O
p.m.)	O
Type	B
I	O
receptors	O
always	O
decrease	O
in	O
controls	O
while	O
the	O
response	O
of	O
Type	B
II	O
is	O
not	O
homogeneous.	O

A	O
basis	O
for	O
differentiation	O
therapy	O
of	O
leukemias	O
is	O
provided	O
by	O
knowledge	O
of	O
agents	O
which	O
induce	O
specific	O
lineage	O
maturation.	O

Cells	O
treated	O
with	O
5	O
nM	O
D3	O
showed	O
little	O
response,	O
but	O
differentiated	O
maximally	O
with	O
5	O
nM	O
D3	O
and	O
10	O
nM	O
RA	O
.	O

Priming	O
with	O
10	O
nM	O
RA	O
,	O
or	O
subsequent	O
treatment	O
with	O
D3	O
(5	O
nM),	O
did	O
not	O
alter	O
expression	O
of	O
mRNAs	B
encoding	O
receptors	B
for	O
D3	O
(	O
VDR	B
),	O
RA	O
(	O
RAR	B
alpha	O
)	O
or	O
9-CIS	O
RA	O
(	O
RXR	O
alpha	O
,	O
beta	O
,	O
gamma	O
).	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	B
receptors	O
(	O
RARs	B
).	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B
alpha	O
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B
RAR	B
alpha	O
(	O
hRAR	B
alpha	O
)	O
into	O
murine	B
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	B
resistant	O
marker	O
(	O
Neo(r)	B
)	O
cultured	O
on	O
the	O
stroma	B
cell	O
line	O
(	O
PA6-neo	B
),	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	B
cells	O
.	O

RAR	B
alpha	O
infected	B
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	B
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	B
colony	O
.	O

Because	O
leukocyte-mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	B
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

IL-8	B
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	B
ECs	B
for	O
the	O
NF-kB	O
site.	O

Taken	O
together,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Furthermore,	O
hirudin	O
and	O
anti-thrombin	B
III	O
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]i	O
rise	O
in	O
Jurkat	B
T	O
cells	O
.	O

Thrombin	B
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B
kinase	O
C	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	B
T	O
cells	O
by	O
a	O
combination	O
of	O
phytohemagglutinin	B
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B
receptor	O
mRNA	O
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B
response	O
.	O

Senescent	B
human	O
T	O
lymphocyte	O
cultures	O
are	O
unable	O
to	O
undergo	O
proliferation,	O
but	O
show	O
no	O
difference	O
from	O
early	B
passage	O
cells	O
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

This	O
suggests	O
that	O
for	O
senescent	B
T	O
cells	O
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	B
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	B
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells.	O

We	O
have	O
detected	O
activatable	O
PLD	B
in	O
Jurkat	B
cells	O
,	O
and	O
we	O
have	O
found	O
that	O
addition	O
of	O
phosphatidic	O
acid	O
(	O
PA	O
),	O
the	O
physiologic	O
product	O
of	O
PLD	B
action	O
on	O
phospholipids	O
,	O
is	O
rapidly	O
incorporated	O
into	O
Jurkat	B
cells	O
and	O
leads	O
to	O
activation	O
of	O
transcription	B
factor	O
AP-1	B
.	O

Furthermore,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B
pathway,	O
blocked	O
the	O
anti-CD3-stimulated	O
AP-1	B
enhancer	O
activity	O
.	O

These	O
data	O
indicate	O
that	O
PLD	B
stimulation	O
can	O
activate	O
the	O
transcription	B
factor	O
AP-1	B
in	O
T	B
lymphocytes	O
,	O
and	O
suggest	O
that	O
the	O
induction	O
of	O
AP-1	B
enhancer	O
factor	O
activity	O
by	O
PA	O
is	O
mediated	O
via	O
PKC	B
stimulation	O
,	O
either	O
through	O
a	O
direct	O
activating	O
effect	O
of	O
PA	O
or	O
through	O
PA	O
-derived	O
diacylglycerol	O
formation	O
.	O

However,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	B
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2	B
+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B
.	O

In	O
the	O
second	O
approach,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	B
B	O
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B
signal	O
transduction	O
,	O
other	O
cell-specific	B
factors	O
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B
protein	O
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3	B
-mediated	O
stimulation	O
in	O
peripheral	B
T	O
cells	O
,	O
we	O
used	O
two	O
anti-CD3	B
mAbs	O
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	B
T	O
cells	O
:	O
OKT3	B
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	B
cells	O
without	O
a	O
second	O
signal,	O
and	O
64.1	B
,	O
which	O
stimulates	O
T	B
cell	O
proliferation	O
on	O
its	O
own.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	B
B	O
components	O
(	O
c-Rel	B
,	O
p65	B
(	O
RelA	B
),	O
and	O
p50	B
(	O
NF-kappa	B
B1	O
))	O
and	O
NF-kappa	B
B	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus.	O

HLA-DR-	O
,	O
CD33+	O
,	O
CD56+	O
,	O
CD16-	O
myeloid/natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French-American-British	O
acute	O
myeloid	O
leukemia-M3	O
[see	O
comments]	O

Although	O
two	O
cases	O
expressed	O
CD4	B
,	O
no	O
case	O
expressed	O
CD2	B
,	O
CD3	B
,	O
or	O
CD8	B
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T-cell	B
receptor	O
(	O
TCR	O
beta	O
,	O
gamma	O
,	O
delta	O
).	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell-mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33+,	O
CD56+,	O
CD16	B
-acute	O
leukemias	O
and	O
normal	B
CD56+,	O
CD16-	O
NK	O
precursor	O
cells	O
.	O

IL-4	B
down-regulates	O
IL-2	B
-,	O
IL-3	B
-,	O
and	O
GM-CSF	B
-induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes.	O

IL-4	B
also	O
suppressed	O
the	O
IL-2	B
-induced	O
IL-6	B
mRNA	O
expression	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

The	O
induced	O
expression	O
of	O
IL-1	O
beta	O
and	O
TNF	O
alpha	O
mRNA	O
in	O
the	O
monocytic	O
THP-1	B
cell	O
line	O
increased	O
as	O
quickly	O
as	O
in	O
primary	B
cells	O
.	O

Although	O
these	O
data	O
suggest	O
AP-1	B
regulated	O
cytokine	B
mRNA	O
expression,	O
results	O
from	O
PBMo	B
are	O
not	O
in	O
accordance	O
with	O
this	O
notion.	O

These	O
differences	O
may	O
represent	O
different	O
regulatory	O
pathways	O
of	O
the	O
two	O
cell	O
systems.	O

Fast	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
Na+/H(+)-exchanger	B
,	O
inositoltrisphosphate	O
generation	O
and	O
corresponding	O
specific	O
binding	O
to	O
plasma	O
membranes	O
at	O
Kd-values	O
of	O
approximately	O
0.1	O
nM	O
have	O
been	O
found	O
in	O
human	B
mononuclear	O
leukocytes	O
and	O
vascular	B
smooth	O
muscle	O
cells	O
.	O

Solubilization	O
of	O
the	O
receptor	B
protein	O
from	O
membranes	O
by	O
high	O
salt	O
concentrations	O
(1	O
M	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
)	O
was	O
not	O
achieved.	O

These	O
findings	O
and	O
other	O
related	O
results	O
are	O
reviewed	O
here.	O

A	O
500-bp	B
fragment	O
encompassing	O
this	O
hypersensitive	B
site	O
(	O
nt	B
4481	O
to	O
4982	O
)	O
exhibited	O
transcription-enhancing	O
activity	O
(two-	O
to	O
threefold)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV-1	B
promoter	O
after	O
transient	O
transfection	O
in	O
U937	B
and	O
CEM	B
cells	O
.	O

Factors	O
binding	O
to	O
site	B
C	O
(	O
nt	B
4681	O
to	O
4701	O
)	O
had	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	B
B	O
,	O
except	O
for	O
PU.1/Spi-1	B
.	O

Expression	O
of	O
v-src	B
in	O
T	B
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B
B	O
.	O

We	O
now	O
demonstrate	O
that	O
v-src	B
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B
B	O
binding	O
complex	O
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	B
B	O
sites	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	B
LTR	O
by	O
v-src	B
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal,	O
rather	O
than	O
the	O
distal,	O
kappa	B
B	O
element	O
.	O

Co-infection	O
of	O
T	B
cells	O
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	B
promoter	O
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects.	O

When	O
cotransfected	O
with	O
the	O
HIV	B
LTR	O
CAT	O
into	O
CV-1	B
cells	O
,	O
both	O
the	O
pCD41	B
and	O
pGD41	B
clones	O
trans-activated	O
the	O
HIV	B
LTR	O
.	O

By	O
using	O
HIV	B
LTR	O
deletion	O
mutants	O
,	O
the	O
NF-kappa	B
B	O
binding	B
sites	O
were	O
found	O
to	O
be	O
critical	O
for	O
response	O
to	O
the	O
pCD41	B
trans-activation	O
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B
,	O
which	O
has	O
no	O
transmembrane	B
domain	O
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/	B
CD14	B
cells	O
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	B
B	O
activation	O
to	O
the	O
CD14	B
receptor	O
system	O
.	O

Furthermore,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF-kappa	B
B	O
in	O
CHO/CD14	B
or	O
RAW	B
264.7	O
cells	O
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS	O
-induced	O
TK	O
activity	O
in	O
RAW	B
264.7	O
cells	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B
molecule	O
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B
abrogates	O
its	O
activity.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B
receptor	O
on	O
peripheral	B
blood	O
lymphocytes	O
during	O
pregnancy	O
[see	O
comments]	O

The	O
ZR-75-1	B
cell	O
line	O
showed	O
an	O
expression	O
of	O
642	O
fmol/mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol/mg.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	B
factor	O
kappa	O
B	O
with	O
predominance	O
of	O
p50	B
homodimers.	O

The	O
CD14	B
LPS	O
receptor	O
is,	O
however,	O
up-regulated	O
(not	O
down-regulated)	O
in	O
tolerant	B
cells	O
,	O
and	O
LPS	O
can,	O
in	O
fact,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	B
cells	O
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	B
factor	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
).	O

Similar	O
to	O
Mono	B
Mac	O
6	O
cells	O
,	O
primary	B
blood	O
monocytes	O
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	B
after	O
LPS	O
stimulation	O
.	O

Oct2-isoform	B
expression	O
in	O
splenic	B
B	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
lipopolysaccharide	O
plus	O
phorbol-di-butyrate	O
was	O
analysed	O
by	O
cDNA	O
cloning	O
.	O

A	O
new	O
exon	B
containing	O
a	O
highly	O
basic	O
region	O
(4c)	O
was	O
characterized,	O
between	B
exons	O
4	O
and	O
5	O
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	B
factor	O
GATA-1	B
in	O
differentiating	B
erythroid	O
cells	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	B
gene	O
in	O
embryonic	B
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Nuclei	O
from	O
GATA-1	B
-mutant	O
embryonic	B
stem	O
cells	O
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	B
genes	O
in	O
erythroid	B
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	B
is	O
not	O
required	O
for	O
globin	B
gene	O
activation	O
following	O
cell	O
fusion	O
.	O

These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B
expression	O
in	O
Jurkat	B
cells	O
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	B
activation	O
in	O
Nef	B
+	O
Jurkat	B
cells	O
.	O

Tat-binding	B
protein	O
7	O
is	O
a	O
subunit	O
of	O
the	O
26S	B
protease	O
.	O

Based	O
on	O
peptide	O
matches	O
covering	O
more	O
than	O
10%	O
of	O
the	O
TBP7	B
sequence	O
,	O
and	O
the	O
fact	O
that	O
the	O
migration	O
of	O
S6	B
on	O
SDS-PAGE	O
is	O
consistent	O
with	O
the	O
estimated	O
molecular	O
mass	O
for	O
TBP7	B
,	O
we	O
conclude	O
that	O
subunit	B
6	O
of	O
the	O
26S	B
protease	O
is	O
TBP7	B
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	B
kinase	O
inhibitors	O
and	O
the	O
dominant	B
negative	O
allele	O
of	O
c-Raf-1	B
(	O
Raf	B
301	O
)	O
inhibited	O
I	B
kappa	O
B	O
alpha	O
degradation	O
,	O
NF-kappa	B
B	O
binding	O
,	O
and	O
transactivation	O
of	O
kappa	B
B	O
reporter	O
constructs	O
by	O
hypoxia	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
alpha	O
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF-kappa	B
B	O
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B
B	O
/Rel	O
family	O
of	O
transcription	B
factors	O
,	O
pleiotropic	B
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

We	O
propose	O
that	O
NFKB2	B
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	B
protein	O
and,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c-Rel	B
,	O
NFKB2	B
alters	O
the	O
NF-kappa	B
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	B
cells	O
by	O
HTLV-I	O
.	O

In	O
clonogenetic	O
fetal	O
calf	O
serum	O
-supplemented	O
(FCS+)	O
or	O
-nonsupplemented	O
(FCS-)	O
culture	O
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
and	O
erythropoietin	B
(	O
Ep	B
)	O
(combined	O
with	O
c-kit	B
ligand	O
in	O
FCS(-)-culture	O
conditions	O
),	O
RA	O
induces	O
a	O
dramatic	O
dose-dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	B
clones	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	B
GATA1	O
gene	O
,	O
which	O
encodes	O
a	O
finger	B
transcription	O
factor	O
required	O
for	O
normal	O
erythroid	O
development;	O
addition	O
of	O
RA	O
to	O
HPC	B
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	B
mRNA	O
induction	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	B
B	O
lymphoma	O
cell	O
line,	O
B104	O
,	O
expressed	O
surface	B
IgM	B
(	O
sIgM	B
)	O
and	O
surface	B
IgD	B
(	O
sIgD	B
),	O
and	O
that	O
crosslinking	O
of	O
sIgM	B
and	O
sIgD	B
by	O
anti-	B
IgM	B
antibody	O
(Ab)	O
and	O
anti-	B
IgD	B
Ab	O
,	O
respectively,	O
induced	O
Ca2+	O
influx	O
to	O
almost	O
the	O
same	O
degree,	O
whereas	O
only	O
sIgM	B
-crosslinking	O
caused	O
B104	B
cell	O
death	O
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	B
mRNA	O
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B
and	O
sIgD	B
in	O
B104	B
cells	O
is	O
discussed.	O

Co-treatment	O
of	O
RBCs	B
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD	O
-induced	O
increase	O
in	O
parasitemia	O
.	O

Thymocytes	B
,	O
activated	B
peripheral	O
T	O
lymphocytes	O
,	O
or	O
an	O
activated	B
T-cell	O
clone	O
were	O
used	O
as	O
human	O
partners	O
,	O
respectively,	O
in	O
three	O
independent	O
fusions.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non-syntenic	B
trans-active	O
locus	O
,	O
or	O
loci,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	B
CD5	B
gene	O
.	O

In	O
addition	O
to	O
the	O
CD11b	B
gene	O
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	B
and	O
CD11c	B
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B
and	O
MS-2gamma	B
interact	O
with	O
nuclear	B
factors	O
that	O
are	O
induced	O
during	O
U937	B
differentiation	O
.	O

The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS-2	B
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	B
myeloid	O
cells	O
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF-kappa	B
B	O
prototypic	O
probe	O
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B
B/c-Rel	O
proteins	O
.	O

PML	B
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern.	O

We	O
report	O
here	O
that	O
PML	B
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	B
monocytes	B
,	O
lymphocytes	B
,	O
and	O
polymorphonucleate	B
cells	O
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	B
;	O
that	O
PML	B
and	O
PML/RAR	B
alpha	O
expression	O
is	O
augmented	O
by	O
interferon	B
in	O
the	O
NB4	B
APL	O
cell	O
line	O
,	O
which	O
carries	O
the	O
t(15;	B
17)	O
,	O
and	O
in	O
APL	B
blasts	O
from	O
patients	O
;	O
that	O
interferon	B
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	B
cells	O
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	B
cells	O
;	O
and,	O
finally,	O
that	O
interferon	O
gamma	O
,	O
but	O
not	O
alpha	O
or	O
beta	O
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	B
cells	O
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

Ara-C	O
activated	O
SMase	B
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	B
cells	O
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	O
effect.	O

Thus,	O
ceramide	O
is	O
not	O
a	O
positive	O
signal	O
for	O
ERK	B
activation	O
in	O
T-cell	B
lines	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic,	O
biologic,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus-induced	O
tumorigenesis.	O

Nevertheless,	O
the	O
simian	B
EBV	O
LMP1s	B
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-(kappa)B	B
activity	O
in	O
human	B
cells	O
,	O
to	O
bind	O
the	O
tumor	B
necrosis	O
factor-associated	O
factor	O
3	O
(	O
TRAF3	B
)	O
in	O
vitro,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	B
necrosis	O
factor-responsive	O
genes	O
,	O
such	O
as	O
ICAM1	B
,	O
in	O
human	B
B	O
lymphocytes	O
.	O

The	O
conserved	O
TRAF3	B
binding	O
sites	O
in	O
LMP1	B
and	O
the	O
CD30	B
Hodgkin's	O
disease	O
marker	O
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Relative	O
1p36	B
under-representation	O
was	O
found	O
in	O
79/95.	O

In	O
ductal	O
carcinomas	O
,	O
chromosome	B
1	O
alterations	O
increased	O
with	O
histologic	O
grade,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	B
B-2	O
expression.	O

G(Anh)MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	B
beta	O
and	O
interleukin-6	B
expression	O
in	O
human	B
monocytes	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-	O
isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G(Anh)MTetra	O
),	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B
transglycosylase	O
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B
expression	O
in	O
human	B
monocytes	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G(Anh)MTetra	O
-induced	O
IL-6	B
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein,	O
whereas	O
G(Anh)MTetra	O
-induced	O
IL-1	B
beta	O
mRNA	O
accumulation	O
does	O
not.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	B
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15;153(2):910]	O

In	O
this	O
study,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	B
mAb	O
affects	O
T	O
cell	O
functions	O
.	O

Furthermore,	O
R24	B
treatment	O
resulted	O
in	O
translocation	O
of	O
c-rel	B
,	O
but	O
little	O
or	O
no	O
NF	B
kappa	O
B	O
p50	O
or	O
p65	B
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	B
kappa	O
B	O
binding	O
complexes	O
containing	O
c-rel	B
and	O
p50	B
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	B
T	O
cells	O
by	O
R24	B
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
),	O
we	O
show	O
here	O
that	O
the	O
genes	B
encoding	O
the	O
TATA-box	B
binding	O
protein	O
(	O
TBP	B
),	O
TFIIB	B
,	O
TFIIE	B
alpha	O
,	O
TFIIE	B
beta	O
,	O
RAP30	B
,	O
RAP74	B
and	O
the	O
62	B
kDa	O
subunit	O
,	O
of	O
TFIIH	B
are	O
located	O
at	O
the	O
human	O
chromosomal	O
bands	O
6q26-27	O
,	O
1p21-22	O
,	O
3q21-24	O
,	O
8p12	O
,	O
13q14	O
,	O
19p13.3	O
and	O
11p14-15.1	O
,	O
respectively.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B
gene	O
product	O
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	B
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B
expression	O
may	O
contribute	O
to	O
DLCL	O
development.	O

The	O
fact	O
that	O
BCL-6	B
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups.	O

Studies	O
of	O
pluripotent	B
islet	O
cultures	O
.	O

The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	B
immunoglobulin	O
germline	O
promoter	O
.	O

We	O
find	O
that,	O
although	O
the	O
variant	O
octamer	B
motif	O
binds	O
Oct-1	B
and	O
Oct-2	B
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	B
octamer	B
motif	O
,	O
mutation	O
of	O
the	O
variant	O
octamer	B
motif	O
to	O
either	O
a	O
consensus	B
octamer	O
or	O
non-	B
octamer	B
motif	O
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	B
promoter	O
.	O

Generation	O
of	O
CD1+RelB+	B
dendritic	O
cells	O
and	O
tartrate-resistant	B
acid	O
phosphatase-positive	O
osteoclast-like	O
multinucleated	O
giant	O
cells	O
from	O
human	B
monocytes	O
.	O

In	O
the	O
present	O
study,	O
we	O
showed	O
that	O
CD14+	B
adherent	O
human	B
monocytes	O
can	O
differentiate	O
into	O
CD1+relB+	B
dendritic	O
cells	O
(	O
DC	B
)	O
by	O
the	O
combination	O
of	O
GM-CSF	B
plus	O
interleukin-4	B
(	O
IL-4	B
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate-resistant	B
acid	O
phosphatase	O
(TRAP)-positive	O
osteoclast-like	O
multinucleated	O
giant	O
cells	O
(	O
MGC	B
)	O
by	O
the	O
combination	O
of	O
M-CSF	B
plus	O
IL-4	B
.	O

Rather,	O
IFN-gamma	B
antagonized	O
the	O
effect	O
of	O
IL-4	B
and	O
suppressed	O
the	O
DC	B
and	O
MGC	B
formation	O
induced	O
by	O
GM-CSF	B
+	O
IL-4	B
and	O
M-CSF	B
+	O
IL-4	B
,	O
respectively.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	B
and	O
5-lipoxygenase	B
has	O
been	O
shown	O
to	O
inhibit	O
T-cell	O
activation	O
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65/p50	B
subunit	O
of	O
NF-kappa	B
B	O
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b/CD18	B
on	O
monocytic	B
HL60	O
cells	O
,	O
and	O
endothelial	B
adhesion	O
molecule-1	O
(	O
CD62E	B
)	O
and	O
vascular	B
adhesion	O
molecule-1	O
(	O
CD106	B
)	O
on	O
human	B
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF-kappa	B
B	O
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	B
molecules	O
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

While	O
Jurkat	B
cells	O
co-expressed	O
two	O
discrete	O
cell-surface	B
isoforms	O
of	O
CD43	B
,	O
recognized	O
by	O
mAb	B
J393	O
and	O
mAb	B
G10-2	O
,	O
respectively,	O
only	O
J393/	B
CD43	B
signaled	O
apoptosis	O
.	O

Tyrosine	B
kinase	O
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/	B
CD43	B
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B
phosphatase	O
activity	O
by	O
bis(maltolato)oxovanadium-IV	O
enhanced	O
cell	O
death.	O

Sterol	B
regulatory	O
element	O
(	O
SRE	B
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	B
coding	O
for	O
especially	O
low	B
density	O
lipoprotein	O
(	O
LDL	B
)-receptor	O
,	O
3-hydroxy-3-methylglutaryl	B
coenzyme	O
A	O
(HMG-CoA)	O
reductase	O
and	O
HMG-CoA	B
synthase	O
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

Further,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL	B
-receptor	O
gene	O
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B
kDa	O
factor	O
to	O
the	O
SRE	B
sequence	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B
,	O
we	O
cloned	O
the	O
rat	B
IRF-1	B
gene	O
and	O
functionally	O
characterized	O
the	O
IRF-1	B
promoter	O
.	O

By	O
assaying	O
CAT	B
enzyme	O
activity	O
across	O
a	O
24-h	O
PRL	B
induction	O
time	O
course,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	B
responses	O
of	O
the	O
IRF-1	B
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF-1	B
5'-flanking	B
and	O
promoter	B
DNA	O
.	O

Regulation	O
of	O
the	O
BZLF1	B
promoter	O
of	O
Epstein-Barr	O
virus	O
by	O
second	O
messengers	O
in	O
anti-immunoglobulin-treated	B
B	O
cells	O
.	O

Since	O
anti-Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	B
kinase	O
C	O
(	O
PKC	B
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level,	O
Zp	B
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	B
factors	O
.	O

Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	B
activation	O
with	O
anti-Ig	B
.	O

The	O
SCL	B
protein	O
displays	O
cell-specific	O
heterogeneity	O
in	O
size.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell-specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	B
gene	O
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	B
lines	O
(	O
GP+E-86	B
,	O
AT2.5	B
,	O
M1	B
)	O
but	O
only	O
the	O
22	B
kDa	O
form	O
in	O
the	O
myeloid	B
cell	O
line	O
,	O
WEHI-3B/D+	B
.	O

Description	O
and	O
functional	O
implications	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
sex-determining	B
gene	O
SRY	B
.	O

Using	O
gel	O
shift	O
assay	O
and	O
peptide	O
synthesis	O
such	O
a	O
mutation	O
is	O
shown	O
to	O
abolish	O
the	O
SRY	B
protein	O
DNA	O
binding	O
ability	O
.	O

The	O
regulatory	O
role	O
of	O
protein	B
tyrosine	O
phosphatases	O
(	O
PTPases	B
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	B
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
),	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	B
human	O
leukaemic	O
T-cells	O
.	O

In	O
the	O
CD45-negative	B
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing.	O

We	O
thus	O
conclude	O
that	O
PTPases	B
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B
activation	O
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B
activate	O
the	O
transcription	B
factor	O
nuclear	B
factor-kappaB	O
(	O
NF-kappaB	B
),	O
which,	O
in	O
turn,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B
kinase	O
C	O
is	O
involved	O
in	O
TCR	B
-mediated	O
activation	O
of	O
NF-kappaB	B
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B
by	O
PHA	B
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

Consistent	O
with	O
these	O
observations,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B
and	O
calcineurin	B
synergistically	O
induced	O
kappaB	B
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B
and	O
the	O
phosphatase	B
.	O

Two	O
multicopy	B
basal	O
enhancer	O
motifs	O
within	O
the	O
SCMV	O
MIE	B
enhancer	O
,	O
namely,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B
AMP	O
response	O
element	O
(	O
CRE	B
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B
response	O
factor	O
(	O
SRF	B
)	O
binding	O
sites	O
referred	O
to	O
as	O
the	O
SNE	B
(	O
SRF/NFkappaB-like	B
element	O
),	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B
sites	O
within	O
the	O
HCMV	O
version,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	O
and	O
T-	O
cell	O
types	O
.	O

However,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B
elements	O
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B
binding	O
site	O
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B
binding	O
motifs	O
(	O
TTCC	O
),	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B
complex	O
containing	O
both	O
the	O
cellular	O
SRF	B
and	O
ELK-1	B
proteins	O
.	O

T-cell	B
-directed	O
TAL-1	B
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
survival	O
rate	O
of	O
tal-1	B
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice.	O

To	O
further	O
unravel	O
the	O
tal-1	B
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	B
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	B
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	B
lymphomas	O
.	O

By	O
using	O
a	O
partial	B
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	B
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin-labeled	B
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	B
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy-derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	B
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor/growth	O
suppressor	O
.	O

Overexpression	O
of	O
Bcl-2	B
in	O
tumor	B
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli,	O
but	O
inhibition	O
of	O
Fas	B
-mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed.	O

In	O
contrast,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas	B
-mediated	O
apoptosis	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
),	O
induces	O
hyperproduction	O
of	O
interleukin	B
2	O
(	O
IL-2	B
)	O
and	O
interferon-gamma	B
(	O
IFN-gamma	B
)	O
in	O
stimulated	O
human	B
peripheral	O
blood	O
lymphocytes	O
.	O

Analysis	O
of	O
CAT	B
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL-2	O
gene	O
induction.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF-kappa	B
B2	O
p100	O
gene	O
product	O
:	O
implications	O
for	O
viral	O
latency.	O

In	O
particular,	O
Tax	B
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	B
factors	O
,	O
including	O
members	O
of	O
the	O
NF-kappa	B
B/Rel	O
and	O
CREB/ATF	B
families	O
,	O
as	O
well	O
as	O
the	O
cellular	B
factors	O
HEB-1	B
and	O
p67SRF	B
.	O

In	O
contrast,	O
a	O
mutant	O
of	O
Tax	B
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	B
B	O
expression	O
does	O
not	O
associate	O
with	O
p100	B
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B
binding	O
basic	O
domain	O
of	O
MyoD	B
confers	O
c-myc	B
-like	O
functional	O
characteristics	O
to	O
the	O
protein.	O

Function	O
and	O
activation	O
of	O
NF-kappa	B
B	O
in	O
the	O
immune	O
system	O
.	O

In	O
vertebrates,	O
five	O
distinct	O
DNA	B
binding	O
subunits	O
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity,	O
DNA	O
sequence	O
specificity,	O
and	O
cell	O
type-	O
and	O
cell	O
stage-specific	O
distribution.	O

Other	O
I	B
kappa	O
B	O
proteins	O
are	O
rather	O
involved	O
in	O
terminating	O
NF-kappa	B
B	O
's	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
inhibition	O
of	O
NF-kappa	B
B	O
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	B
blood	O
lymphocytes	O
from	O
four	O
patients	O
in	O
remission	O
(S.R.,	O
F.R.,	O
M.M.,	O
P.	O
G.)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/	O
RAR-alpha	B
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

Clone	B
C3/5	O
showed	O
specific	O
proliferation,	O
cytotoxicity,	O
and	O
cytokine	O
(	O
tumor	B
necrosis	O
factor	O
alpha	O
,	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
)	O
production	O
when	O
challenged	O
with	O
autologous	B
lymphoblastic	O
cell	O
lines	O
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

Since	O
APL	B
cells	O
do	O
not	O
express	O
HLA	B
class	O
II	O
molecules	O
,	O
we	O
tested	O
in	O
two	O
donors	O
(D.E.	O
and	O
C.H.R.)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B
/HLA	B
class	O
I	O
-restricted	O
response	O
.	O

Interferon-gamma	B
(	O
IFN-gamma	B
)	O
is	O
produced	O
by	O
natural	B
killer	O
cells	O
and	O
certain	O
subsets	O
of	O
T	B
cells	O
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown.	O

Jun	B
is	O
essential	O
for	O
activation-induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	B
.	O

CD40	B
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti-IgM	B
stimulation	O
of	O
primary	B
B	O
lymphocytes	O
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B
and	O
c-Rel	B
,	O
whereas	O
nuclear	O
c-Rel	B
,	O
but	O
not	O
RelB	B
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B
signaling	O
pathways	O
exerts	O
a	O
long-lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	B
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

High	O
levels	O
of	O
Sp140	B
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	B
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

Regulation	O
of	O
cytokine	B
and	O
cytokine	B
receptor	O
expression	O
by	O
glucocorticoids	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B
expression	O
,	O
GCS	O
up-regulate	O
cytokine	B
receptor	O
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B
effects	O
on	O
target	B
cells	O
.	O

Murine	B
fra-1	O
was	O
highly	O
homologous	O
to	O
rat	O
and	O
human	O
fra-1	O
.	O

Induction	O
of	O
fra-1	B
following	O
engagement	O
of	O
CD40	B
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	B
-dependent	O
linkage	O
between	O
CD40	B
and	O
fra-1	B
is	O
direct.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Results	O
of	O
preliminary	O
studies,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5'	O
of	O
the	O
human	B
GM-CSF	B
TATA	O
box	O
(	O
bp	B
-34	O
to	O
-52	O
),	O
herein	O
called	O
purine	B
box	O
1	O
(	O
PB1	B
),	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T-cell	B
nuclear	O
protein	O
complex	O
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM-CSF	B
gene	O
following	O
T-cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	B
is	O
composed	O
of	O
adjacent	B
binding	O
sites	O
for	O
Ets	B
and	O
AP-1	B
transcription	B
factors	O
.	O

Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B
binding	O
abnormalities:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(P	O
=	O
0.0001)	O
and	O
normal	O
controls	O
(P	O
=	O
0.0001).	O

Furthermore,	O
GR	B
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B
and	O
IL-4	B
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available.	O

Ductal	B
cells	O
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	B
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(p	O
=	O
0.095).	O

Inhibition	O
of	O
nuclear	B
factor	O
kappa	O
B	O
subunit	O
p65	O
mRNA	O
accumulation	O
in	O
lipopolysaccharide	B
-stimulated	O
human	O
monocytic	O
cells	O
treated	O
with	O
sodium	O
salicylate	O
.	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF-kappa	B
B	O
p65	B
mRNA	O
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF-kappa	B
B	O
,	O
p50	B
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide	O
-induced	O
NF-kappa	B
B	O
activation	O
.	O

We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	B
mRNA	O
expression	O
dose	O
dependently	O
in	O
anti-CD3	B
activated	O
Hut-78	O
T	O
cells	O
and	O
human	B
PBMCs	O
.	O

The	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
transforming	B
protein	O
LMP1	B
appears	O
to	O
be	O
a	O
constitutively	B
activated	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	B
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B
carboxyl	O
terminus	O
(	O
CT	B
)	O
with	O
TNFR	B
-associated	O
factors	O
(	O
TRAFs	B
).	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	B
(1-231)	O
core	O
TRAF	O
binding	O
motif	O
on	O
TRAF	O
binding	O
and	O
NF-kappaB	B
activation	O
genetically	O
link	O
the	O
TRAFs	B
to	O
LMP1	B
(1-231)-mediated	O
NF-kappaB	B
activation	O
.	O

The	O
constitutive	O
association	O
of	O
TRAFs	B
with	O
LMP1	B
through	O
the	O
aa	B
187	O
to	O
231	O
domain	O
which	O
is	O
important	O
in	O
NF-kappaB	B
activation	O
and	O
primary	O
B-lymphocyte	B
growth	O
transformation	O
implicates	O
TRAF	B
aggregation	O
in	O
LMP1	B
signaling	O
.	O

To	O
this	O
aim,	O
allergen-specific	B
CD4+	O
T	O
cell	O
clones	O
(	O
TCC	B
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B
profiles	O
were	O
analyzed.	O

Consequently,	O
IL-12	B
also	O
failed	O
to	O
induce	O
the	O
DNA-binding	O
activity	O
of	O
STAT4	B
-containing	O
complexes	O
in	O
the	O
nuclei	O
of	O
these	O
Th2	B
clones	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein-Barr	B
virus	O
-encoded	O
dUTPase	O
:	O
patients	O
with	O
acute,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	B
against	O
the	O
enzyme	B
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O

The	O
protein	O
expressed	O
in	O
insect	B
cells	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	B
antibodies	O
in	O
sera	O
from	O
normal,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases.	O

The	O
catalytic	B
domain	O
of	O
pp56(lck)	B
,	O
but	O
not	O
its	O
regulatory	B
domain	O
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B
production	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	O
and	O
catalytic	O
domains	O
of	O
pp56(lck)	B
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B
:	O
TCR-induced	O
IL-2	B
production	O
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56(lck)	B
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B
of	O
the	O
cell	O
membrane	O
at	O
very	O
low,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	B
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity)	O
and	O
kinetic	O
(high	O
turnover)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells.	O

The	O
macrophage	B
transcription	O
factor	O
PU.1	B
directs	O
tissue-specific	O
expression	O
of	O
the	O
macrophage	B
colony-stimulating	O
factor	O
receptor	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	B
factors	O
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	B
genes	O
is	O
the	O
macrophage-	B
and	O
B-cell-specific	O
PU.1	B
transcription	B
factor	O
,	O
we	O
investigated	O
whether	O
PU.1	B
binds	O
and	O
activates	O
the	O
M-CSF	B
receptor	O
promoter	O
.	O

These	O
results	O
suggest	O
that	O
PU.1	B
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	B
macrophage	O
growth	O
factor	O
.	O

The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	B
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

In	O
patients	O
with	O
breast	O
cancer	O
,	O
NK	B
cell	O
activity	O
was	O
significantly	O
higher	O
compared	O
with	O
patients	O
with	O
benign	B
tumors	O
(P	O
=	O
0.006)	O
or	O
healthy	O
control	O
subjects	O
(P	O
=	O
0.002).	O

Thus,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2/neu	B
expression	O
of	O
the	O
tumor	O
(P	O
=	O
0.003),	O
and	O
HER-2/neu	B
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	B
receptor	O
status	O
(P	O
=	O
0.005).	O

In	O
order	O
to	O
inquire	O
into	O
the	O
functional	O
state	O
of	O
adrenal	O
cortex	O
in	O
patients	O
with	O
pulmonary	O
heart	O
disease	O
,	O
the	O
number	O
of	O
glucocorticoid	B
receptors	O
(	O
GCR	B
)	O
of	O
peripheral	B
blood	O
leukocytes	O
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
was	O
determined	O
with	O
radioligand-binding	O
assay	O
and	O
the	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
with	O
radioimmune	O
assays	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(P	O
>	O
0.05).	O

Signaling	O
via	O
IL-2	B
and	O
IL-4	B
in	O
JAK3	B
-deficient	O
severe	O
combined	O
immunodeficiency	O
lymphocytes	O
:	O
JAK3	B
-dependent	O
and	O
independent	O
pathways	O
.	O

Although	O
IL-2	B
-induced	O
phosphorylation	O
of	O
IL-2R	B
beta	O
,	O
JAK1	B
,	O
and	O
STAT5	B
all	O
required	O
the	O
presence	O
of	O
JAK3	B
,	O
IL-4	B
-mediated	O
phosphorylation	O
of	O
JAK1	B
,	O
STAT6	B
,	O
and	O
insulin	B
receptor	O
substrates	O
1	O
and	O
2	O
did	O
not.	O

Elf-1	B
and	O
Stat5	B
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	B
interleukin-2	O
receptor	O
alpha	O
gene	O
[published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr;17(4):2351]	O

transcription,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high-affinity	B
receptor	O
.	O

However,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	B
.	O

PRRIII	B
contains	O
a	O
Stat	B
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	B
motif	O
(	O
GASd/EBSd	B
).	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd/EBSd	B
element	O
in	O
IL-2R	B
alpha	O
regulation	O
and	O
suggest	O
that	O
the	O
T-cell-specific	B
Elf-1	B
factor	O
can	O
serve	O
as	O
a	O
transcriptional	B
repressor	O
.	O

DR3	B
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	B
signaling	O
molecules	O
including	O
TRADD	B
,	O
TRAF2	B
,	O
FADD	B
,	O
and	O
FLICE	B
.	O

Recently,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B
knockout	O
mice	O
have	O
no	O
dendritic	B
cells	O
(	O
DC	B
).	O

Therefore,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/	B
NF-kappa	B
B	O
proteins	O
in	O
accessory	B
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

p52	B
and	O
RelB	B
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	B
and	O
CD68+	B
cells	O
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B
was	O
found	O
only	O
in	O
CD68-	O
and	O
CD1a-	O
cells	O
.	O

Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	B
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	B
promoter	O
activity	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	B
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	B
to	O
promote	O
T	O
cell	O
activation	O
.	O

Interferon	B
regulatory	O
factor	O
2	O
(	O
IRF-2	B
)	O
is	O
a	O
transcriptional	B
regulatory	O
protein	O
that	O
terminates	O
interferon	B
beta	O
expression	O
initiated	O
by	O
interferon	B
regulatory	O
factor	O
1	O
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	B
nucleotides	O
5'	O
to	O
the	O
major	B
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	B
promoter	O
of	O
IRF-2	B
.	O

The	O
human	B
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	B
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	B
lineage	O
,	O
appearing	O
in	O
myeloblast	B
cells	O
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	B
stage	O
cells	O
as	O
well	O
as	O
in	O
all	O
later	B
stage	O
cells	O
including	O
peripheral	B
blood	O
monocytes	O
and	O
granulocytes	B
.	O

The	O
MNDA	B
mRNA	O
level	O
in	O
primary	B
granulocytes	O
was	O
unaffected	O
by	O
addition	O
of	O
interferon	B
alpha	O
and	O
other	O
agents	O
including	O
interferon	B
gamma	O
,	O
endotoxin	B
,	O
poly	B
(I).poly	O
(C)	O
,	O
and	O
FMLP	B
.	O

The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B
mRNA	O
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B
mRNA	O
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B
mRNA	O
levels	O
were	O
not	O
observed.	O

Sequences	O
which	O
control	O
basal	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
transcription	O
likely	O
play	O
an	O
important	O
role	O
in	O
initiation	O
and	O
maintenance	O
of	O
virus	O
replication	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	B
clone	O
(	O
15B-7	B
),	O
from	O
a	O
Jurkat	B
expression	O
library	O
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	B
1	O
regulatory	O
sequence	O
.	O

Cotransfection	O
of	O
a	O
YB-1	B
expression	O
plasmid	O
increases	O
HTLV-I	O
basal	O
transcription	O
approximately	O
14-fold	O
in	O
Jurkat	B
T	O
lymphocytes	O
.	O

To	O
study	O
the	O
response	O
of	O
the	O
nuclear	B
T3	O
receptor	O
(	O
NT3R	B
)	O
in	O
this	O
condition,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	B
mononuclear	O
leukocytes	O
(	O
MNL	B
).	O

Mononuclear	B
leukocytes	O
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began,	O
and	O
then	O
after	O
every	O
20	O
exposures.	O

This	O
change	O
in	O
MBC	O
represents	O
a	O
311%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo-treated	O
subjects	O
.	O

CD40-stimulated	B
human	O
B	O
lymphocytes	O
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	B
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF-kappaB	B
.	O

Comparison	O
of	O
cDNA	B
and	O
genomic	B
sequences	O
reveals	O
a	O
4-exon	B
structure	O
characteristic	O
of	O
the	O
FOS	B
family	O
of	O
genes	O
.	O

Levels	O
of	O
FOSB	B
mRNA	O
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	B
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr.	O

Regions	O
of	O
low	O
base	O
order-dependent	O
stem-loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined.	O

All	O
human	O
adenoviruses	O
transform	O
rodent	B
cells	O
in	O
vitro,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O

The	O
MHC	B
class	O
1	O
gene	O
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
the	O
Ad12	B
13S	O
mRNA	O
product	O
and	O
in	O
cells	O
transformed	O
with	O
Ad2/Ad12	B
hybrid	O
E1A	O
gene	O
product	O
harboring	O
the	O
C-terminal	B
part	O
of	O
the	O
conserved	B
region	O
(CR)	O
3	O
of	O
Ad12	O
.	O

Bruton's	B
agammaglobulinemia	O
tyrosine	O
kinase	O
(	O
Btk	B
)	O
is	O
a	O
cytoplasmic	B
tyrosine	O
kinase	O
involved	O
in	O
the	O
human	O
disease	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
).	O

The	O
transcription	B
factor	O
Spi-1/PU.1	B
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi-B	B
bound	O
to	O
the	O
PU-box	B
in	O
B-cells.	O

In	O
addition	O
Spi-B	B
as	O
well	O
as	O
PU.1	B
were	O
able	O
to	O
transactivate	O
Btk	B
expression	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P-	O
LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	B
cytokines	O
in	O
human	B
gingival	O
fibroblasts	O
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP-1	B
production	O
by	O
the	O
cells.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B
in	O
human	B
gingival	B
fibroblasts	O
and	O
to	O
show	O
that	O
the	O
signal-transducing	O
pathway	O
of	O
P-	O
LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B
.	O

G-CSF	B
receptors	O
lack	O
intrinsic	O
tyrosine	B
kinase	O
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

The	O
consequences	O
of	O
p80c-rel	B
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known;	O
however,	O
tyrosine	O
-phosphorylated	O
p80c-rel	B
is	O
capable	O
of	O
binding	O
to	O
DNA,	O
and	O
G-CSF	B
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	B
which	O
binds	O
to	O
DNA.	O

The	O
Pan	B
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts,	O
Pan-1	B
and	O
Pan-2	B
(also	O
known	O
as	O
E47	B
and	O
E12	B
,	O
respectively),	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B
proteins	O
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B
proteins	O
in	O
GH/PRL-	O
and	O
insulin-	O
producing	O
,	O
B-	O
and	O
T-	O
lymphocyte	O
cells	O
.	O

NF-kappa	B
B	O
,	O
a	O
50	B
kDa/65	O
kDa	O
(p50/p65)	O
heterodimer	O
,	O
is	O
a	O
ubiquitous	B
transcription	O
factor	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B
genes	O
.	O

Furthermore,	O
p50	B
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	B
.	O

We	O
next	O
studied	O
p65	O
and	O
c-Rel	O
protein	O
expression	O
in	O
FDC	B
clusters.	O

Our	O
results	O
indicated	O
that,	O
in	O
the	O
context	O
of	O
T	O
cell-dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	B
clusters,	O
p50	B
is	O
mainly	O
related	O
to	O
FDC	B
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	B
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	B
and	O
c-Rel	O
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	B
from	O
FDC	B
clusters.	O

The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B
receptor	O
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	B
phosphatase	O
calcineurin	B
.	O

NF-ATn	B
is	O
a	O
ubiquitous	O
protein,	O
can	O
be	O
synthesized	O
in	O
response	O
to	O
PMA	O
,	O
and	O
has	O
many	O
similarities	O
to	O
AP-1	B
.	O

Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	B
is	O
increased	O
recruitment	O
of	O
monocytes	B
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation.	O

In	O
contrast,	O
the	O
binding	O
activities	O
of	O
AP-1	B
and	O
GATA	B
,	O
on	O
the	O
other	O
hand,	O
are	O
increased	O
by	O
LDL	B
.	O

Nuclear	B
factor-kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	B
DNA	O
sequence	O
in	O
the	O
cis-acting	B
elements	O
of	O
various	B
genes	O
.	O

n-Acetyl-L-cysteine	O
(	O
NAC	O
),	O
a	O
potent	O
antioxidant,	O
blocked	O
NF-kappa	B
B	O
activation	O
caused	O
by	O
IL-4	B
and	O
by	O
anti-CD40	B
mAb	O
.	O

However,	O
NAC	O
did	O
not	O
significantly	O
affect	O
the	O
spontaneous	O
production	O
of	O
IgE	B
by	O
atopic	B
B	O
cells	O
.	O

Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	B
factors	O
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP	B
-regulated	O
genes	O
.	O

More	O
interestingly,	O
transfection	O
experiments	O
with	O
CRE	B
-CAT	O
plasmide	O
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE	B
-containing	O
promoter	O
.	O

Both	O
NK-	O
and	O
T-cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
).	O

RT-PCR	O
demonstrated	O
that	O
NL	B
of	O
both	O
subtypes	O
expressed	O
EBNAI	B
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	B
membrane	O
proteins	O
,	O
LMP	O
1	O
and	O
2	O
and	O
the	O
BamHI	B
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	B
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

Down-regulation	O
of	O
immunogenic	B
proteins	O
(	O
EBNA2-EBNA6	B
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	B
cells	O
to	O
evade	O
host	O
cytotoxic	O
T-cell	O
surveillance	O
.	O

However,	O
hypercalcemia	O
is	O
a	O
side	O
effect,	O
which	O
is	O
caused	O
by	O
VD	O
's	O
classical	O
action,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(VDR)	O
than	O
VD	O
.	O

This	O
observation	O
supports	O
a	O
model,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

p21(ras)	B
,	O
a	O
guanine	B
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T-cell	O
signal	O
transduction	O
through	O
PKC	B
-dependent	O
and	O
PKC	B
-independent	O
pathways	O
.	O

This	O
inhibition	O
of	O
calcium	O
-activated	O
IE	B
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	B
in	O
this	O
regulation.	O

The	O
interleukin-2	B
(	O
IL-2	B
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	B
cell	O
receptor	O
(	O
TcR	B
)	O
responsive	O
elements	O
.	O

Calcineurin	B
stimulates	O
the	O
NF-kappa	B
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	B
kappa	O
B/MAD3	O
,	O
an	O
inhibitor	O
of	O
NF-kappa	B
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	B
B	O
DNA	O
binding	O
activity	O
.	O

We	O
examined	O
bone	O
marrow	O
cells	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
to	O
detect	O
residual	O
PML/RAR	B
alpha	O
mRNA	O
-containing	O
cells	O
following	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
cytotoxic	O
chemotherapy	O
in	O
a	O
patient	O
with	O
APL	O
.	O

Glucocorticoid	O
-mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells.	O

In	O
T	B
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	B
(	O
PHA-p	B
)	O
and	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60%	O
reduction	O
in	O
IL-2R	B
alpha	O
and	O
a	O
30%	O
reduction	O
in	O
IL-2R	B
beta	O
membrane	O
expression	O
compared	O
to	O
T	B
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(p	O
<	O
0.01).	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	B
alpha	O
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
),	O
a	O
transcription	B
factor	O
that	O
stimulates	O
IL-2R	B
alpha	O
gene	O
expression	O
.	O

Alteration	O
of	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membrane	O
by	O
glucocorticoids	O
and	O
the	O
influence	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486.	O

In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
).	O

We	O
observed	O
no	O
change	O
in	O
membrane	O
structural	O
order	O
with	O
RU	O
486	O
up	O
to	O
a	O
concentration	O
of	O
10(-4)	O
M.	O

The	O
protein-tyrosine	B
kinase	O
ZAP-70	B
is	O
implicated,	O
together	O
with	O
the	O
Src	B
kinase	O
p56(lck)	B
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	B
)	O
signaling	O
cascade	O
.	O

Moreover,	O
TCR	B
-induced	O
phosphorylation	O
of	O
pp36-38	B
,	O
thought	O
to	O
play	O
a	O
role	O
upstream	O
of	O
these	O
pathways,	O
was	O
found	O
to	O
be	O
reduced.	O

Our	O
data	O
are	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
recruitment	O
to	O
the	O
TCR	B
allows	O
ZAP-70	B
autophosphorylation	O
and	O
binding	O
to	O
p56(lck)	B
,	O
which	O
in	O
turn	O
phosphorylates	O
Tyr-492	O
and/or	O
Tyr-493	O
with	O
consequent	O
up-regulation	O
of	O
the	O
ZAP-70	B
kinase	O
activity	O
.	O

Synthetic	O
glucocorticoids	O
vary	O
in	O
their	O
binding	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(GCR).	O

The	O
mean	O
concentrations	O
necessary	O
to	O
cause	O
50%	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50s	O
)	O
for	O
the	O
steroid-sensitive	O
group	O
ranged	O
from	O
2	O
x	O
10(-10)	O
mol/L	O
for	O
budesonide	O
to	O
7	O
x	O
10(-8)	O
mol/L	O
for	O
hydrocortisone	O
,	O
whereas	O
the	O
mean	O
IC50s	O
for	O
the	O
steroid-resistant	O
group	O
ranged	O
from	O
approximately	O
2	O
x	O
10(-8)	O
mol/L	O
for	O
budesonide	O
to	O
greater	O
than	O
10(-6)	O
mol/L	O
for	O
hydrocortisone	O
.	O

CONCLUSION:	O
These	O
data	O
suggest	O
that	O
glucocorticoids	O
such	O
as	O
budesonide	O
,	O
by	O
virtue	O
of	O
their	O
high	O
GCR	B
binding	O
affinities	O
and	O
greater	O
ability	O
to	O
suppress	O
lymphocyte	O
proliferation	O
,	O
may	O
therefore	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
difficult-to-control	O
asthma	O
.	O

Interestingly,	O
the	O
expression	O
level	O
of	O
p27Kip1	B
mRNA	O
was	O
maximal	O
in	O
resting	B
Go	O
T-cells	O
and	O
rapidly	O
declined	O
following	O
anti-CD3	B
activation	O
.	O

The	O
promoter	B
region	O
lacked	O
a	O
TATA	B
box	O
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	B
factors	O
including	O
two	O
Sp1	B
,	O
CRE	B
,	O
Myb	B
and	O
NFkB	B
located	O
at	O
positions	O
-153	O
,	O
-178	O
,	O
-286	O
,	O
-875	O
,	O
and	O
-1011	O
,	O
respectively.	O

B	B
lymphocytes	O
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	B
factors	O
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	B
cells	O
.	O

Constitutive	O
binding	O
of	O
further	O
factor	B
proteins	O
to	O
DNA,	O
such	O
as	O
JunD	B
,	O
c-Fos	B
and	O
FosB	B
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c-Jun	B
,	O
RelA/p65	B
and	O
c-Rel	B
was	O
unaltered.	O

Naive	B
(CD45RA+)	O
T	O
lymphocytes	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress-induced	O
signals	O
than	O
memory	B
(CD45RO+)	O
cells	O
.	O

When	O
CD45RA+	B
(naive)	O
and	O
CD45RO+	B
(memory)	O
T	O
lymphocytes	O
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF-kappaB	B
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	B
cells	O
than	O
in	O
memory	B
cells	O
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses.	O

These	O
findings	O
indicate	O
that	O
T	B
cells	O
representing	O
different	O
activation	O
and/or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI	O
-mediated	O
signals	O
.	O

Here	O
we	O
report	O
that	O
sustained	O
high	O
concentrations	O
of	O
Ca2+	O
,	O
but	O
not	O
transient	O
pulses	O
,	O
are	O
required	O
to	O
maintain	O
NF-AT	B
transcription	B
factors	O
in	O
the	O
nucleus,	O
where	O
they	O
participate	O
in	O
Ca2+	O
-dependent	O
induction	O
of	O
genes	B
required	O
for	O
lymphocyte	B
activation	O
and	O
proliferation	O
.	O

RelA	B
(	O
p65	B
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	B
p50-	O
p65	B
NF-kappa	B
B	O
complex	O
and	O
contains	O
a	O
high-affinity	B
binding	O
site	O
for	O
its	O
cytoplasmic	B
inhibitor	O
,	O
I	B
kappa	O
B	O
alpha	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(i)	O
cytoplasmic	B
RelA	B
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B
kappa	O
B	O
alpha	O
but	O
also	O
with	O
other	O
ankyrin	B
motif-rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF-kappa	O
B2	O
(p100)	O
and	O
NF-kappa	O
B1	O
(p105)	O
genes	O
;	O
(ii)	O
in	O
contrast	O
to	O
RelA	B
-I	B
kappa	O
B	O
alpha	O
,	O
RelA	B
-p100	O
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	B
necrosis	O
factor	O
alpha	O
activation;	O
(iii)	O
p100	B
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B
-mediated	O
transcription	O
in	O
vivo;	O
(iv)	O
the	O
interaction	O
of	O
RelA	B
and	O
p100	B
involves	O
the	O
conserved	B
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	B
localization	O
signal	O
of	O
RelA	B
,	O
which	O
is	O
required	O
for	O
I	B
kappa	O
B	O
alpha	O
binding	O
;	O
(v)	O
p100	B
inhibition	O
of	O
RelA	B
function	O
requires	O
the	O
C-terminal	B
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B
;	O
and	O
(vi)	O
as	O
observed	O
with	O
I	B
kappa	O
B	O
alpha	O
,	O
nuclear	O
RelA	B
stimulates	O
p100	B
mRNA	O
and	O
protein	O
expression	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	B
T	O
cells	O
through	O
the	O
TCR	B
.	O

First,	O
anti-	B
CD45	B
antibodies	O
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	B
LTR	O
.	O

Thus,	O
CD45	B
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	B
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	B
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	B
(	O
CN	B
),	O
a	O
Ca2+/calmodulin-dependent	B
protein	O
phosphatase	O
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	B
promoter	O
through	O
the	O
NF-AT-binding	B
site	O
.	O

By	O
multimerizing	O
the	O
regulatory	B
elements	O
of	O
the	O
GM-CSF	B
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	B
sites	O
for	O
the	O
CN	B
action	O
is	O
the	O
conserved	B
lymphokine	O
element	O
0	O
(	O
CLE0	B
),	O
located	O
at	O
positions	O
between	O
-54	B
and	O
-40	O
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	B
stem	O
cells	O
and	O
extrathymic	B
T-cell	O
development	O
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T-cell	O
differentiation	O
in	O
the	O
liver	O
.	O

The	O
Bcd	B
proto-oncogene	B
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5'	B
UTR	O
.	O

Transfection	O
of	O
an	O
expression	B
vector	O
containing	O
ORF2	B
but	O
not	O
full	B
length	O
cDNA	O
was	O
able	O
to	O
transform	O
NIH3T3	B
cells	O
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

However,	O
stimulation	O
of	O
B-cells	B
from	O
B-CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	B
cells	O
was	O
associated	O
with	O
induction	O
of	O
Bcd	B
gene	O
expression	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	B
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely,	O
and	O
specifically,	O
abolished	O
the	O
binding	O
of	O
two	O
low-mobility	B
complexes	O
and	O
led	O
to	O
a	O
95%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL-1beta	B
(-170/+108).	O

In	O
this	O
paper	O
we	O
have	O
investigated	O
the	O
role	O
of	O
Egr-1	B
in	O
B	O
cell	O
growth	O
regulation	O
by	O
examining	O
the	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
B	B
cell	O
lines	O
,	O
including	O
both	O
EBV	B
genome	O
negative	O
and	O
EBV	B
carrying	O
cell	O
lines	O
.	O

Activated	O
viral	O
gene	O
expression	O
associated	O
with	O
phenotypic	O
conversion	O
of	O
group	B
I	O
cell	O
lines	O
in	O
to	O
group	B
II	O
or	O
III	B
restores	O
the	O
Egr-1	B
gene	O
expression	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other,	O
and	O
there	O
may	O
exist	O
progenitor	B
cells	O
common	O
to	O
those	O
two	O
lineages	O
may	O
exist.	O

Stat3	B
recruitment	O
by	O
two	O
distinct	O
ligand-induced,	B
tyrosine-phosphorylated	O
docking	O
sites	O
in	O
the	O
interleukin-10	B
receptor	O
intracellular	O
domain	O
.	O

IL-10	B
also	O
activated	O
Stat5	B
in	O
Ba/F3	B
cells	O
that	O
stably	O
expressed	O
the	O
murine	O
IL-10	B
receptor	O
.	O

These	O
data	O
demonstrate	O
that	O
Stat3	B
but	O
not	O
Stat1	B
or	O
Stat5	B
is	O
directly	O
recruited	O
to	O
the	O
ligand-activated	B
IL-10	O
receptor	O
by	O
binding	O
to	O
specific	O
but	O
redundant	O
receptor	B
intracellular	B
domain	O
sequences	O
containing	O
phosphotyrosine	O
.	O

A	O
switch	O
from	O
human	B
fetal	O
(gamma)	O
-to	O
adult	B
(beta)-globin	O
expression	O
occurs	O
within	O
erythroid	B
precursor	O
cells	O
of	O
the	O
adult	B
lineage	O
.	O

Impaired	O
silencing	O
of	O
gamma-globin	B
expression	O
identifies	O
EKLF	B
as	O
the	O
first	O
transcription	B
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma-globin	B
to	O
beta-globin	B
switch	O
.	O

Here,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide-free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	B
1	O
beta	O
(	O
IL-1	B
beta	O
)	O
and	O
tumour	B
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	B
in	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	B
).	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc	O
-mediated	O
immune	O
modulation	O
.	O

E3	B
,	O
one	O
of	O
nine	O
sequences	O
identified,	O
was	O
upregulated	O
in	O
an	O
immediate-early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

The	O
murine	O
E3	B
promoter	O
harbors	O
a	O
single	O
bipartite	B
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs,	O
we	O
created	O
a	O
reporter	B
construct	O
containing	O
as	O
an	O
enhancer	B
four	O
copies	O
of	O
the	O
NF-AT	B
site	O
and	O
one	O
copy	O
of	O
the	O
octamer	B
site	O
(	O
4X	B
NF-AT-Oct	O
).	O

Because	O
the	O
-180	B
site	O
is	O
not	O
required	O
for	O
trans-activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	B
IL-2	B
enhancer	O
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O

Although	O
phenotypically	O
normal,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens'	O
T	B
cells	O
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	B
(	O
IL-2	B
).	O

In	O
contrast,	O
expression	O
of	O
the	O
activation-dependent	B
cell	B
surface	O
markers	O
CD25	B
and	O
CD69	B
was	O
within	O
normal	O
limits.	O

oriP	B
is	O
essential	O
for	O
EBNA	B
gene	O
promoter	O
activity	O
in	O
Epstein-Barr	B
virus-immortalized	O
lymphoblastoid	O
cell	O
lines	O
.	O

It	O
was	O
determined	O
that	O
oriP	B
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	B
or	O
Wp	B
in	O
LCLs	B
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt's	B
lymphoma	O
cell	O
lines	O
.	O

Site-directed	O
mutagenesis	O
of	O
these	O
cis	B
elements	O
demonstrated	O
that	O
Cp	B
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	B
box	O
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	B
CCAAT	B
box	O
apparent	O
only	O
when	O
the	O
proximal	B
CCAAT	B
box	O
was	O
deleted	O
or	O
mutated.	O

Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	B
1beta	O
and	O
NFkappaB	B
activation	O
,	O
but	O
not	O
NFkappaB	B
nuclear	O
translocation	O
.	O

We	O
have	O
found	O
that,	O
in	O
the	O
human	O
pro-monocytic	B
cell	O
line	O
,	O
THP-1	B
,	O
the	O
lipopolysaccharide	O
-induced	O
expression	O
of	O
interleukin	B
1beta	O
is	O
dependent	O
on	O
tyrosine	B
kinase	O
activation	O
.	O

These	O
results	O
suggest	O
that,	O
while	O
lipopolysaccharide	O
-induced	O
expression	O
of	O
inflammatory	B
mediators	O
requires	O
tyrosine	B
kinase	O
activity	O
,	O
tyrosine	B
kinase	O
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF-kappaB	B
DNA-binding	O
activity	O
in	O
HIV1	B
-infected	O
cells	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B
protein,	O
the	O
activity	O
of	O
the	O
double-stranded	B
RNA-dependent	O
protein	O
kinase	O
(	O
PKR	B
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B
subunits	O
in	O
the	O
PLB-985	B
and	O
U937	B
myeloid	O
cell	O
models	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	B
subunits	O
c-Rel	B
and	O
NF-kappaB2	B
p100	O
and	O
a	O
moderate	O
increase	O
in	O
NF-kappaB2	B
p52	O
and	O
RelA(p65)	B
were	O
detected	O
in	O
HIV-1	B
-infected	O
cells	O
,	O
whereas	O
NF-kappaB1	B
p105/p50	O
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	B
cells	O
.	O

The	O
c-Jun	B
delta-domain	O
inhibits	O
neuroendocrine	B
promoter	O
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary-	O
specific	O
manner	O
.	O

Moreover,	O
alteration	O
of	O
any	O
one	O
of	O
these	O
features	O
(e.g.,	O
cis-element	B
,	O
trans-factor	B
,	O
or	O
cell-specific	O
background	O
)	O
switched	O
c-Jun	B
to	O
a	O
transcriptional	B
activator	O
of	O
the	O
rPRL	B
promoter	O
.	O

Retinoic	O
acid	O
activates	O
interferon	B
regulatory	O
factor-1	O
gene	O
expression	O
in	O
myeloid	B
cells	O
.	O

The	O
NB4	B
cell	O
line	O
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	B
cells	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	B
gene	O
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN-gamma	B
in	O
NB4	B
cells	O
.	O

Transcription	B
factors	O
of	O
the	O
NFAT	B
family	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	B
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	B
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	B
transfected	O
T	O
cells	O
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA	O
-sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

We	O
previously	O
characterized	O
Drosophila	O
and	O
human	O
TAF	O
subunits	O
that	O
make	O
up	O
the	O
core	O
TFIID	B
complex	O
found	O
in	O
all	O
cells.	O

Transient	O
overexpression	O
of	O
hTAFII105	B
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	B
cells	O
.	O

The	O
association	O
of	O
20q	B
deletions	O
with	O
myeloid	O
"stem	O
cell"	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	B
hematopoietic	O
progenitors	O
.	O

In	O
each	O
case,	O
cytogenetic	O
analysis	O
had	O
either	O
failed	O
or	O
had	O
shown	O
no	O
abnormalities	O
of	O
chromosome	B
20	O
.	O

In	O
each	O
case	O
the	O
allele	O
loss	O
was	O
caused	O
by	O
an	O
interstitial	O
deletion	O
because	O
heterozygosity	O
at	O
distal	B
markers	O
was	O
retained	O
and	O
because	O
quantitative	O
Southern	O
blotting	O
demonstrated	O
hemizygosity	O
.	O

In	O
5	O
patients	O
the	O
granulocytes	B
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	B
and	O
T	B
cells	O
.	O

Interleukin-6	B
(	O
IL-6	B
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	B
myeloma	O
(MM)	O
cells	O
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

In	O
MM	B
cells	O
that	O
proliferated	O
in	O
response	O
to	O
IL-6	B
,	O
exogenous	O
IL-6	B
downregulated	O
dephosphorylated	B
pRB	B
and	O
decreased	O
dephosphorylated	O
pRB	B
-E2F	O
complexes	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	B
pRB	B
is	O
constitutively	O
expressed	O
in	O
MM	B
cells	O
and	O
that	O
IL-6	B
further	O
shifts	O
pRB	B
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	B
pRB	B
due	O
to	O
reduced	O
dephosphorylated	B
pRB	B
,	O
thereby	O
releasing	O
growth	O
arrest;	O
and	O
by	O
upregulating	O
IL-6	B
secretion	O
by	O
MM	B
cells	O
and	O
related	O
IL-6	B
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

In	O
this	O
report,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	B
T-lymphocytes	O
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	B
,	O
TGF-beta	B
2	O
in	O
glial	B
cells	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF-beta	B
2	O
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T-lymphocytes	B
and	O
astrocytes	B
via	O
TGF-beta	B
2	O
to	O
regulate	O
the	O
immune	O
response	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E-boxes	B
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
T-	O
and	O
B-	O
cell	O
lines	O
,	O
the	O
E(gre)	B
motifs	O
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA/S	B
motif	O
had	O
some	O
effect.	O

In	O
conclusion,	O
E(gre)	B
motifs	O
and	O
interacting	O
basic	B
helix-loop-helix	O
proteins	O
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	B
cell	O
lines	O
.	O

Moreover,	O
when	O
introduced	O
into	O
murine	B
pro-B	O
lymphocytes	O
,	O
the	O
oncogenic	B
E2A-HLF	B
fusion	O
protein	O
reversed	O
both	O
interleukin-3-dependent	O
and	O
p53-mediated	O
apoptosis	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	B
factor	O
products	O
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream,	O
function-related	B
genes	O
.	O

Finally,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc-finger	B
transcription	B
factor	O
encoded	O
by	O
egr-1	B
include	O
the	O
interleukin-2	O
,	O
CD44	O
,	O
ICAM-1	O
,	O
and	O
tumor	O
necrosis	O
factor	O
genes	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	B
adenovirus	O
type	O
5	O
E1A-region	O
(	O
Ad5E1A234-243	B
),	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor-eradicating	B
CTL	O
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O

NGFI-B/nur77	B
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI-B/nur77	B
family	O
consists	O
of	O
three	O
subtypes,	O
named	O
nur77	B
alpha	O
,	O
nur77	B
beta	O
,	O
nur77	B
gamma	O
.	O

Assuming	O
that	O
9-cis-retinoic	O
acid	O
(	O
9-cis-RA	O
)	O
inhibits	O
TCR-mediated	O
apoptosis	O
,	O
nur77	B
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis-RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	B
in	O
the	O
presence	O
of	O
9-cis-RA	O
.	O

Therefore,	O
we	O
examined	O
glucocorticoid	B
receptor	O
characteristics	O
on	O
monocytes	B
by	O
[3H]dexamethasone	O
binding	O
and	O
measured	O
IFN	B
alpha	O
,	O
cortisol	O
,	O
and	O
ACTH	O
in	O
AIDS	O
patients	O
with	O
(	O
AIDS	O
-GR	O
)	O
or	O
without	O
glucocorticoid	O
resistance	O
(	O
AIDS	O
-C	O
)	O
and	O
controls	O
(C).	O

Correlations	O
were	O
found	O
between	O
plasma	B
IFN	B
alpha	O
and	O
receptor	O
Kd	O
on	O
monocytes	B
of	O
AIDS	O
-GR	O
(r	O
=	O
0.77)	O
and	O
between	O
IFN	B
alpha	O
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(r	O
=	O
0.74).	O

JNK	B
(	O
c-Jun	B
NH2-terminal	O
kinase	O
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	B
lymphocytes	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	B
against	O
the	O
T	B
cell	O
receptor-CD3	O
complex	O
and	O
to	O
CD28	B
.	O

Transfection	O
of	O
trans-dominant	B
negative	O
expression	O
vectors	O
of	O
ras	B
and	O
raf	B
,	O
together	O
with	O
AP-1	B
-dependent	O
reporter	O
constructs	O
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	B
(	O
extracellular	B
signal-regulated	O
kinase	O
)	O
antibodies	O
,	O
indicated	O
that	O
the	O
Ras/Raf/ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant.	O

Aging	O
is	O
classically	O
accompanied	O
by	O
a	O
dysregulation	O
of	O
the	O
immunologic	O
machinery	O
.	O

The	O
most	O
extensively	O
studied	O
phenomenon	O
is	O
the	O
progressive	O
decline	O
in	O
the	O
proliferative	O
capacities	O
of	O
T	B
lymphocytes	O
with	O
aging.	O

The	O
biochemical	O
modifications	O
responsible	O
for	O
the	O
defect	O
in	O
transduction	O
and	O
execution	O
of	O
the	O
proliferative	O
signal	O
are	O
analyzed	O
as	O
a	O
function	O
of	O
age.	O

Levels	O
of	O
bcl-2	B
mRNA	O
and	O
protein	O
increase	O
with	O
cross-linking	O
of	O
surface	B
immunoglobulin	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro.	O

Treatment	O
of	O
the	O
more	O
immature	B
B-cell	O
line	O
,	O
Ramos	B
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

Although	O
the	O
CRE	B
site	O
is	O
necessary,	O
optimal	O
induction	O
of	O
bcl-2	B
expression	O
requires	O
participation	O
of	O
the	O
upstream	B
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	B
alters	O
its	O
interaction	O
with	O
the	O
upstream	B
regulatory	O
element	O
.	O

MNDA	B
(	O
myeloid	B
cell	O
nuclear	O
differentiation	O
antigen	O
)	O
is	O
an	O
interferon	B
alpha	O
regulated	O
nuclear	O
protein	O
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	B
myelomonocytic	O
lineage	O
.	O

In	O
addition,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	B
expression	O
.	O

Primary	O
Sjogren's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O

This	O
abnormality	O
was	O
not	O
seen	O
in	O
resting	B
T	O
cells	O
nor	O
T	B
cells	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
),	O
or	O
SS	O
accompanied	O
by	O
RA	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	B
(	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
)	O
gene	O
family	O
member	O
NFATc	B
[published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27;271(52):33705]	O

The	O
cDNA	B
clone	O
encodes	O
a	O
new	O
isoform,	O
NFATc.beta	B
,	O
of	O
the	O
NFAT	B
gene	O
family	O
member	O
NFATc	B
(designated	O
here	O
NFATc.alpha	B
).	O

Transient	O
expression	O
of	O
NFATc.beta	B
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	B
NFAT	B
-driven	O
reporter	O
gene	O
in	O
stimulated	B
Jurkat	B
cells	O
in	O
a	O
CsA	O
-sensitive	O
manner	O
.	O

Interferon-gamma	B
(	O
IFN-gamma	B
),	O
also	O
known	O
as	O
type	B
II	O
interferon	O
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development,	O
maturation,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein-Barr	O
virus	O
gene	O
expression	O
in	O
EBV-positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	B
cells	O
.	O

The	O
EBNA	B
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	B
promoters	O
,	O
Qp	B
:	O
by	O
contrast,	O
both	O
Cp	B
and	O
Wp	B
were	O
silent,	O
thus	O
resulting	O
in	O
the	O
lack	O
of	O
EBNA2	B
mRNA	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	B
carcinoma	O
cells	O
at	O
the	O
protein	O
level,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I'	O
represented	O
by	O
Burkitt's	O
lymphoma	O
than	O
'latency	O
II'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	B
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST-construct	B
containing	O
the	O
SH2	O
and	O
SH3	O
domains	O
of	O
phospholipase	B
C	O
gamma	O
1	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p38	B
and	O
p63	B
is	O
also	O
observed	O
in	O
platelets	B
stimulated	O
by	O
the	O
tyrosine	B
kinase	O
-linked	O
receptor	O
agonist	O
collagen	B
and	O
by	O
the	O
G	B
protein	O
-coupled	O
receptor	O
agonist	O
thrombin	B
,	O
although	O
phosphorylation	O
of	O
SLP-76	B
is	O
only	O
observed	O
in	O
collagen	B
-stimulated	O
platelets	B
.	O

The	O
activated	O
form	O
of	O
the	O
interferon-induced	B
transcription	O
factor	O
complex	O
ISGF3	B
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	B
cells	O
.	O

An	O
IL-2	B
response	O
element	O
in	O
the	O
human	B
IL-2	O
receptor	O
alpha	O
chain	O
promoter	O
is	O
a	O
composite	B
element	O
that	O
binds	O
Stat5	B
,	O
Elf-1	B
,	O
HMG-I(Y)	B
and	O
a	O
GATA	B
family	O
protein	O
.	O

Multiple	O
factors	O
including	O
Stat5	B
,	O
Elf-1	B
,	O
HMG-I(Y)	B
and	O
GATA	B
family	O
proteins	O
bind	O
to	O
the	O
IL-2	B
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
).	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	B
encoding	O
PTF	B
beta	O
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti-	B
PTF	B
beta	O
antibodies	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B
gamma/PTF	O
delta	O
and	O
TBP	B
and	O
the	O
involvement	O
of	O
TFIIIB90	B
in	O
the	O
transcription	O
of	O
class	B
III	O
snRNA	B
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP	B
-containing	O
complex	O
related	O
to	O
TFIIIB	B
is	O
required	O
for	O
the	O
transcription	O
of	O
class	B
III	O
snRNA	B
genes	O
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four-subunit	B
PTF	O
.	O

Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1.1	B
kb	O
Id-3L	O
transcript	O
together	O
with	O
the	O
predominant	O
0.95	B
kb	O
Id-3	B
transcript	O
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(from	O
463	O
+/-	O
133	O
to	O
128	O
+/-	O
52	O
centipoise).	O

In	O
this	O
study,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	B
),	O
tissue	B
factor	O
,	O
endothelial	B
leukocyte	O
adhesion	O
molecule-1	O
,	O
and	O
vascular	B
cell	O
adhesion	O
molecule-1	O
genes	O
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	B
containing	O
multimerized	B
kappaB	O
sites	O
by	O
p65	B
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B
subunit	O
of	O
PKA	B
.	O

Therefore,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	B
adhesion	O
molecule-1	O
(	O
ICAM-1	B
)	O
as	O
adhesion	B
molecules	O
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell-cell	O
and	O
cell-matrix	O
interactions	O
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B
receptor	O
and	O
nuclear	B
factor-kappa	O
B	O
factors	O
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	B
diseases	O
.	O

Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups.	O

Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas	O
/glioblastomas	O
and	O
their	O
subsequent	O
recurrences,	O
which	O
are	O
clinically	O
indistinguishable,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment.	O

By	O
using	O
a	O
DNA	B
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	B
BCL-6	B
in	O
vitro,	O
we	O
show	O
here	O
that	O
BCL-6	B
is	O
present	O
in	O
DNA-binding	B
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B-cell	B
lines	O
.	O

Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF-kappa	B
B	O
transcription	O
factor	O
are	O
stronger	O
in	O
neonatal	O
than	O
adult	O
T	O
lymphocytes	O
.	O

The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate/calcium	O
ionophore	O
A23187	O
(	O
PDBu/iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF-kappa	B
B	O
in	O
neonatal	O
than	O
adult	O
T	O
cells	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic/fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent/erythroid/monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

On	O
this	O
basis,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(1)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP-CFC	B
colonies	O
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(2)	O
inhibited	O
HSC	B
proliferation	O
.	O

The	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
is	O
considered	O
an	O
indicator	O
of	O
the	O
function	O
of	O
the	O
adrenal	O
pituitary	O
axis	O
.	O

Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O

In	O
elderly	O
healthy	O
subjects	O
,	O
Type	B
II	O
receptors	O
were	O
also	O
significantly	O
decreased	O
(from	O
1796	O
+/-	O
671	O
to	O
720	O
+/-	O
345).	O

They	O
are	O
composed	O
of	O
different	O
structural	B
domains	O
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B
alpha-LBD	O
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding.	O

IL13	B
induces	O
the	O
same	O
biological	O
effects	O
as	O
IL4	B
in	O
normal	B
human	O
B	O
cells	O
.	O

The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O

In	O
this	O
report,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	B
render	O
the	O
T	B
cell	O
receptor	O
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	B
Jurkat	O
T	O
cells	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

Here	O
we	O
show	O
that,	O
unexpectedly,	O
expression	O
of	O
another	O
viral	B
immediate-early	O
protein	O
,	O
BRLF1	B
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell-specific	O
fashion	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
conversion	O
of	O
the	O
unprimed	O
eosinophil	O
phenotype	O
in	O
the	O
peripheral	O
blood	O
of	O
normal	O
individuals	O
to	O
the	O
primed	O
phenotype	O
found	O
in	O
the	O
peripheral	O
blood	O
and	O
tissues	O
of	O
allergic	O
patients	O
,	O
a	O
phenomenon	O
called	O
priming.	O

The	O
extent	O
to	O
which	O
peptides	O
containing	O
chemically	O
and	O
post-translationally	O
modified	O
amino	B
acid	O
side	O
chains	O
are	O
recognized	O
by	O
primed	B
CTL	O
has	O
not	O
been	O
clearly	O
defined.	O

Similarly,	O
CTL	B
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	O
recognize	O
the	O
succinimide	O
derivative	O
of	O
this	O
peptide	O
.	O

A	O
3'	O
-->	O
5'	O
XPB	B
helicase	O
defect	O
in	O
repair/transcription	B
factor	O
TFIIH	B
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	B
,	O
TFIIHmut	B
shows	O
a	O
reduced	O
3'	O
-->	O
5'	O
XPB	B
helicase	O
activity.	O

The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O

Here	O
we	O
show	O
that	O
contrary	O
to	O
previous	O
reports,	O
PU.1	B
and	O
Spi-B	B
have	O
very	O
different	O
expression	O
patterns	O
.	O

In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi-B	B
mRNA	O
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O

Finally,	O
both	O
PU.1	B
and	O
Spi-B	B
function	O
as	O
transcriptional	O
activators	O
of	O
the	O
immunoglobulin	B
light-chain	O
enhancer	O
E	B
lambda	O
2.4	O
when	O
coexpressed	O
with	O
Pip	B
(	O
PU.1	B
-interaction	O
partner	O
)	O
in	O
NIH-3T3	B
cells	O
.	O

DNase	B
I	O
hypersensitive	O
site	O
(	O
DHS	B
)	O
mapping	O
revealed	O
that	O
the	O
perforin	B
locus	O
contained	O
six	O
DHS	B
within	O
7.0	O
kb	O
of	O
the	O
5'	B
upstream	O
sequence	O
(-7.0	O
kb)	O
and	O
two	O
DHS	B
in	O
intron	B
2	O
.	O

The	O
proximal	B
region	O
in	O
PFP9a20	B
contained	O
two	O
potential	O
Sp1	B
binding	O
sites	O
(	O
GC	B
box	O
and	O
GT	B
box	O
)	O
and	O
one	O
Ets	B
binding	O
site	O
(	O
EBS	B
).	O

The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B
activity	O
.	O

The	O
primary	B
RNA	O
transcript	O
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O

The	O
human	B
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	B
cell	O
through	O
its	O
antigen	B
receptor	O
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

In	O
A20	B
B	O
cells	O
,	O
the	O
TNF-alpha	B
gene	O
is	O
not	O
regulated	O
by	O
NFATp	B
bound	O
to	O
the	O
kappa	B
3	O
element	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp	B
-binding	O
sites	O
in	O
the	O
proximal	O
TNF-alpha	B
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c-ErbB	B
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	B
transcription	O
factor	O
family	O
.	O

These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c-ErbB	B
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	B
progenitors	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA-protein	O
interactions	O
in	O
anergic	B
T	O
cells	O
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	B
family	O
members	O
c-Fos	B
,	O
FosB	B
,	O
and	O
JunB	B
.	O

B-cell-specific	O
transcription	O
of	O
immunoglobulin	B
genes	O
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	B
domain	O
containing	O
transcription	B
factor	O
Oct-1	B
or	O
Oct-2	B
,	O
with	O
the	O
B-cell-specific	B
coactivator	O
OCA-B	B
(	O
Bob-1	B
,	O
OBF-1	B
)	O
and	O
a	O
prototype	B
octamer	O
element	O
.	O

The	O
recognition	O
of	O
both	O
the	O
POU	B
domain	O
and	O
the	O
octamer	B
sequence	O
by	O
OCA-B	B
provides	O
a	O
mechanism	O
for	O
differential	O
regulation	O
of	O
octamer	B
sites	O
containing	O
genes	O
by	O
the	O
ubiquitous	B
factor	O
Oct-1	B
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	B
in	O
blood	B
leucocytes	O
,	O
skin	B
fibroblasts	O
,	O
Epstein-Barr	B
virus	O
transformed	O
lymphoid	O
cell	O
lines	O
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation.	O

The	O
basis	O
for	O
the	O
discordant	O
expression	O
of	O
this	O
d	O
novo	O
mutation	O
in	O
the	O
twins	O
was	O
investigated	O
by	O
studying	O
their	O
X	O
inactivation	O
status	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B
proteins	O
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	B
helix	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	B
bend	O
induced	O
by	O
PU.1	B
.	O

Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease,	O
their	O
anti-inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
-1	O
.	O

The	O
activity	O
of	O
the	O
NH2-terminal	B
transactivation	O
domain	O
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	B
region	O
that	O
contains	O
several	O
conserved	B
sequence	O
motifs	O
represented	O
only	O
in	O
the	O
NFAT	B
family	O
.	O

To	O
overcome	O
this	O
problem,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	B
T	O
cell	O
blasts	O
can	O
be	O
stimulated	O
via	O
the	O
CD28	B
surface	O
molecule	O
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	B
T	O
cells	O
to	O
CD28	B
activation	O
in	O
isolation.	O

Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28	B
-mediated	O
induction	O
of	O
AP-1	B
and	O
NF-kappaB	B
.	O

Presence	O
of	O
a	O
variant	O
form	O
of	O
the	O
estrogen	B
receptor	O
in	O
peripheral	B
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
and	O
lupus	O
patients	O
.	O

Our	O
results,	O
although	O
limited,	O
suggest	O
that	O
normal	O
individuals	O
can	O
express	O
both	O
the	O
wild-type	O
and	O
truncated	O
version	O
at	O
the	O
same	O
time,	O
whereas	O
lupus	O
patients	O
only	O
express	O
either	O
the	O
wild-type	O
or	O
the	O
truncated	O
ER	O
.	O

Sialoadhesin	B
is	O
a	O
macrophage-restricted	B
member	O
of	O
the	O
Ig	B
superfamily	O
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

Sialoadhesin	B
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	B
RBCs	O
.	O

The	O
regulation	O
of	O
sialoadhesin	B
expression	O
was	O
mediated	O
by	O
the	O
GC	B
receptor	O
,	O
and	O
not	O
by	O
mineralocorticoid	B
receptor	O
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Expression	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
)	O
protease	O
in	O
cultured	B
cells	O
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	B
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	B
muteins	O
that	O
have	O
noncleavable	B
alterations	O
surrounding	O
the	O
HIV	B
protease	O
cleavage	O
site	O
.	O

alpha	B
4	O
beta	O
1	O
ligation	O
alone	O
had	O
no	O
effect	O
on	O
transcription	B
factor	O
binding	O
.	O

Furthermore,	O
the	O
dose	O
of	O
OKT3	B
required	O
to	O
achieve	O
half-maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B
4	O
beta	O
1	O
ligands.	O

The	O
induction	O
of	O
T	O
cell	O
proliferation	O
requires	O
signals	O
from	O
the	O
TCR	B
and	O
a	O
co-receptor	B
molecule	O
,	O
such	O
as	O
CD28	B
,	O
that	O
activate	O
parallel	O
and	O
partially	O
cross-reactive	O
signaling	O
pathways	O
.	O

Nevertheless,	O
forskolin	O
also	O
inhibits	O
PKC	B
downstream	O
events	O
,	O
such	O
as	O
c-jun	B
expression	O
,	O
which	O
is	O
critical	O
for	O
the	O
activation	O
process	O
of	O
T	B
cells	O
.	O

Furthermore,	O
the	O
effect	O
of	O
12-O-tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c-Jun	B
N-terminal	O
kinase	O
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	B
encoding	O
gamma-globin	B
and	O
porphobilinogen	O
deaminase	O
(	O
PBGD	B
),	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

Because	O
the	O
increase	O
in	O
erythroid	B
mRNA	O
steady-state	O
level	O
in	O
anthracycline	B
-treated	O
cells	O
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA	B
-treated	O
cells	O
and	O
mRNA	O
stabilization	O
in	O
DOX	B
-treated	O
cells	O
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Interleukin-7	B
signaling	O
in	O
human	B
B	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
and	O
murine	B
BAF3	O
cells	O
involves	O
activation	O
of	O
STAT1	B
and	O
STAT5	B
mediated	O
via	O
the	O
interleukin-7	B
receptor	O
alpha	O
chain	O
.	O

Gel	O
retardation	O
assays	O
with	O
STAT-binding	O
oligonucleotides	O
showed	O
that	O
IL-7	B
induces	O
the	O
formation	O
of	O
two	O
major	O
STAT	B
complexes	O
in	O
BCP-ALL	B
cells	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
the	O
cytoplasmic	B
domain	O
of	O
the	O
IL-7	B
receptor	O
alpha	O
chain	O
(	O
IL-7R	B
alpha	O
)	O
to	O
activation	O
of	O
STAT	B
proteins	O
,	O
transfectants	O
of	O
the	O
murine	B
pro-B	O
cell	O
line	O
BAF3	O
were	O
made	O
that	O
express	O
chimeric	B
receptors	O
consisting	O
of	O
the	O
extracellular	B
domain	O
of	O
human	B
granulocyte	O
colony-stimulating	O
factor	O
receptor	O
(	O
G-CSF-R	B
)	O
and	O
the	O
transmembrane	O
and	O
intracellular	O
domains	O
of	O
human	B
IL-7R	O
alpha	O
.	O

The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B
alpha	O
chains	O
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B
and	O
STATs	B
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	B
B	O
cells	O
.	O

The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B
in	O
T	O
and	O
B	O
cell	O
co-cultures	O
increased	O
from	O
4.2%	O
to	O
13.8%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7%	O
to	O
48.6%	O
in	O
healthy	O
controls	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligos	O
against	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
have	O
mitogenic	O
effects	O
on	O
the	O
proliferation	O
of	O
human	B
lymphocytes	O
in	O
a	O
non-specific	O
manner	O
and	O
may	O
activate	O
T	B
cells	O
to	O
express	O
CD40	B
antigen	O
.	O

CaMKIV/	B
Gr	O
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c-fos	B
but	O
is	O
independent	O
of	O
p21ras	B
or	O
calcineurin	B
.	O

IL-12	B
-induced	O
activation	O
of	O
NK	O
and	O
T	O
cells	O
occurs	O
in	O
the	O
absence	O
of	O
immediate-early	B
activation	O
gene	O
expression	O
.	O

Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA	B
-encoding	O
members	O
of	O
the	O
AP-1	B
transcription	O
factor	O
family	O
demonstrated	O
that	O
c-fos	B
and	O
junB	B
are	O
also	O
expressed	O
upon	O
stimulation	O
of	O
NK	O
and	O
T	O
cells	O
with	O
IL-2	B
,	O
but	O
not	O
IL-12	B
,	O
whereas	O
expression	O
of	O
c-jun	B
and	O
junD	B
is	O
not	O
modified	O
by	O
either	O
cytokine	B
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	O
and	O
IL-12-	O
stimulated	O
cells	O
may	O
depend,	O
at	O
least	O
in	O
part,	O
on	O
differential	O
gene	O
regulation	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell-specific	O
repressor	O
function	O
,	O
designated	O
SIR	B
(	O
suppressor	B
of	O
immune	O
response	O
genes	O
),	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	B
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR-1	B
gene	O
,	O
whose	O
product,	O
the	O
class	B
II	O
transactivator	O
(	O
CIITA	B
),	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	B
class	B
II	O
genes	O
.	O

Interestingly,	O
in	O
CIITA	B
-transfected	O
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	B
HLA-DQ	O
heterodimer	O
was	O
not	O
observed.	O

Mature	O
human	B
lymphocytes	O
are	O
unique	O
targets	O
of	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha,25(OH)2D3	O
)	O
in	O
that	O
vitamin	B
D	O
receptors	O
(	O
VDR	B
)	O
are	O
not	O
constitutively	O
expressed,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	O
for	O
both	O
the	O
up-regulation	O
of	O
VDR	B
and	O
establishment	O
of	O
reactivity	O
to	O
the	O
lipophilic	O
ligand	O
.	O

In	O
the	O
presence	O
of	O
1	O
alpha,25(OH)2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up-regulation	O
of	O
VDR	B
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	B
binding	O
complexes	O
and	O
the	O
induction	O
of	O
24-hydroxylase	B
message	O
.	O

BCL-2	B
-deficient	O
T	O
cells	O
demonstrate	O
accelerated	O
cell	O
cycle	O
progression	O
and	O
increased	O
apoptosis	O
following	O
activation.	O

In	O
contrast,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	O
substantial	O
affect	O
upon	O
cytokine	B
production	O
.	O

The	O
Tax	B
protein	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
a	O
40-kDa	B
transcriptional	O
activator	O
which	O
is	O
critical	O
for	O
HTLV-1	O
gene	O
regulation	O
and	O
virus-induced	O
cellular	O
transformation	O
.	O

First,	O
Tax	B
was	O
found	O
to	O
interact	O
with	O
the	O
35-kDa	B
(alpha)	O
subunit	O
of	O
TFIIA	B
in	O
the	O
yeast	O
two-hybrid	O
interaction	O
system	O
.	O

Finally,	O
TFIIA	B
facilitates	O
Tax	B
transactivation	O
in	O
vitro	O
and	O
in	O
vivo.	O

Inhibition	O
of	O
transcription	B
factor	O
Stat1	B
activity	O
in	O
mononuclear	B
cell	O
cultures	O
and	O
T	B
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	B
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	B
-activated	O
Janus	B
kinase	O
-STAT	B
signaling	O
pathway	O
.	O

Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C-JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
between	O
2	O
and	O
10	O
microM.	O

Effects	O
of	O
IL-10	B
and	O
IL-4	B
on	O
LPS-induced	O
transcription	B
factors	O
(	O
AP-1	B
,	O
NF-IL6	B
and	O
NF-kappa	B
B	O
)	O
which	O
are	O
involved	O
in	O
IL-6	B
regulation	O
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL-10	B
and	O
IL-4	B
affected	O
the	O
expression	O
of	O
transcription	B
factors	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL-6	B
transcription	O
rate	O
,	O
namely	O
activator	O
protein-1	O
(	O
AP-1	B
),	O
nuclear	B
factor	O
IL-6	B
(	O
NF-IL6	B
),	O
and	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappaB	B
).	O

Binding	O
activity	O
of	O
NF-IL6	B
was	O
also	O
strongly	O
inhibited	O
by	O
IL-4	B
whereas	O
IL-10	B
showed	O
no	O
effect.	O

Furthermore,	O
neither	O
IL-10	B
nor	O
IL-4	B
showed	O
any	O
effect	O
on	O
I-kappa	B
B	O
mRNA	O
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

GM-CSF	B
gene	O
activation	O
in	O
T	B
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	B
factors	O
nuclear	B
factor-kappa	O
B	O
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
Sp1.	O

The	O
GM-CSF	B
promoter	O
CBF	B
site	O
TGTGGTCA	O
is	O
located	O
51	B
bp	O
upstream	O
of	O
the	O
transcription	B
start	O
site	O
and	O
also	O
overlaps	O
a	O
YY-1	B
binding	O
site	O
.	O

This	O
study	O
adds	O
GM-CSF	B
to	O
a	O
growing	O
list	O
of	O
cytokines	B
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	B
and	O
which	O
control	O
the	O
growth,	O
differentiation,	O
and	O
activation	O
of	O
hemopoietic	B
cells	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c-Fos/c-Jun	B
AP-1	B
and	O
the	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	B
).	O

However,	O
PHA/	O
PMA	O
but	O
not	O
oxidative	O
signals	O
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	B
constructs	O
containing	O
the	O
AP-1	B
-TRE	O
,	O
NF-AT	B
,	O
and	O
IL-2	B
promoter	O
regions	O
along	O
with	O
IL-2	B
mRNA	O
expression	O
.	O

Inorganic	O
lead	O
activates	O
NF-kappa	B
B	O
in	O
primary	B
human	O
CD4+	O
T	O
lymphocytes	O
.	O

NF-kappa	B
B	O
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV-LTR	B
activation	O
.	O

Pb	O
did	O
not	O
activate	O
NF-kappa	B
B	O
in	O
4	O
different	O
T	B
cell	O
lines	O
,	O
suggesting	O
that	O
lymphoid	O
cell	O
lines	O
may	O
not	O
be	O
reliable	O
surrogates	O
for	O
the	O
study	O
of	O
transcriptional	O
activation	O
in	O
human	B
T	O
cells	O
.	O

The	O
nature	O
of	O
CD40	B
-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	B
Epstein-Barr	O
virus	O
-negative	O
B	O
lymphocytes	O
is	O
currently	O
unknown.	O

The	O
use	O
of	O
the	O
protein	B
tyrosine	O
kinase	O
(	O
PTK	B
)-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	B
immunodeficiency	O
virus-1	O
long	O
terminal	O
repeat	O
(	O
HIV-1	B
LTR	O
),	O
a	O
promoter	B
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-	B
kappa	O
B	O
).	O

These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	B
activation	O
of	O
B	B
lymphocytes	O
.	O

Up-regulation	O
of	O
RAR(alpha)	B
and	O
PML-RAR	B
gene	O
expression	O
by	O
IFN(alpha)	B
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	B
-dependent	O
granulocytic	O
markers	O
,	O
i.e.,	O
granulocyte-colony-stimulating	B
factor	O
receptor	O
mRNA	O
and	O
leukocyte	B
alkaline	O
phosphatase	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	B
and	O
retinoic	O
acid	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

Dexamethasone	O
inhibited	O
LPS	O
-induced	O
bioactive	O
IL-12	B
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations;	O
it	O
had	O
no	O
effect	O
on	O
IL-10	B
secretion	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and,	O
hence,	O
TH1/TH2	O
balance	O
via	O
the	O
peripheral	O
end-effectors	O
of	O
the	O
stress	O
system	O
.	O

Activation	O
of	O
human	B
monocytic	O
cells	O
by	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
lipoproteins	O
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	B
B	O
.	O

Acylation	O
of	O
OspA	B
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B
lipoproteins	O
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid-restricted	B
gene	O
,	O
LYSP100	B
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	B
.	O

We	O
term	O
the	O
LYSP100	B
structures	O
"	O
LANDs	O
,"	O
for	O
LYSP100	B
-associated	O
nuclear	O
domains	O
.	O

By	O
double-immunogold	O
labeling	O
of	O
PML	B
and	O
LYSP100	B
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	B
and	O
LYSP100	B
.	O

However,	O
more	O
recent	O
studies	O
in	O
human	B
T	B
cell	O
lines	O
have	O
suggested	O
that	O
the	O
N-terminal	B
domain	O
is	O
not	O
necessary	O
for	O
steroid-regulated	O
apoptosis	O
and	O
that	O
GR	B
-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism.	O

In	O
contrast,	O
we	O
found	O
that	O
AR	B
can	O
initiate	O
apoptosis	O
in	O
S49	B
cells	O
after	O
treatment	O
with	O
5	O
alpha-dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

Multiple	O
p21ras	B
effector	O
pathways	O
regulate	O
nuclear	O
factor	O
of	O
activated	B
T	O
cells	O
.	O

Constitutively	O
active	O
MAPKK-1	B
fully	O
activates	O
ERK-2	B
and	O
the	O
transcription	B
factor	O
Elk-1	B
,	O
but	O
does	O
not	O
substitute	O
for	O
activated	O
p21ras	B
and	O
synergize	O
with	O
calcium	O
/calcineurin	B
signals	O
to	O
induce	O
NFAT	B
.	O

Activated	B
Rac-1	B
could	O
mimic	O
activated	B
p21ras	B
to	O
induce	O
AP-1	B
but	O
not	O
to	O
induce	O
NFAT	B
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	B
cells	O
,	O
a	O
specific	O
t(15;17)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O

IL-2-	O
,	O
IL-12-	O
,	O
and	O
IFN-alpha-	O
mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	B
NK	O
cells	O
and	O
in	O
the	O
NK3.3	B
cell	O
line	O
.	O

In	O
NK3.3	B
cells	O
,	O
IL-2	B
induced	O
comparable	O
formation	O
of	O
c-fos	B
promoter	O
sis-inducible	O
element	O
IFN-gamma-activated	B
sequence-binding	O
complexes	O
containing	O
STAT3	B
alone	O
with	O
complexes	O
containing	O
STAT3	B
and	O
STAT1	B
alpha	O
,	O
while	O
in	O
preactivated	B
primary	O
NK	O
cells	O
,	O
it	O
preferentially	O
induced	O
complexes	O
containing	O
STAT3	B
and	O
STAT1	B
alpha	O
.	O

STAT1	B
alpha	O
activation	O
by	O
IL-12	B
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O

Direct	O
evidence	O
that	O
N-acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	B
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF(kappa)B	B
is	O
presented.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(to	O
less	O
than	O
1%)	O
the	O
levels	O
of	O
NF(kappa)B	B
(but	O
not	O
Oct-1	B
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	B
T	O
cells	O
.	O

Signaling	O
by	O
IL-2	B
and	O
related	O
cytokines	B
:	O
JAKs	B
,	O
STATs	B
,	O
and	O
relationship	O
to	O
immunodeficiency.	O

The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B
c	O
and	O
JAK3	B
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
).	O

Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
).	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	B
protein	O
and	O
mRNA	B
in	O
peripheral	B
blood	O
mononuclear	O
cells	O
.	O

Vitamin	O
D3-	O
and	O
retinoic	O
acid-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	B
vitamin	O
D3	O
receptor	O
,	O
retinoic	B
acid	O
receptors	O
,	O
and	O
retinoid	B
X	O
receptors	O
in	O
U-937	B
cells	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR	B
/RXR	O
DNA-binding	O
complexes	O
on	O
both	O
VitD3	B
response	O
elements	O
and	O
RA	B
response	O
elements	O
(	O
RAREs	B
).	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA	O
-stimulated	O
formation	O
of	O
RAR	B
beta	O
/RXR	O
heterodimers	O
,	O
favoring	O
VDR	B
/RXR	B
binding	O
to	O
the	O
RARE	B
.	O

The	O
human	B
T-cell	O
leukemia	O
virus	O
type	O
1	O
posttranscriptional	O
trans-activator	O
Rex	B
contains	O
a	O
nuclear	B
export	O
signal	O
.	O

Granulocyte-macrophage	B
colony-stimulating	O
factor	O
preferentially	O
activates	O
the	O
94-kD	B
STAT5A	O
and	O
an	O
80-kD	B
STAT5A	O
isoform	O
in	O
human	O
peripheral	O
blood	O
monocytes.	O

Freshly	O
isolated	O
monocytes	O
expressed	O
94-kD	B
STAT5A	B
,	O
92-kD	O
STAT5B	B
,	O
and	O
an	O
80-kD	B
STAT5A	B
molecule	O
.	O

Therefore,	O
activation	O
of	O
STAT5A	B
predominates	O
compared	O
to	O
STAT5B	B
when	O
assayed	O
by	O
direct	O
immunoprecipitation	O
and	O
by	O
evaluation	O
of	O
bound	O
STATs	B
to	O
immobilized	O
GRR	B
.	O

She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	B
cells	O
at	O
presentation.	O

Cosmid	B
probe	O
of	O
BCL6	B
hybridized	O
to	O
14q11	B
and	O
3q27	B
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
).	O

The	O
translocation	O
found	O
in	O
acute	O
promyelocytic	O
leukemia	O
rearranges	O
the	O
promyelocytic	B
leukemia	O
gene	O
(	O
PML	B
)	O
on	O
chromosome	B
15	O
with	O
the	O
retinoic	B
acid	O
receptor	O
alpha	O
(	O
RARalpha	B
)	O
on	O
chromosome	B
17	O
.	O

A	O
full-length	O
PML/RARalpha	B
cDNA	O
driven	O
by	O
the	O
CD11b	B
promoter	O
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O

However,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	B
progenitors	O
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte/	B
macrophage	O
colony-stimulating	O
factor	O
.	O

As	O
expected,	O
nearly	O
all	O
control	O
mice	O
(94.4%)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8%	O
of	O
PML/RARalpha	B
transgenic	O
mice	O
.	O

C/EBP	B
activators	O
are	O
required	O
for	O
HIV-1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	B
cell	O
lines	O
.	O

U1	B
lines	O
overexpressing	O
C/EBP	B
activator	O
NF-IL-6	B
produced	O
more	O
viral	B
mRNA	O
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	B
lines	O
,	O
demonstrating	O
that	O
C/EBP	B
proteins	O
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

B-cell	B
immortalization	O
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B
in	O
a	O
number	O
of	O
normal	O
cell	O
types.	O

Tissue-specific	O
expression	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
is	O
mediated	O
via	O
cis-acting	B
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	B
start	O
.	O

Together	O
the	O
Act-1	B
and	O
CBF	B
sites	O
form	O
a	O
functional	B
unit	O
(	O
AC	B
unit	O
)	O
with	O
dual	O
activity.	O

Finally,	O
a	O
novel	O
positive	B
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL-3	B
promoter	O
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	B
cells	O
.	O

Therefore,	O
any	O
event	O
that	O
enables	O
T	B
cells	O
to	O
become	O
less	O
responsive	O
to	O
IFN-	B
gamma	O
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	B
.	O

T	B
cell	O
blasts	O
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN-gamma	B
.	O

Although	O
transcriptional	B
factors	O
AP-1	B
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	B
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL-2	B
,	O
it	O
is	O
unknown	O
if	O
the	O
age-related	O
decline	O
in	O
IL-2	B
production	O
by	O
activated	O
human	B
T	O
cells	O
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	B
regulatory	O
proteins	O
.	O

By	O
contrast,	O
T	B
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL-2	B
production	O
exhibited	O
normal	O
activation	O
of	O
AP-1	B
and	O
NF-AT	B
.	O

IL-13	B
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	B
Janus	O
kinase	O
in	O
human	B
colon	O
carcinoma	O
cell	O
lines	O
:	O
similarities	O
between	O
IL-4	B
and	O
IL-13	B
signaling.	O

Within	O
1	O
min	O
of	O
activation,	O
JAK2	B
was	O
phosphorylated,	O
and	O
peaked	O
in	O
10	O
min.	O

Both	O
IL-13	B
and	O
IL-4	B
induced	O
phosphorylation	O
of	O
IL-4	B
STAT	O
(	O
STAT6	B
)	O
but	O
not	O
STAT1	B
,	O
STAT3	B
,	O
or	O
STAT5	B
.	O

IL-4	B
and	O
IL-10	B
inhibit	O
the	O
cytokine	B
production	O
and	O
mRNA	O
expression	O
by	O
monocytes/macrophages	B
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	B
,	O
but	O
not	O
IL-10	B
,	O
inhibited	O
nuclear	O
NF-kappaB	B
activity	O
,	O
and	O
that	O
IL-4	B
and	O
IL-10	B
did	O
not	O
affect	O
NF-	O
IL-6	B
activity	O
.	O

Activation	O
of	O
nuclear	B
factor	O
of	O
activated	O
T	B
cells	O
in	O
a	O
cyclosporin	O
A	O
-resistant	O
pathway	O
.	O

We	O
demonstrate	O
here,	O
however,	O
that	O
NFAT	B
can	O
be	O
activated,	O
and	O
significant	O
levels	O
of	O
IL-2	B
can	O
be	O
produced	O
by	O
the	O
CsA	O
-resistant	O
CD28	B
-signaling	O
pathway	O
.	O

Collectively,	O
these	O
data	O
suggest	O
that	O
NFAT	B
can	O
be	O
activated	O
and	O
IL-2	B
can	O
be	O
produced	O
in	O
a	O
calcineurin	B
independent	O
manner	O
.	O

IL-10	B
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
)	O
release	O
in	O
PBMC	B
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90%	O
inhibition	O
noted	O
with	O
10	O
U/ml.	O

In	O
contrast,	O
inhibition	O
of	O
IL-1	B
beta	O
mRNA	O
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL-10	B
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

Inhibition	O
by	O
IL-10	B
of	O
proinflammatory	B
cytokine	O
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF-alpha	B
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	B
.	O

p60	B
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent,	O
and	O
was	O
induced	O
by	O
cell-permeable	O
diacylglycerol	O
,	O
but	O
not	O
by	O
inactive	O
phorbol	O
esters	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	B
factors	O
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

Several	O
methods	O
for	O
specific	O
down-regulation	O
of	O
transcription	B
factors	O
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O

Although	O
the	O
mechanism	O
of	O
LTR	B
activation	O
remains	O
obscure,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF-kappa	B
B	O
transcription	B
factor	O
(s)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O

Receptors	O
for	O
interleukin	O
(IL)-10	O
and	O
IL-6	O
-type	O
cytokines	O
use	O
similar	O
signaling	O
mechanisms	O
for	O
inducing	O
transcription	O
through	O
IL-6	B
response	O
elements	O
.	O

The	O
cell	O
response	O
to	O
IL-10	B
characteristically	O
differed	O
from	O
that	O
to	O
IL-2/IL-15	B
,	O
IL-4	B
,	O
and	O
interferon	B
gamma	O
.	O

The	O
IL-10R	B
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL-6-responsive	B
gene	O
elements	O
,	O
reconstituted	O
in	O
hepatoma	B
cells	O
an	O
induction	O
of	O
transcription	O
by	O
IL-10	B
that	O
was	O
comparable	O
to	O
that	O
by	O
IL-6	B
.	O

The	O
data	O
demonstrate	O
that	O
the	O
IL-10R	B
,	O
unlike	O
other	O
members	O
of	O
the	O
interferon	O
receptor	O
family,	O
is	O
highly	O
effective	O
in	O
recruiting	O
the	O
signaling	O
pathways	O
of	O
IL-6	B
-type	O
cytokine	O
receptors	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	B
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	B
trans-activator	O
,	O
a	O
crucial	O
MHC	B
class	O
II	O
gene	O
regulatory	O
factor	O
.	O

However,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	B
,	O
either	O
IFN-gamma	B
-induced	O
or	O
not,	O
and	O
the	O
constitutive	O
B	B
cells	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	B
necrosis	O
factor	O
(TNF)-alpha	O
gene	O
and	O
on	O
nuclear	B
factor	O
(NF)-kappa	O
B	O
activation	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner.	O

E3330	O
decreased	O
activated	O
NF-kappa	B
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF-kappa	B
B	O
activation	O
and/or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Pax-5	B
encodes	O
the	O
transcription	B
factor	O
BSAP	B
which	O
plays	O
an	O
essential	O
role	O
in	O
early	O
B	O
cell	O
development	O
and	O
midbrain	O
patterning	O
.	O

The	O
function	O
of	O
the	O
transactivation	B
domain	O
is	O
negatively	O
regulated	O
by	O
adjacent	O
sequences	O
from	O
the	O
extreme	B
C-terminus	O
.	O

Second	O
messenger	O
up-regulation	O
of	O
androgen	B
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	B
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC-3	B
and	O
DU-145	B
.	O

The	O
ability	O
to	O
regulate	O
AR	B
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	O
and	O
DU-145	O
cell	O
lines	O
.	O

Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types,	O
including	O
monocyte/macrophages	B
.	O

Within	O
the	O
above	O
region,	O
the	O
fragment	O
spanning	O
nucleotides	B
-158	O
to	O
-90	O
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	B
cells	O
.	O

HLA-DQB1	B
codon	O
57	O
is	O
critical	O
for	O
peptide	O
binding	O
and	O
recognition	O
.	O

We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen-specific	O
T	O
cell	O
stimulation	O
.	O

This	O
structural	O
and	O
functional	O
complementarity	O
for	O
residue	O
57	O
and	O
a	O
specific	O
peptide	O
residue	O
identifies	O
this	O
interaction	O
as	O
a	O
key	O
controlling	O
determinant	O
of	O
restricted	O
recognition	O
in	O
HLA-DQ	O
-specific	O
immune	O
response	O
.	O

We	O
report	O
here	O
that	O
a	O
DNA-binding	B
factor	O
containing	O
STAT1	B
also	O
becomes	O
activated	O
in	O
human	B
peripheral	O
blood	O
T	O
lymphocytes	O
or	O
Jurkat	B
cells	O
,	O
although	O
not	O
until	O
1-2	O
h	O
after	O
stimulation.	O

Therefore,	O
a	O
STAT1	B
transcription	B
factor	O
is	O
activated	O
by	O
IFN-gamma	B
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	B
lymphocyte	O
populations	O
.	O

The	O
information	O
obtained	O
from	O
these	O
cell	B
lines	O
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H-RS	B
cells	O
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	B
markers	O
and	O
Ig/TcR	B
gene	O
rearrangements	O
in	O
these	O
cells.	O

All	O
three	O
types	O
of	O
H-RS	B
cell	O
lines	O
were	O
consistently	O
negative	O
for	O
BSAP	B
,	O
TCF-1	B
,	O
and	O
GATA-3	B
.	O

The	O
absence	O
of	O
BSAP	B
,	O
TCF-1	B
,	O
and	O
GATA-3	B
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H-RS	B
cells	O
and	O
lymphoid	B
cells	O
.	O

Raf-1	B
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	B
lymphocytes	O
.	O

Expression	O
of	O
the	O
MAP	B
kinase-specific	O
phosphatase	O
,	O
MKP-1	B
,	O
which	O
blocks	O
ERK	B
activation	O
,	O
inhibited	O
IL-2	B
promoter	O
and	O
NF-AT	B
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition,	O
MKP-1	B
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
demonstrated	O
that	O
IL-9	B
gene	O
expression	O
is	O
controlled,	O
at	O
least	O
in	O
part,	O
by	O
transcriptional	O
activation.	O

Within	O
this	O
region,	O
an	O
NF-kappaB	B
site	O
at	O
-59	B
to	O
-50	O
and	O
its	O
adjacent	O
20-base	B
pair	O
upstream	O
sequence	O
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL-9	B
promoter	O
activity	O
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
gene	O
expression	O
in	O
human	O
T	O
cells.	O

We	O
investigated	O
oligonucleotide	O
-directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	B
sequence	O
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM-CSF	B
gene	O
transcription	O
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	B
T-cell	O
lymphotrophic	O
virus-1	O
Tax	O
transactivator-induced	O
luciferase	B
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM-CSF	B
promoter	O
in	O
Jurkat	B
T	O
cells	O
.	O

Reversible	O
differentiation	O
of	O
human	B
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	B
light	O
chain	O
kinase	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)-reducing	O
activity	O
of	O
U937	B
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day,	O
respectively.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	B
monoblastic	O
cells	O
,	O
THP-1	B
.	O

it	O
became	O
irreversible,	O
however,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	B
growth	O
factor-beta	O
1	O
(	O
TGF-beta	B
1	O
),	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	B
cells	O
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	B
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram-negative	O
bacteria	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM-CSF	B
induced	O
the	O
production	O
of	O
proinflammatory	B
cytokines	O
,	O
IL-8	B
,	O
IL-1	B
beta	O
and	O
IL-6	B
,	O
but	O
not	O
TNF-alpha	B
.	O

Herpesvirus	B
saimiri	O
immortalized	O
gamma	O
delta	O
T	O
cell	O
line	O
activated	O
by	O
IL-12	B
.	O

To	O
gain	O
further	O
knowledge	O
of	O
the	O
IL-12R	B
complex	O
and	O
the	O
IL-12	B
signal	O
transduction	O
pathway	O
in	O
cytotoxic	B
T	O
cells	O
,	O
we	O
studied	O
a	O
number	O
of	O
human	B
T	O
cell	O
lines	O
that	O
had	O
been	O
transformed	O
to	O
permanent	O
growth	O
with	O
Herpesvirus	O
saimiri	O
,	O
an	O
oncogenic	O
virus	O
of	O
nonhuman	O
primates	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B-lymphocyte	O
and	O
T-lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription.	O

We	O
describe	O
the	O
isolation	O
of	O
human	B
LH-2	O
,	O
a	O
putative	B
transcription	O
factor	O
containing	O
two	O
cysteine	B
-rich	O
regions	O
(	O
LIM	B
domains	O
)	O
and	O
a	O
homeobox	B
(Hox)	O
DNA-binding	O
domain	O
.	O

In	O
addition	O
to	O
finding	O
hLH-2	B
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	B
cell	O
lines	O
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O

In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4+	B
infected	O
T-lymphoid	O
cells	O
.	O

At	O
the	O
cellular	O
level,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	B
lymphocytes	O
.	O

These	O
cells	O
showed	O
reduced	O
numbers	O
of	O
binding	B
sites	O
with	O
little	O
alteration	O
in	O
apparent	O
affinity	O
between	O
ligand	O
and	O
receptor.	O

Transcription	B
factor	O
NF-E2	O
is	O
crucial	O
for	O
regulation	O
of	O
erythroid-specific	O
gene	O
expression	O
.	O

As	O
neutrophils	B
occupy	O
approximately	O
92%	O
of	O
the	O
cells	O
in	O
this	O
fraction,	O
the	O
cells	O
expressing	O
p45	B
is	O
most	O
likely	O
to	O
be	O
neutrophils	B
.	O

The	O
expression	O
of	O
p45	B
megakaryocytic	B
lineage	O
cells	O
,	O
p45	B
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF-E2	B
promoter	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	B
binding	O
activity	O
from	O
p62c-fos	B
,	O
and	O
p39c-jun	B
AP-1	B
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2/M-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S-phase	O
enriched	O
samples	O
of	O
HL60	B
cells	O
,	O
while	O
levels	O
of	O
nuclear	O
p62c-fos	O
and	O
p39c-jun	O
were	O
constant.	O

However,	O
no	O
cytoplasmic	B
p62c-fos	B
was	O
detected	O
in	O
unstimulated	B
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	B
p39c-jun	B
was	O
detected,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	B
may	O
occur	O
under	O
certain	O
circumstances.	O

Here	O
we	O
show	O
that	O
the	O
murine	B
PU.1	B
promoter	O
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	B
cell	O
lines	O
as	O
well.	O

This	O
B	B
cell	O
restricted	O
coactivator	B
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	B
mediated	O
by	O
the	O
octamer	B
site	O
.	O

In	O
the	O
present	O
study,	O
we	O
demonstrate	O
that	O
signal-mediated	O
induction	O
of	O
p105	B
processing	O
in	O
human	B
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	B
protein	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	B
undergoes	O
degradation	O
in	O
lipopolysaccharide	B
-stimulated	O
human	O
monocytic	O
cells	O
.	O

Resting	B
T	O
cells	O
express	O
very	O
low	O
levels	O
of	O
c-Myb	B
protein	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c-myb	B
5'	O
flanking	O
sequence	O
in	O
activated	B
T	O
cells	O
but	O
not	O
in	O
unactivated	B
T	O
cells	O
.	O

The	O
NFAT	B
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
than	O
the	O
CMAT	B
protein	O
did.	O

CNI-1493	O
inhibits	O
monocyte/macrophage	B
tumor	O
necrosis	O
factor	O
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

CNI-1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(LPS)-induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	B
mRNA	O
nor	O
the	O
translocation	O
of	O
nuclear	B
factor	O
NF-kappa	O
B	O
to	O
the	O
nucleus	O
in	O
macrophages	B
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI-1493	O
does	O
not	O
interfere	O
with	O
early	O
NF-kappa	B
B	O
-mediated	O
transcriptional	O
regulation	O
of	O
TNF	B
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	B
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

Maximal	O
inhibition	O
of	O
p24	B
antigen	O
production	O
in	O
T-lymphocytic	B
ACH-2	O
cells	O
was	O
47%	O
with	O
r-hTBP-1	B
and	O
42%	O
with	O
rhu	B
TNFR:Fc	O
.	O

r-hTBP-1	B
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

The	O
human	B
T-cell	O
leukemia	O
virus	O
-encoded	O
tax	B
protein	O
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
genes	O
transcribed	O
by	O
RNA	B
polymerase	O
II	O
.	O

Surprisingly,	O
we	O
find	O
that	O
Tax	B
increases	O
the	O
effective	O
concentration	O
of	O
active	B
TFIIIB	B
molecules	O
.	O

Its	O
effects	O
are	O
mediated	O
by	O
its	O
nuclear	B
receptor	O
(	O
VDR	B
).	O

We	O
also	O
demonstrated	O
that	O
fresh	O
leukemic	B
cells	O
,	O
whatever	O
their	O
stage	O
of	O
differentiation,	O
as	O
well	O
as	O
myelomonocytic	B
cell	O
lines	O
,	O
respond	O
to	O
VD	O
by	O
an	O
increase	O
in	O
RXR	B
alpha	O
levels.	O

T-cell	O
prolymphocytic	O
leukemia	O
(	O
T-PLL	O
),	O
a	O
rare	O
form	O
of	O
mature	O
T-cell	O
leukemias	O
,	O
and	O
ataxia	O
telangiectasia	O
clonal	O
proliferation	O
,	O
a	O
related	O
condition	O
occurring	O
in	O
patients	O
suffering	O
from	O
ataxia	O
telangiectasia	O
,	O
have	O
been	O
associated	O
to	O
translocations	O
involving	O
the	O
14q32.1	B
or	O
Xq28	B
regions	O
,	O
where	O
are	O
located	O
the	O
TCL1	B
and	O
MTCP1	B
putative	O
oncogenes	O
,	O
respectively.	O

We	O
have	O
generated	O
rabbit	O
antisera	O
against	O
this	O
putative	O
p13MTCP1	B
protein	O
and	O
screened	O
for	O
expression	O
of	O
p13MTCP1	B
normal	O
lymphoid	O
tissues	O
and	O
33	O
cases	O
of	O
immature	O
and	O
mature	O
lymphoid	O
T-cell	O
proliferations	O
using	O
a	O
sensitive	O
Western	O
blot	O
assay	O
.	O

Preassociation	O
of	O
STAT1	B
with	O
STAT2	B
and	O
STAT3	B
in	O
separate	O
signalling	B
complexes	O
prior	O
to	O
cytokine	B
stimulation	O
.	O

When	O
unstimulated	B
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B
or	O
STAT2	B
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	B
protein	O
.	O

Newly	O
translated	O
STAT1	B
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B
and	O
STAT3	B
,	O
but	O
we	O
show	O
that	O
STAT2	B
and	O
STAT3	B
exist	O
in	O
separate	O
heterocomplexes	B
with	O
STAT1	B
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	B
proteins	O
.	O

Priming	O
of	O
human	B
monocytes	O
with	O
IFN-gamma	B
resulted	O
in	O
the	O
down	O
regulation	O
of	O
c-fos	O
and	O
c-jun	O
mRNA	O
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone.	O

Priming	O
with	O
IFN-gamma	B
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	B
mRNA	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	B
contained	O
p50	B
and	O
p65	B
protein	O
in	O
response	O
to	O
LPS	O
and	O
IFN-gamma	B
stimulation	O
.	O

HIV-1	B
tat	O
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	B
cell-specific	O
transcription	O
factor	O
and	O
downregulates	O
MIP-1	B
alpha	O
gene	O
expression	O
in	O
activated	B
T-cells	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	B
B-cells	O
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	B
in	O
Jurkat	B
T-cells	O
expressing	O
HIV-1	B
tat	O
.	O

Interleukin-4	B
(	O
IL-4	B
)	O
and	O
interleukin-12	B
(	O
IL-12	B
)	O
control	O
the	O
differentiation	O
of	O
T-helper	B
cells	O
.	O

Receptor/Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	B
homology	O
2	O
(SH2)	O
domain	O
of	O
the	O
corresponding	O
Stat	B
protein	O
.	O

Role	O
of	O
EGR1	B
in	O
regulation	O
of	O
stimulus-dependent	O
CD44	B
transcription	O
in	O
B	O
lymphocytes.	O

Kinetics	O
of	O
egr-1	B
transcription	O
and	O
the	O
appearance	O
of	O
nuclear	O
EGR1	B
protein	O
precede	O
CD44	B
induction	O
and	O
occur	O
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1	B
-expressing	O
subclone	O
.	O

These	O
studies	O
identify	O
EGR1	B
as	O
an	O
intermediary	O
linking	O
BCR	B
-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B
.	O

In	O
Jurkat	B
cells	O
this	O
effect	O
was	O
rapid	O
and	O
transient,	O
but	O
in	O
Wurzburg	B
cells	O
the	O
response	O
was	O
slow	O
and	O
sustained.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[Ca2+]i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant-induced	O
NF-kappaB	B
activation	O
.	O

IL-1alpha	B
promoter	O
constructs	O
drive	O
transcription	O
of	O
the	O
chloramphenicol	B
acetyltransferase	O
(CAT)	O
reporter	O
gene	O
in	O
HTLV-I	B
-positive	O
MT-2	O
cells	O
,	O
which	O
constitutively	O
produce	O
IL-1alpha	B
.	O

Moreover,	O
deletion	O
of	O
either	O
5'	O
or	O
3'	O
NF-kappaB	O
sites	O
reduced	O
IL-1alpha	B
promoter	O
activity	O
in	O
MT-2	B
cells	O
and	O
transactivation	O
of	O
the	O
IL-1alpha	B
promoter	O
by	O
exogenous	O
NF-kappaB	B
and	O
Tax	B
in	O
Jurkat	B
cells	O
.	O

The	O
protein	O
product	O
of	O
the	O
c-fps/fes	B
(c-fes)	O
proto-oncogene	O
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	B
cells	O
(	O
macrophages	B
and	O
neutrophils	B
).	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	B
human	O
c-fes	O
locus	O
contained	O
positive	B
cis-acting	O
elements	O
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	B
sequences	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	B
region	O
contains	O
nuclear	B
protein	O
binding	O
sites	O
for	O
Sp1	B
,	O
PU.1	B
,	O
and/or	O
Elf-1	B
,	O
and	O
a	O
novel	B
factor	O
.	O

We	O
conclude	O
that	O
the	O
human	B
c-fes	O
gene	O
contains	O
a	O
strong	O
myeloid-cell-specific	B
promoter	O
that	O
is	O
regulated	O
by	O
Sp1	B
,	O
PU.1	B
,	O
and	O
a	O
novel	O
transcription	B
factor	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA-protein	B
complexes	O
with	O
Abs	B
recognizing	O
specific	O
components	O
of	O
the	O
NF-kappa	B
B/Rel	O
protein	O
family	O
,	O
the	O
p50/p65	B
(	O
Rel	B
A	O
)	O
heterodimeric	O
form	O
of	O
NF-kappa	B
B	O
is	O
primarily	O
affected.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	B
B-driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	B
factors	O
.	O

In	O
a	O
panel	O
of	O
32	O
B-cell	B
lines	O
,	O
A-myb	B
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
),	O
4	O
non-Hodgkin's	O
lymphoma	O
(	O
NHL	O
),	O
6	O
Epstein-Barr	B
virus-immortalized	O
lymphoblastoid	O
cell	O
lines	O
,	O
and	O
6	O
myeloma	B
lines	O
.	O

A-myb	B
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(PLL)	O
but	O
was	O
strongly	O
expressed	O
in	O
5/20	O
(25%)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(CLL)	O
samples	O
.	O

Thus,	O
A-myb	B
expression	O
,	O
unlike	O
that	O
of	O
c-myb	B
and	O
B-myb	B
,	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
B-cell	O
neoplasias	O
(in	O
particular	O
BL	O
and	O
slg+B-	O
ALL	O
)	O
representative	O
of	O
a	O
specific	O
stage	O
of	O
B-cell	O
differentiation	O
.	O

Granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
),	O
supports	O
proliferation	O
,	O
differentiation	O
,	O
and	O
functional	O
activation	O
of	O
hemopoietic	O
cells	O
by	O
its	O
interaction	O
with	O
a	O
heterodimeric	O
receptor.	O

Moreover	O
GM-CSF	B
was	O
able	O
to	O
induce	O
JAK2	B
and	O
p93fes	B
catalytic	O
activity	O
.	O

Epstein-Barr	B
virus	O
nuclear	O
antigen	O
2	O
(EBNA2)-oestrogen	O
receptor	O
fusion	O
proteins	O
complement	O
the	O
EBNA2-deficient	O
Epstein-Barr	O
virus	O
strain	O
P3HR1	O
in	O
transformation	O
of	O
primary	B
B	O
cells	O
but	O
suppress	O
growth	O
of	O
human	B
B	O
cell	O
lymphoma	O
lines	O
.	O

Unexpectedly,	O
expression	O
of	O
the	O
same	O
EBNA2	B
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	B
human	O
B	O
cell	O
lymphoma	O
lines	O
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O

Tissue-specific	O
activity	O
of	O
the	O
gammac	B
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	B
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA-binding	B
protein	O
.	O

The	O
-1053/+34	B
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	B
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested.	O

These	O
results	O
indicate	O
that,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	B
promoter	O
,	O
GA-binding	B
protein	O
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

The	O
molecular	O
mechanisms	O
associated	O
with	O
the	O
T-cell	O
dysfunction	O
remain	O
to	O
be	O
elucidated.	O

Antibodies	O
to	O
Stat6	B
detected	O
a	O
unique	O
band	O
in	O
macaque	O
cell	O
lysates	O
.	O

To	O
achieve	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
transactivation	O
by	O
Tax	B
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B
-responsive	O
element	O
1	O
(	O
TRE-1	B
),	O
we	O
developed	O
a	O
genetic	O
approach	O
with	O
Saccharomyces	O
cerevisiae	O
.	O

However,	O
expression	O
of	O
the	O
reporter	B
gene	O
was	O
induced	O
by	O
coexpression	O
of	O
Tax	B
and	O
CREB	B
.	O

Of	O
five	O
positive	O
clones	O
isolated	O
from	O
0.75	O
x	O
10(6)	O
yeast	O
colonies,	O
four	O
were	O
members	O
of	O
the	O
CREB/activating	B
transcription	O
factor	O
(ATF)	O
family	O
:	O
CREB	B
,	O
two	B
isoforms	O
of	O
the	O
cyclic	O
AMP-responsive	O
element	O
modulator	O
(	O
CREM	B
),	O
and	O
ATF-1	B
.	O

The	O
fifth	O
clone	O
identified	O
in	O
this	O
screening	O
corresponded	O
to	O
the	O
Ku	B
autoantigen	O
p70	O
subunit	O
.	O

A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	B
deacetylase	O
activity	O
.	O

Interleukin-13	B
(	O
IL-13	B
)	O
and	O
IL-4	B
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23-31	O
region	O
of	O
human	O
chromosome	O
5.	O

Mutation	O
of	O
the	O
IL-13	B
P	O
element	O
site	O
significantly	O
reduced	O
IL-13	B
promoter	O
activity	O
in	O
response	O
to	O
T-cell	O
activation	O
.	O

Inhibition	O
of	O
alpha	B
interferon	O
but	O
not	O
gamma	B
interferon	O
signal	O
transduction	O
by	O
phorbol	O
esters	O
is	O
mediated	O
by	O
a	O
tyrosine	B
phosphatase	O
.	O

Phorbol	O
ester	O
treatment	O
of	O
monocytes	O
inhibited	O
IFN	O
alpha-stimulated	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factors	O
Stat1alpha	B
,	O
Stat2	B
,	O
and	O
Stat3	B
and	O
of	O
the	O
tyrosine	B
kinase	O
Tyk2	B
but	O
had	O
no	O
effect	O
on	O
IFN-gamma	B
activation	O
of	O
Stat1alpha	B
.	O

These	O
observations	O
suggest	O
that	O
PMA	O
exerts	O
its	O
inhibitory	O
effects	O
by	O
activation	O
of	O
a	O
tyrosine	B
phosphatase	O
which	O
selectively	O
regulates	O
Tyk2	B
but	O
not	O
Jak1	B
activity	O
.	O

Interleukin-2	B
(	O
IL-2	B
)	O
promoter	O
-reporter	B
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	B
gene	O
in	O
response	O
to	O
T	B
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

We	O
conclude	O
that	O
IL-2	B
transcriptional	O
regulation	O
differs	O
in	O
tumor	B
cell	O
lines	O
compared	O
with	O
normal	B
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis-elements	B
in	O
the	O
IL-2	B
promoter	O
.	O

Specifically,	O
9-cis-RA	O
potently	O
inhibited	O
the	O
growth	O
of	O
BFU-E	O
response	O
to	O
erythropoietin	B
(	O
Epo	B
)	O
(100%),	O
stem	B
cell	O
factor	O
(	O
SCF	B
)	O
+	O
Epo	B
(92%),	O
IL-3	B
+	O
Epo	B
(97%),	O
IL-4	B
+	O
Epo	B
(88%),	O
and	O
IL-9	B
+	O
Epo	B
(100%).	O

At	O
this	O
concentration,	O
Ro	O
13-7410	O
potently	O
inhibited	O
G-CSF	B
-stimulated	O
myeloid	O
as	O
well	O
as	O
SCF	B
+	O
Epo	B
-induced	O
erythroid	O
colony	O
growth	O
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto-differentiating	O
effects	O
on	O
acute	B
promyelocytic	O
leukemia	O
cells	O
.	O

After	O
treatment	O
of	O
APL	B
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	B
colony-stimulating	O
factor	O
(	O
G-CSF	B
),	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	O
alkaline	O
phosphatase	O
,	O
CD11b	O
,	O
CD33	O
,	O
and	O
G-CSF	O
receptor	O
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects.	O

Binding	O
experiments,	O
using	O
COS-7	B
cells	O
transiently	O
transfected	O
with	O
PML-RAR	B
and	O
the	O
normal	O
RAR	B
alpha	O
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	B
of	O
the	O
human	O
osteocalcin	O
and	O
the	O
mouse	O
osteopontin	O
gene	O
promoters	O
.	O

BCL-6	B
expression	O
during	O
B-cell	O
activation.	O

Resting	O
B	O
and	O
T	O
lymphocytes	O
contain	O
high	O
levels	O
of	O
BCL-6	B
mRNA	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	B
cells	O
in	O
vitro	O
invariably	O
decreased	O
BCL-6	B
MRNA	O
expression,	O
activated	B
B	O
cells	O
from	O
human	O
germinal	O
centers	O
expressed	O
BCL-6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells.	O

To	O
define	O
novel	B
proteins	O
involved	O
in	O
the	O
early	O
transcriptional	O
response	O
during	O
the	O
activation	O
of	O
human	B
T	O
lymphocytes	O
,	O
we	O
used	O
a	O
high-resolution,	O
two-dimensional	O
gel	O
electrophoresis	O
system	O
to	O
identify	O
nuclear,	B
deoxyribonucleic	B
acid	O
(DNA)	O
binding	O
proteins	O
exhibiting	O
rapid	O
changes	O
in	O
phosphorylation	O
following	O
cell	O
stimulation.	O

Phosphoamino	O
acid	O
analysis	O
revealed	O
several	O
sets	O
of	O
proteins	O
with	O
different	O
phosphorylated	O
residues	O
Kinetic	O
analysis	O
of	O
the	O
phosphorylation	O
of	O
the	O
selected	O
proteins	O
was	O
performed	O
and	O
revealed	O
a	O
complex	O
group	O
of	O
transient	O
and	O
sustained	O
responses	O
to	O
cell	O
activation	O
.	O

In	O
resting	B
T	O
lymphocytes	O
,	O
the	O
transcription	B
factor	O
NF-kappaB	B
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	B
kappa	O
B	O
family	O
of	O
inhibitors,	O
including	O
IkappaBalpha	B
and	O
IkappaBbeta	B
.	O

However,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B
protein	O
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	B
response	O
.	O

Consequently,	O
IkappaBbeta	B
protein	O
expression	O
is	O
chronically	O
downregulated	O
in	O
HTLV-1	B
-infected	O
T	O
lymphocytes	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B
protein	O
by	O
cyclin-dependent	O
kinases	O
4	O
and	O
6	O
prevents	O
its	O
interaction	O
with	O
the	O
transcription	B
factor	O
E2F	B
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	B
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	B
kinase	O
.	O

Transient	O
expression	O
of	O
p16	B
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT-4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B
protein	O
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	B
gene	O
contains	O
a	O
transcriptional	B
activator	O
(	O
META	B
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	B
terminal	O
repeat	O
region	O
.	O

META(D+)	B
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	B
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible,	O
CsA	B
-sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	B
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Among	O
T-cell	B
lines	O
investigated,	O
ICSAT	B
was	O
abundantly	O
expressed	O
in	O
human	B
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)-infected	O
T	O
cells	O
.	O

ICSAT	B
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	B
stimulation	O
or	O
by	O
IRF-1	B
cotransfection	O
.	O

Regulation	O
of	O
[	O
Ca2+	O
]i	O
rise	O
activated	O
by	O
doxepin-sensitive	B
H1-histamine	O
receptors	O
in	O
Jurkat	B
cells	O
,	O
cloned	B
human	O
T	O
lymphocytes	O
.	O

Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine	O
-induced	O
[	O
Ca2+	O
]i	O
rise	O
.	O

STAT-related	O
transcription	B
factors	O
are	O
constitutively	O
activated	O
in	O
peripheral	B
blood	O
cells	O
from	O
acute	O
leukemia	O
patients	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	O
gene	O
promoters	O
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B
proteins	O
in	O
nuclear	O
extracts	O
from	O
acute	B
leukemia	O
cells	O
in	O
bandshift	O
assays	O
.	O

STAT5-	O
and	O
STAT1-	O
related	O
factors	O
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	O
,	O
STAT3-	O
,	O
and	O
STAT5-	O
related	O
proteins	O
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	B
factor	O
specific	O
to	O
adult	B
hematopoietic	O
cells	O
(	O
polypryrimidine-binding	B
factor	O
,	O
PYBF	B
)	O
binds	O
to	O
a	O
pyrimidine-rich	B
region	O
1	B
kb	O
upstream	O
from	O
the	O
human	B
delta-globin-encoding	O
gene	O
(	O
HBD	B
).	O

The	O
results	O
suggest	O
that	O
PYBF	B
and	O
the	O
pyrimidine-rich	B
region	O
upstream	O
from	O
HBD	B
can	O
specifically	O
enhance	O
HBB	B
transcription	O
in	O
adult	B
erythroid	O
cells	O
.	O

Here,	O
we	O
present	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
data	O
from	O
a	O
new	O
CMPD1	O
/SRA1	O
patient	O
with	O
t(6;17)(q14;q24)	B
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi-B	B
transcription	B
factor	O
.	O

Up	O
to	O
date,	O
the	O
biological	O
function	O
of	O
Spi-B	B
remains	O
unknown.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	B
Spi-B	B
might	O
affect	O
Spi-B	B
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi-B	B
activity	O
.	O

Both	O
CIITA	B
and	O
Bob1	B
increase	O
the	O
expression	O
from	O
the	O
DRA	B
promoter	O
,	O
which	O
is	O
a	O
prototypic	O
class	B
II	O
promoter	O
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF-kappaB	O
and	O
Sp1	O
binding	O
elements	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	O
and	O
R	O
regions	O
of	O
proviral	B
DNA	O
from	O
CEMxl74	B
cells	O
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Analysis	O
of	O
long	B
terminal	O
repeat	O
-driven	O
secreted	O
alkaline	B
phosphatase	O
activity	O
in	O
transient	O
assays	O
showed	O
that,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	B
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	B
region	O
just	O
upstream	O
of	O
the	O
NF-kappaB	B
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF-kappaB	O
and	O
Sp1	O
sites	O
.	O

cAMP	O
inducibility	O
of	O
transcriptional	B
repressor	O
ICER	B
in	O
developing	O
and	O
mature	B
human	O
T	O
lymphocytes	O
[published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23;93(15):8154]	O

Further,	O
in	O
transcriptional	O
assays	O
in	O
vivo,	O
ICER	B
inhibits	O
calcineurin	B
-mediated	O
expression	O
of	O
the	O
interleukin	B
2	O
promoter	O
as	O
well	O
as	O
Tax	B
-mediated	O
transactivation	O
of	O
the	O
human	B
T-lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
promoter	O
.	O

As	O
reported	O
here,	O
structure-function	O
analysis	O
of	O
the	O
CAML	B
gene	O
in	O
Jurkat	B
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	B
's	O
putative	B
membrane-spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

EBNA-5	B
is	O
one	O
of	O
the	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)-encoded	O
nuclear	O
proteins	O
required	O
for	O
immortalization	O
of	O
human	B
B	O
lymphocytes	O
.	O

Translocation	B
t(15;17)(q22;q21	O
)	O
is	O
an	O
acquired	O
clonal	O
cytogenetic	O
change	O
present	O
in	O
almost	O
all	O
cases	O
of	O
acute	O
promelocytic	O
leukemia	O
(	O
APL	O
).	O

The	O
chromosome	B
17	O
breakpoint	O
was	O
localized	O
to	O
intron	B
2	O
of	O
RARA	B
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	B
locus	O
.	O

A	O
model	O
of	O
latent	O
adenovirus	O
5	O
infection	O
in	O
the	O
guinea	O
pig	O
(Cavia	O
porcellus).	O

In	O
situ	O
hybridization	O
to	O
viral	B
DNA	O
and	O
immunocytochemistry	O
for	O
Ad5	O
E1A	B
protein	O
localized	O
the	O
virus	O
to	O
airway	O
and	O
alveolar	B
epithelial	O
cells	O
.	O

Ad5	B
E1A	O
DNA	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
five	O
of	O
six	O
animals	O
20	O
days	O
after	O
infection	O
and	O
in	O
five	O
of	O
five	O
animals	O
47	O
days	O
after	O
infection.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
genome-positive	O
B	B
cells	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate-early	B
EBV	O
Zebra	O
gene	O
,	O
followed	O
by	O
virus	O
replication	O
(L.Flamand,	O
I.Stefanescu,	O
D.V.Ablashi,	O
and	O
J.Menezes,	O
J.Virol.67:6768-6777,	O
1993).	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	B
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	B
but	O
not	O
by	O
AP-1	B
consensus	O
sequences	O
.	O

Two	O
Jurkat	B
cell	O
clones	O
have	O
been	O
stably	O
transfected	O
with	O
a	O
reporter	B
vector	O
for	O
the	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
).	O

NFAT	B
activation	O
was	O
also	O
inhibited	O
by	O
agents	O
that	O
increase	O
cAMP	O
concentrations	O
such	O
as	O
dibutyryl	O
cAMP	O
,	O
forskolin	O
and	O
prostaglandin	O
E2	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	B
receptor	O
and	O
the	O
AP-1	B
complex	O
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes,	O
including	O
glucocorticoid	B
receptor	O
itself.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down-regulation	O
for	O
the	O
glucocorticoid	B
receptor	O
mRNA	B
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	B
cell-specific	O
coactivators	O
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity.	O

Eosinophils	B
and	O
neutrophils	B
are	O
closely	O
related,	O
terminally	B
differentiated	O
cells	O
that	O
in	O
vitro	O
undergo	O
constitutive	O
cell	O
death	O
by	O
apoptosis	O
.	O

We	O
found	O
that	O
treatment	O
with	O
dexamethasone	O
induced	O
eosinophil	B
apoptosis	O
.	O

Permanent	O
occupancy	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
by	O
NF-kappa	B
B	O
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	B
.	O

This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF-kappaB	B
DNA-binding	O
activity	O
and	O
endogenous	B
long	O
terminal	O
repeat	O
transcriptional	O
activity	O
.	O

Compared	O
with	O
its	O
wild-type	O
counterpart,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased,	O
Z-LLL-H	O
-insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	B
monocytes	B
.	O

The	O
c-rel	B
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF-kappa	B
B	O
-like	O
family	O
of	O
transcription	B
factors	O
.	O

In	O
Rel	B
-/-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3,	O
IL-5,	O
granulocyte-	B
macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	B
),	O
tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
),	O
and	O
gamma	B
interferon	O
(	O
IFN-gamma	B
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells.	O

These	O
findings	O
establish	O
that	O
Rel	B
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	B
lymphocytes	O
for	O
production	O
of	O
IL-3	B
and	O
GM-CSF	B
.	O

The	O
IL-2	B
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B
response	O
element	O
(	O
CD28RE	B
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF-MATp35	B
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	B
inducible	O
nitric	B
oxide	O
synthase	O
gene	O
to	O
lipopolysaccharide/interferon-gamma.	O

The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O

In	O
addition,	O
dual	O
colour	O
FISH	O
analysis	O
using	O
centromere	O
specific	O
probes	O
for	O
chromosomes	O
X	B
and	O
17	B
showed	O
that	O
the	O
breakpoints	O
on	O
both	O
chromosomes	B
lie	O
within	O
the	O
alphoid	O
arrays	O
,	O
making	O
interruption	O
of	O
a	O
locus	O
on	O
either	O
chromosome	O
unlikely.	O

Immortalized	O
and	O
transformed	O
T	B
cells	O
harbor	O
several	O
copies	O
of	O
the	O
viral	B
genome	O
as	O
a	O
persisting	B
genome	O
.	O

This	O
viral	O
fragment	O
permits	O
stable	O
plasmid	B
replication	O
without	O
deletion	O
or	O
rearrangement	O
as	O
well	O
as	O
episomal	O
maintenance	O
without	O
integration	O
or	O
recombination	O
.	O

In	O
vivo	O
anergized	B
CD4+	O
T	B
cells	O
express	O
perturbed	O
AP-1	O
and	O
NF-kappa	B
B	O
transcription	B
factors	O
.	O

Injection	O
of	O
SEA	B
to	O
adult	O
mice	O
activates	O
CD4+	B
T	B
cells	O
expressing	O
certain	O
T-cell	B
receptor	O
(TCR)	O
variable	O
region	O
beta-chain	O
families	O
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	O
2	O
(	O
IL-2	B
).	O

In	O
contrast,	O
anergic	B
CD4+	O
T	O
cells	O
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B
and	O
Fos/Jun-containing	B
NF-AT	B
complexes	O
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	B
B	O
and	O
Oct	B
binding	O
proteins	O
after	O
SEA	B
stimulation	O
.	O

Stimulation	O
through	O
the	O
Fas/APO-1	B
receptor	O
results	O
in	O
apoptosis	O
through	O
an	O
incompletely	O
characterized	O
signaling	O
pathway	O
.	O

Further,	O
in	O
normal	O
and	O
CD45-	O
or	O
Lck-	O
deficient	O
cell	O
lines	O
,	O
Fas	O
stimulation	O
results	O
in	O
activation	O
of	O
Jun	B
kinase	O
(	O
JNK	B
),	O
a	O
proposed	O
mediator	O
of	O
stress	O
activation	O
pathways.	O

Globin	O
gene	O
switching.	O

In	O
contrast,	O
in	O
vivo	O
footprints	O
on	O
GT	B
(CACCC)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

Antisense	O
inhibition	O
of	O
vitamin	B
D	O
receptor	O
expression	O
induces	O
apoptosis	O
in	O
monoblastoid	B
U937	B
cells	O
.	O

A	O
2-kb	B
VDR	B
cDNA	O
insert	O
(including	O
the	O
complete	O
VDR	B
coding	O
region	O
)	O
was	O
cloned	O
in	O
an	O
antisense	O
orientation	O
into	O
the	O
EBV	O
episomal	O
vector	O
pMEP4	O
under	O
the	O
control	O
of	O
an	O
inducible	B
promoter	O
and	O
transfected	O
into	O
U937	B
.	O

Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O

Animal	O
lectins	B
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

In	O
addition,	O
the	O
galectin-3	B
level	O
was	O
markedly	O
increased	O
in	O
human	B
thymocytes	O
after	O
infection	O
with	O
HTLV-I	O
as	O
compared	O
with	O
uninfected	B
thymocytes	O
.	O

Transfection	O
of	O
human	B
promonocytic	O
U-937	O
cells	O
with	O
an	O
HTLV-I	O
Tax	O
expression	O
vector	O
induced	O
galectin-3	B
expression	O
in	O
this	O
cell	O
line.	O

Interstitial	O
collagenase	B
(	O
MMP-1	B
),	O
a	O
metalloproteinase	B
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover,	O
cleaves	O
type	B
I	O
collagen	O
fibrils	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5'	B
-flanking	O
sequence	O
of	O
the	O
collagenase	B
promoter	O
were	O
sufficient	O
for	O
LPS-	O
or	O
zymosan-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	B
enhancer	O
A-binding	O
protein-3	O
site	O
(	O
-83	B
to	O
-91	O
)	O
and	O
TTCA	B
sequence	O
(	O
-102	B
to	O
-105	O
)	O
in	O
both	O
monocytic	B
cells	O
and	O
fibroblasts	B
.	O

Furthermore,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	B
induction	O
in	O
monocytic	B
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	B
promoter	O
sequences	O
.	O

Consistent	O
with	O
this	O
notion,	O
we	O
found	O
that	O
LPS	O
stimulated	O
AP-1	B
-mediated	O
transcription	O
of	O
a	O
transfected	B
reporter	O
gene	O
in	O
the	O
murine	B
macrophage	O
cell	O
line	O
RAW	O
264.7	O
.	O

Binding	O
of	O
LPS	O
-	O
LPS	B
binding	O
protein	O
(LBP)	O
complexes	O
to	O
CD14	B
,	O
a	O
surface	B
receptor	O
that	O
mediates	O
many	O
LPS	O
responses	O
,	O
was	O
found	O
to	O
be	O
crucial,	O
as	O
pretreatment	O
of	O
THP-1	B
cells	O
with	O
the	O
monoclonal	B
antibody	O
60b	O
,	O
which	O
blocks	O
this	O
binding,	O
inhibited	O
JNK	B
activation.	O

We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	O
endotoxin-stimulated	O
inflammatory	B
c	O
ytokine	O
mRNA	O
levels	O
and	O
protein	B
products	O
(	O
tumor	B
necrosis	O
factor-alpha	O
[TNF],	O
interleukin-1-beta	B
[	O
IL-1	B
],	O
interleukin-6	B
[	O
IL-6	B
])	O
in	O
human	B
alveolar	O
macrophages	B
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF-kappa	B
B	O
.	O

The	O
costimulatory	B
molecule	O
B7.1	O
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

This	O
183-bp	B
region	O
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7.1	B
expression	O
.	O

Ubiquitinylation	O
of	O
transcription	B
factors	O
c-Jun	B
and	O
c-Fos	B
using	O
reconstituted	B
ubiquitinylating	O
enzymes	O
.	O

The	O
E3-dependent	O
ubiquitinylation	O
of	O
c-Jun	B
was	O
inhibited	O
upon	O
the	O
heterodimerization	O
of	O
c-Jun	B
with	O
c-Fos	B
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	B
B-cell	O
specific	O
transcriptional	O
coactivator	O
Bob1	B
.	O

Analysis	O
of	O
its	O
intron-exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C-terminal	B
splice	O
variant	O
.	O

Involvement	O
of	O
Janus	B
kinase	O
/signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
and	O
protein	B
kinase	O
C	O
signaling	O
pathways	O
.	O

The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	B
-mediated	O
enhancement	O
of	O
ICAM-1	B
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	B
kinase	O
C	O
and	O
tyrosine	B
kinase	O
,	O
because	O
inhibitors	O
of	O
protein	B
kinase	O
C	O
and	O
tyrosine	B
kinase	O
abrogate	O
gp120	B
-mediated	O
ICAM-1	B
expression	O
in	O
both	O
astrocytes	B
and	O
microglia	B
.	O

IL-10	B
cooperates	O
with	O
TNF-alpha	B
to	O
activate	O
HIV-1	O
from	O
latently	O
and	O
acutely	O
infected	O
cells	O
of	O
monocyte/macrophage	B
lineage	O
.	O

Neutralizing	O
mAbs	B
to	O
IL-10	B
and	O
TNF-alpha	B
indicated	O
that	O
both	O
cytokines	B
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
IL-10	B
,	O
in	O
addition	O
to	O
down-regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV-1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF-alpha	B
-mediated	O
activation	O
of	O
HIV-1	O
replication	O
in	O
the	O
monocyte/macrophage	B
lineage	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	B
induces	O
transformation	O
are	O
still	O
unknown,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	B
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	B
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process.	O

Upon	O
cellular	O
activation,	O
I	B
kappa	O
B	O
alpha	O
is	O
phosphorylated,	O
polyubiquitinated,	O
and	O
degraded	O
in	O
the	O
proteasome	B
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B
and	O
the	O
HsN3	B
subunit	O
of	O
the	O
human	B
proteasome	B
.	O

We	O
used	O
histochemical	O
markers	O
to	O
define	O
the	O
immunophenotype	O
of	O
43	O
IDCs	O
with	O
respect	O
to	O
comedo	O
versus	O
noncomedo	O
status	O
and	O
patterns	O
of	O
angiogenesis	O
.	O

Periductal	O
angiogenesis	O
was	O
not	O
significantly	O
related	O
to	O
the	O
type	O
of	O
IDC	O
but	O
was	O
more	O
pronounced	O
with	O
comedo	O
carcinomas	O
.	O

Signal	B
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	B
)	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
in	O
response	O
to	O
cytokine	B
and	O
growth	B
factor	O
stimulation	O
of	O
cell	B
surface	O
receptors	O
.	O

We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B
phosphatases	O
(	O
PPs	B
)	O
PP1/PP2A	B
,	O
calyculin	B
A	O
,	O
induces	O
(i)	O
phosphorylation	O
of	O
STAT3	B
on	O
serine	O
and	O
threonine	O
residues,	O
(ii)	O
inhibition	O
of	O
STAT3	B
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity,	O
and	O
(iii)	O
relocation	O
of	O
STAT3	B
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Moreover,	O
our	O
findings	O
suggest	O
that	O
the	O
level	O
of	O
STAT3	B
phosphorylation	O
is	O
balanced	O
between	O
a	O
staurosporine	B
-sensitive	O
kinase	O
(s)	O
and	O
PP2A	B
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
value	O
of	O
the	O
polyamine	O
patterns	O
of	O
tumor	O
tissues	O
and	O
erythrocytes	O
in	O
comparison	O
with	O
clinical	O
and	O
histological	O
prognostic	O
factors	O
.	O

Erythrocyte	O
polyamines	O
levels	O
were	O
identical	O
between	O
cancer	O
patients	O
and	O
controls	O
.	O

Alveolar	B
macrophages	O
and	O
peripheral	B
blood	O
monocytes	O
are	O
activated	O
when	O
IgE/allergen	B
immune	O
complexes	O
bind	O
to	O
the	O
CD23	B
receptor	O
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	B
cytokines	B
.	O

Surface	O
expression	O
of	O
CD23	B
was	O
determined	O
by	O
FACS	O
analysis	O
.	O

CD23	B
-induced	O
NF-kappaB	O
is	O
a	O
heterodimer	O
composed	O
of	O
p65/p50	B
subunits	O
.	O

CONCLUSIONS:	O
NF-kappaB	B
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	B
in	O
monocytes	B
.	O

In	O
view	O
of	O
the	O
nuclear	B
factor-kappaB	O
(	O
NFkappaB	B
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	B
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O

Furthermore,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	B
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	B
cells	O
.	O

Bcl-2	B
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	B
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)-induced	O
expression	O
of	O
FasL	B
and	O
blocks	O
paclitaxel	O
-induced	O
apoptosis	O
.	O

Furthermore,	O
Bcl-2	B
antagonizes	O
drug-induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B
activation	O
,	O
blocking	O
NFAT	B
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	B
expression	O
.	O

Antigen-specific	O
T	O
cell	O
recognition	O
is	O
dependent	O
on	O
the	O
functional	O
density	O
of	O
the	O
TCR	B
-ligand	O
,	O
which	O
consists	O
of	O
specific	O
MHC	B
molecules	O
and	O
a	O
specifically	O
bound	O
peptide	O
.	O

MHC	B
class	O
II	O
density	O
on	O
the	O
APC	B
was	O
modified	O
using	O
DQ2	O
homo	O
-and	O
hetero	O
zygous	O
B-LCLs	O
as	O
APCs	B
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	B
cell	O
proliferation	O
.	O

IL-11	B
mRNA	O
and	O
protein	O
were	O
both	O
up-regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

However,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	B
.	O

Recently,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	B
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
and	O
other	O
proteins	O
in	O
human	B
platelets	O
and	O
BaF3	B
cells	O
,	O
genetically	O
engineered	O
to	O
express	O
c-Mpl	B
,	O
a	O
receptor	O
for	O
thrombopoietin	B
.	O

Thrombopoietin	B
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	B
and	O
Stat5	B
in	O
these	O
cells.	O

Recent	O
studies	O
have	O
defined	O
genetic	O
alterations	O
commonly	O
associated	O
with	O
transformed	B
lymphocytes	O
.	O

In	O
contrast,	O
it	O
is	O
also	O
becoming	O
clear	O
that	O
the	O
dysregulated	O
expression	O
of	O
proteins	O
that	O
are	O
not	O
genetically	O
altered	O
can	O
also	O
contribute	O
to	O
the	O
progression	O
of	O
lymphoid	O
malignancies	O
.	O

Taken	O
together,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	B
expression	O
.	O

This	O
study	O
has	O
investigated	O
DHEA	O
modulation	O
of	O
LPS	O
-induced	O
monocyte	O
cytotoxicity	O
.	O

Finally,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	B
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS	B
-stimulated	O
monocytes	B
are	O
mediated	O
through	O
a	O
receptor-dependent	O
process	O
.	O

IL-4	B
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	B
transcription	O
factor	O
,	O
STAT6	B
(	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription-6	O
).	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	B
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	B
stimulation	O
.	O

An	O
activation-responsive	O
element	O
in	O
single	O
C	B
motif-1/lymphotactin	O
promoter	O
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA-protein	O
interactions	O
involving	O
nuclear	B
factor	O
of	O
activated	O
T	O
cell	O
.	O

The	O
luciferase	B
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
5'	B
flanking	O
region	O
of	O
0.7	O
kb	O
was	O
strongly	O
induced	O
upon	O
activation	O
with	O
anti-CD3	B
or	O
PHA	B
plus	O
PMA	O
only	O
in	O
SCM-1-producer	B
T	O
cell	O
lines	O
through	O
a	O
cyclosporin	O
A-sensitive	O
mechanism	O
.	O

Both	O
complexes	O
were	O
critically	O
dependent	O
on	O
the	O
NF-AT	B
core	O
sequence	O
TTTCC	O
in	O
the	O
E1	B
element	O
and	O
were	O
partially	O
supershifted	O
by	O
anti-NF-ATp	B
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	B
produce,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF-kappaB	B
element	O
present	O
in	O
the	O
long	B
terminal	O
repeat	O
.	O

The	O
combination	O
of	O
dopamine	O
and	O
TNF-alpha	B
led	O
to	O
a	O
stimulation	O
of	O
HIV-1	O
transcription	O
and	O
replication.	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood-glucose	O
,	O
cholesterol	O
,	O
HDL-cholesterol	B
,	O
triglyceride	O
,	O
beta-lipoproteins	B
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	B
,	O
T3	B
,	O
T4	B
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	O
and	O
progesterone	O
receptor	O
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

IL-10	B
-activated	O
STAT1	B
could	O
bind	O
to	O
the	O
GAS-motif	B
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B
receptor	O
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	B
region	O
of	O
the	O
COX-2	B
gene	O
,	O
whereas	O
IFN-gamma	B
-activated	O
STAT1	B
and	O
STAT5	B
could	O
bind	O
to	O
both	O
sequences.	O

This	O
may	O
explain	O
the	O
difference	O
between	O
IL-10	B
and	O
IFN-gamma	B
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL-10	B
on	O
IFN-gamma	B
activities	O
.	O

A	O
truncated	O
version	O
of	O
430-444	O
,	O
i.e.,	O
VP16	O
433-442	O
,	O
binds	O
with	O
an	O
affinity	O
10-fold	O
lower	O
compared	O
to	O
430-444	O
at	O
acidic	O
pH,	O
and	O
binding	O
at	O
neutral	O
pH	O
was	O
barely	O
detectable.	O

Much	O
higher	O
concentrations	O
of	O
wild	O
type	O
peptides	O
were	O
needed	O
to	O
activate	O
T	B
cells	O
at	O
neutral	O
pH	O
.	O

ETS	B
transcription	O
factors	O
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	B
intron	O
of	O
TNF-alpha	B
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	B
20-bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	B
or	O
if	O
a	O
dominant-negative	B
ets-binding	O
factor	O
was	O
co-transfected	O
with	O
the	O
reporter	B
gene	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	B
transcription	O
factors	O
in	O
the	O
production	O
of	O
TNF-alpha	B
.	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F-1	B
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	B
to	O
form	O
platelets	B
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O

Additionally,	O
E2F-1	B
caused	O
massive	O
megakaryocyte	B
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	B
gene	O
and	O
multiple	O
minor	O
susceptibility	B
genes	O
.	O

In	O
support	O
of	O
this	O
model,	O
we	O
report	O
that	O
the	O
human	B
IL-4	B
promoter	O
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4	B
-positive	O
T	O
cells	O
.	O

The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	O
in	O
overexpression	O
of	O
the	O
IL-4	B
gene	O
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O

The	O
age-related	O
decline	O
in	O
induction	O
of	O
NF	B
kappa	O
B	O
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits,	O
p50	B
and	O
p65	B
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	B
kappa	O
B	O
in	O
T	B
cells	O
from	O
young	O
as	O
well	O
as	O
elderly	O
donors.	O

Glucocorticoids	O
,	O
as	O
a	O
part	O
of	O
their	O
physiological	O
role	O
in	O
the	O
control	O
of	O
inflammatory	O
and	O
immune	O
processes	O
,	O
suppress	O
the	O
expression	O
of	O
interleukin-1	B
(	O
IL-1	B
)	O
and	O
other	O
cytokines	B
.	O

Oral	O
administration	O
of	O
276	O
mumol	O
cortisol	O
to	O
normal	O
subjects	O
also	O
decreased	O
LPS	O
-induced	O
IL-1ra	B
synthesis	O
in	O
cultured	B
monocytes	O
.	O

Our	O
results	O
further	O
indicate	O
that	O
corticosteroids	O
physiologically	O
control	O
the	O
IL-1/	O
IL-1ra	B
system	O
during	O
inflammatory	O
or	O
immune	O
processes	O
.	O

However,	O
only	O
a	O
few	O
CD8(+)-T-cell	B
epitopes	O
are	O
known,	O
with	O
the	O
majority	O
being	O
contained	O
in	O
the	O
pp65	B
phosphoprotein	O
,	O
which	O
is	O
believed	O
to	O
dominate	O
the	O
CD8(+)-T-cell	O
response	O
to	O
HCMV	O
.	O

At	O
least	O
10	O
new	O
epitopes	B
were	O
identified,	O
and	O
the	O
fine	O
specificity	O
and	O
presenting	O
HLA	B
molecule	O
of	O
the	O
first	O
of	O
them	O
was	O
determined.	O

E1A	B
oncogene	O
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	B
lymphocytes	O
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O

In	O
contrast,	O
E1A	B
-positive	O
cells	O
were	O
no	O
more	O
susceptible	O
to	O
injury-induced	O
necrosis	O
than	O
E1A	B
-negative	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
E1A	B
induces	O
susceptibility	O
to	O
killer	O
cell-induced	O
lysis	O
through	O
sensitization	O
of	O
cells	O
to	O
injury-induced	O
apoptosis	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	B
or	O
tumor-suppressor	B
genes	O
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

However,	O
TCL1	B
expression	O
has	O
not	O
been	O
reported	O
in	O
AIDS	O
NHL	O
.	O

These	O
results	O
establish	O
TCL1	B
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	B
associated	O
with	O
AIDS	O
IBLP	O
.	O

Although	O
the	O
role	O
of	O
CD28	B
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear.	O

In	O
addition,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
).	O

The	O
Epstein-Barr	B
virus	O
latency	O
BamHI-Q	O
promoter	O
is	O
positively	O
regulated	O
by	O
STATs	B
and	O
Zta	B
interference	O
with	O
JAK	B
/STAT	B
activation	O
leads	O
to	O
loss	O
of	O
BamHI-Q	B
promoter	O
activity	O
.	O

We	O
have	O
determined	O
that	O
the	O
JAK	B
/STAT	B
pathway	O
positively	O
regulates	O
Qp	B
activity	O
.	O

We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV-positive	B
NPC	O
cell	O
lines	O
in	O
culture	O
was	O
related	O
to	O
Qp	B
activity	O
.	O

This	O
negative	O
regulation	O
required	O
Zta	B
DNA-binding	O
activity	O
.	O

Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	B
epithelial	O
cells	O
.	O

After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT-	O
PCR	O
were	O
used	O
to	O
measure	O
protein	B
tyrosine	O
kinase	O
activity	O
,	O
protein	O
activity	O
of	O
NF-kappaB	B
and	O
cytokine	B
(	O
IL-1beta	B
,	O
IL-6	B
,	O
TNF-alpha	B
)	O
specific	O
mRNA	B
levels	O
in	O
BEAS-2B	B
cells	O
.	O

These	O
data	O
suggest	O
a	O
ROI-dependent	O
NF-kappaB	B
mediated	O
transcription	O
of	O
inflammatory	B
cytokines	B
in	O
bronchial	B
epithelial	B
cells	O
.	O

Mutagenesis	O
of	O
NF	O
kappa	O
B	O
or	O
Sp-1	O
elements	O
within	O
the	O
LTR	B
resulted	O
in	O
no	O
change	O
in	O
the	O
ability	O
of	O
CD8+	B
T	O
cell	O
supernatants	O
to	O
inhibit	O
Tat-	O
or	O
mitogen-	O
mediated	O
LTR	O
transcription	O
.	O

Taken	O
together,	O
these	O
observations	O
suggest	O
that	O
mitogenic	O
activation	O
,	O
mediated	O
primarily	O
through	O
the	O
NF	B
kappa	O
B	O
enhancer	O
,	O
is	O
susceptible	O
to	O
CD8	B
-mediated	O
inhibition	O
,	O
however,	O
inhibition	O
of	O
Tat	B
-mediated	O
activation	O
may	O
rely	O
upon	O
a	O
different	O
pathway	O
that	O
is	O
NFAT-1	B
dependent	O
.	O

Therefore,	O
inhibition	O
of	O
NF-kappa	B
B	O
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

ADT	O
(0.1	O
mM)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	B
factor	O
in	O
the	O
peroxide	B
sensitive	O
human	O
Wurzburg	O
T-cells	O
.	O

Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	B
adhesion	O
molecule	O
induction	O
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(e.g.	O
inflammation	O
and	O
atherosclerosis	O
).	O

Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF-kappa	B
B	O
activation	O
in	O
monocytes-macrophages	B
is	O
available,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	B
kinase	O
C	O
(	O
PKC	B
)	O
isoenzymes	O
were	O
not	O
involved	O
in	O
the	O
HIV	O
-mediated	O
NF-kappa	B
B	O
activation	O
.	O

The	O
HIV	O
-mediated	O
NF-kappa	B
B	O
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC-zeta	B
.	O

Altogether,	O
these	O
results	O
suggest	O
that	O
atypical	B
PKC	O
isoenzymes	O
,	O
including	O
PKC-zeta	B
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	B
B	O
in	O
human	B
monocytic	O
cells	O
and	O
macrophages	B
.	O

In	O
this	O
study,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl-xl	B
but	O
not	O
bcl-2	B
,	O
bcl-xs	B
,	O
bak	B
,	O
bad	B
,	O
or	O
bax	B
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	B
deprivation	O
in	O
CTLL-2	B
cells	O
that	O
expressed	O
Tax	B
.	O

This	O
NF-kappaB	B
-like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF-kappaB	B
family	O
proteins	O
in	O
vitro.	O

Erythroid	B
Kruppel-like	O
factor	O
(	O
EKLF	B
),	O
which	O
binds	O
to	O
the	O
CACCC	O
box	O
in	O
the	O
beta-globin	B
promoter	O
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
beta-globin	B
gene	O
in	O
adult	B
erythroid	O
cells	O
.	O

We	O
find	O
that	O
recruitment	O
of	O
EKLF	B
to	O
5'HS2	B
requires	O
the	O
TATA	B
box	O
,	O
but	O
recruitment	O
to	O
5'HS3	B
depends	O
on	O
the	O
CACCC	O
and	O
TATA	B
boxes	O
of	O
the	O
beta-globin	B
promoter	O
.	O

We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	B
to	O
5'HS3	B
depends	O
on	O
the	O
presence	O
of	O
5'HS2	B
in	O
cis,	O
but	O
the	O
recruitment	O
to	O
5'HS2	B
does	O
not	O
depend	O
on	O
5'HS3	B
.	O

However,	O
the	O
mechanism	O
by	O
which	O
E(2)	O
downregulates	O
TNF	B
production	O
is	O
presently	O
unknown.	O

The	O
consequent	O
decrease	O
in	O
the	O
nuclear	O
levels	O
of	O
c-Jun	B
and	O
JunD	B
leads	O
to	O
diminished	O
binding	O
of	O
c-Jun	B
/c-Fos	O
and	O
JunD	B
/c-Fos	O
heterodimers	O
to	O
the	O
AP-1	B
consensus	O
sequence	O
in	O
the	O
TNF	B
promoter	O
and,	O
thus,	O
to	O
decreased	O
transactivation	O
of	O
the	O
TNF	B
gene	O
.	O

In	O
contrast,	O
IL-2	B
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	B
.	O

Moreover,	O
we	O
provide	O
evidence	O
that	O
TCR/	B
CD3	B
and	O
IL-2	B
induce	O
Stat3	B
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

PPARgamma	B
is	O
also	O
expressed	O
in	O
hematopoietic	B
cells	O
and	O
is	O
up-regulated	O
in	O
activated	O
monocytes/	B
macrophages	B
.	O

Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	B
and	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFATp	B
).	O

However,	O
a	O
physical	O
interaction	O
between	O
calcineurin	B
and	O
NFATp	B
has	O
not	O
been	O
demonstrated.	O

Of	O
note,	O
both	O
the	O
phosphorylated	O
and	O
the	O
dephosphorylated	O
form	O
of	O
NFATp	B
bound	O
to	O
calcineurin	B
.	O

The	O
B	B
cell-associated	O
surface	O
molecule	O
CD40	B
plays	O
a	O
key	O
role	O
in	O
T	O
cell-dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O

Furthermore,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B
kinase	O
C	O
.	O

Stimulation	O
of	O
the	O
T-cell	B
antigen	O
receptor-CD3	O
complex	O
signaling	O
pathway	O
by	O
the	O
tyrosine	B
phosphatase	O
inhibitor	O
pervanadate	O
is	O
mediated	O
by	O
inhibition	O
of	O
CD45	B
:	O
evidence	O
for	O
two	O
interconnected	O
Lck/Fyn-	O
or	O
zap-70-	O
dependent	O
signaling	O
pathways	O
.	O

By	O
contrast,	O
stimulation	O
of	O
calcium	O
influx	O
,	O
a	O
CD3	B
-dependent	O
event	O
,	O
paralleled	O
zap-70	B
activation	O
.	O

Here	O
we	O
demonstrate	O
that	O
these	O
analogs,	O
as	O
well	O
as	O
the	O
6-cis-locked	O
conformer	O
,	O
1alpha,25-dihydroxy-lumisterol3	B
(JN)	O
prime	O
NB4	O
cells	O
for	O
monocytic	O
differentiation	O
.	O

Here	O
we	O
show	O
that	O
1alpha,25(OH)2-d5-previtamin	O
D3	O
(	O
HF	O
),	O
JN	O
,	O
KH1060	O
,	O
and	O
MC903	O
induce	O
expression	O
of	O
PKC	B
alpha	O
and	O
PKC	B
delta	O
and	O
translocation	O
of	O
both	O
isoforms	O
to	O
the	O
particulate	O
fraction	O
,	O
and	O
PKC	B
alpha	O
to	O
the	O
nuclear	O
fraction	O
.	O

Neutrophil	B
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	B
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources.	O
Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	B
acid	O
receptor	O
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	B
maturation	O
.	O

In	O
this	O
study,	O
we	O
show	O
that	O
MIP-1alpha	B
is	O
selectively	O
expressed	O
and	O
secreted	O
in	O
the	O
tax	B
transfected	O
Jurkat	O
cell	O
line	O
upon	O
mitogen	B
stimulation	O
.	O

Dendritic	B
cells	O
and	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis.	O

Circulating	B
dendritic	O
cells	O
(	O
DC	B
)	O
are	O
phenotypically	O
and	O
functionally	O
identical	O
with	O
normal	B
peripheral	O
blood	O
(	O
PB	O
)	O
DC	B
.	O

Like	O
a	O
delayed-type	O
hypersensitivity	O
response	O
,	O
the	O
rheumatoid	O
synovium	O
represents	O
an	O
effector	O
site.	O

Permanently	O
arresting	O
this	O
ongoing	O
immune	O
response	O
with	O
either	O
pharmaceutical	O
agents	O
or	O
immunotherapy	O
is	O
a	O
major	O
challenge	O
for	O
immunology	O
.	O

Tumor	B
necrosis	O
factor	O
(	O
TNF	B
)	O
and	O
interleukin-7	B
(	O
IL-7	B
),	O
secreted	O
during	O
this	O
interaction,	O
are	O
critical	O
cytokines	O
for	O
HIV	B
long	O
terminal	O
repeat	O
transactivation	O
through	O
NF-kappaB	B
-dependent	O
activation	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B
receptor	O
,	O
namely,	O
the	O
double-positive	B
(DP)	O
CD4	B
(+)	O
CD8(+)	O
CD3	B
(+/-)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B
and	O
IL-7	B
.	O

Activation	O
of	O
CD40	B
is	O
essential	O
for	O
thymus-dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	B
cells	O
from	O
apoptosis	O
.	O

Within	O
the	O
upstream	B
promoter	O
region	O
of	O
Bcl-x	B
,	O
a	O
potential	O
NF-kappaB	B
-binding	O
sequence	O
was	O
found	O
to	O
support	O
NF-kappaB	B
-dependent	O
transcriptional	O
activation	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B
granule	O
major	O
basic	O
protein	O
(	O
MBP	B
)	O
to	O
stimulate	O
interleukin	B
(IL)-8	O
production	O
by	O
neutrophils	B
.	O

MBP	B
stimulated	O
2-fold	O
increases	O
in	O
IL-8	B
messenger	O
RNA	O
(	O
mRNA	B
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation,	O
which	O
were	O
blocked	O
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O

MBP	B
also	O
induced	O
transient	O
increases	O
in	O
mRNA	B
for	O
macrophage	B
inflammatory	O
protein	O
(MIP)-1alpha	O
and	O
MIP-1beta	B
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B
.	O

Patients	O
with	O
the	O
recessively	O
inherited	O
disorder	O
ataxia	O
telangiectasia	O
(	O
A-T	O
)	O
have	O
a	O
high	O
level	O
of	O
specific	O
chromosome	B
translocations	O
which	O
can	O
be	O
easily	O
observed	O
in	O
peripheral	B
T	O
cells	O
and	O
show	O
a	O
greatly	O
increased	O
predisposition	O
to	O
leukaemia/lymphoma	O
,	O
mainly	O
of	O
T	B
cell	O
origin	O
.	O

We	O
show	O
here,	O
that	O
expression	O
of	O
TCL1	B
occurs	O
in	O
leukaemic	B
T	O
cells	O
from	O
A-T	O
patients	O
with	O
chromosome	B
14	O
rearrangements	O
.	O

[Correlation	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
tissue	O
with	O
the	O
hormonal	O
and	O
metabolic	O
state	O
in	O
patients	O
with	O
breast	O
cancer	O
]	O

There	O
was	O
a	O
direct	O
correlation	O
between	O
the	O
rate	O
of	O
lymphocyte	O
infiltration	O
and	O
the	O
level	O
of	O
progesterone	B
receptors	O
in	O
tumor.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G-protein-coupled	B
chemoattractant	O
receptors	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G-protein	B
coupling	O
and	O
the	O
activation	O
of	O
protein	B
kinases	O
.	O

The	O
flow	O
of	O
information	O
from	O
calcium-mobilizing	B
receptors	O
to	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)-dependent	O
genes	O
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	B
calcineurin	B
and	O
the	O
transcription	B
factor	O
NFAT	B
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	B
-NFAT	B
interaction	O
without	O
affecting	O
calcineurin	B
phosphatase	B
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs.	O

In	O
the	O
current	O
study,	O
we	O
show	O
9-cis	O
retinoic	O
acid	O
(	O
RA	O
),	O
a	O
ligand	O
for	O
the	O
nuclear	B
hormone	O
receptor	O
retinoid	O
X	O
receptor	O
(	O
RXR	B
)	O
and	O
retinoic	B
acid	O
receptor	O
(	O
RAR	B
),	O
markedly	O
induces	O
the	O
expression	O
of	O
MCP-1	B
.	O

However,	O
BRL49653	O
,	O
a	O
PPARgamma	B
ligand	O
,	O
failed	O
to	O
induce	O
MCP-1	B
secretion	O
either	O
alone	O
or	O
to	O
modify	O
the	O
expression	O
level	O
induced	O
by	O
RA	O
.	O

These	O
studies	O
identify	O
RA	O
as	O
a	O
nuclear	O
signal	O
for	O
MCP-1	B
induction	O
in	O
undifferentiated	B
human	O
monocytic	O
cells	O
.	O

In	O
this	O
syndrome,	O
tumorigenesis	O
classically	O
initiates	O
from	O
an	O
inherited	O
mutation	O
in	O
one	O
allele	B
followed	O
by	O
somatic	O
deletion	O
of	O
the	O
normal	B
allele	O
.	O

The	O
DNA	O
change	O
,	O
2418delA	O
,	O
is	O
considered	O
a	O
mutation	O
that	O
inactivated	O
one	O
BRCA1	B
allele	O
because	O
it	O
caused	O
a	O
frameshift	O
and	O
generation	O
of	O
a	O
premature	B
stop	O
codon	O
,	O
resulting	O
in	O
synthesis	O
of	O
a	O
truncated	O
peptide	O
as	O
evidenced	O
by	O
an	O
in	O
vitro	O
protein	O
truncation	O
test.	O

Using	O
the	O
technique	O
of	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
RNA	O
isolated	O
from	O
lymphoid	B
cell	O
lines	O
of	O
the	O
patient	O
and	O
of	O
controls,	O
no	O
evidence	O
was	O
found	O
that	O
IVS1-10TC	O
abnormally	O
disrupted	O
mRNA	B
splicing	O
or	O
caused	O
the	O
absence	O
of	O
BRCA1	B
mRNA	O
.	O

Myb-transformed	B
hematopoietic	B
cells	O
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	B
cells	O
and	O
macrophages	B
.	O

To	O
address	O
the	O
question	O
of	O
DC	B
lineage	O
and	O
to	O
determine	O
what	O
genes	O
are	O
involved	O
in	O
lineage	O
commitment,	O
we	O
have	O
generated	O
a	O
series	O
of	O
GM-CSF-responsive	B
cell	O
lines	O
that	O
can	O
be	O
induced	O
to	O
differentiate	O
in	O
a	O
homogeneous	O
manner	O
in	O
vitro.	O

When	O
the	O
same	O
MTHC	B
lines	O
are	O
exposed	O
to	O
TNF-alpha	B
in	O
combination	O
with	O
IFN-gamma	B
,	O
the	O
cells	O
instead	O
become	O
DC	B
.	O

A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	B
is	O
evident	O
where	O
macrophage-specific	B
cDNAs	B
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	O
and	O
cell-surface	O
proteins	O
,	O
whereas	O
the	O
DC	B
-specific	O
cDNAs	B
are	O
homologous	O
to	O
signaling	O
,	O
chemokine	O
,	O
and	O
IFN-gamma-inducible	O
genes	O
.	O

An	O
open	B
reading	O
frame	O
that	O
is	O
approximately	O
60%	O
identical	O
to	O
the	O
E.	B
coli	O
rpoS	B
gene	O
was	O
identified.	O

This	O
finding	O
indicates	O
that	O
L.	O
pneumophila	O
RpoS	B
is	O
not	O
required	O
for	O
a	O
stationary-phase-dependent	O
resistance	O
to	O
stress.	O

Monoallelic	O
expression	O
of	O
Pax5	B
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	B
Pax	O
genes	O
?	O

However,	O
a	O
minority	O
of	O
genes	O
are	O
semi-dominant	O
,	O
as	O
heterozygous	O
loss-of-function	O
mutation	O
in	O
these	O
genes	O
leads	O
to	O
phenotypic	O
abnormalities	O
.	O

As	O
a	O
consequence,	O
B-lymphoid	O
tissues	O
are	O
mosaic	O
with	O
regard	O
to	O
the	O
transcribed	O
allele	B
,	O
and	O
heterozygous	O
mutation	O
of	O
Pax5	B
therefore	O
results	O
in	O
deletion	O
of	O
B	B
lymphocytes	O
expressing	O
only	O
the	O
mutant	B
allele	B
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	B
activation	O
through	O
the	O
human	B
IL-4	B
receptor	O
(	O
IL-4R	B
).	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	B
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL-4	B
,	O
and	O
that	O
both	O
STAT5a	B
and	O
STAT5b	B
can	O
contribute	O
to	O
IL-4	B
-triggered	O
transcriptional	O
control	O
.	O

Immunoprecipitation	O
of	O
epitope-labeled	B
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B
B	O
subunit	O
in	O
Jurkat	B
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B
subunit	O
.	O

Monoclonal	B
anti-D	O
antibodies	O
submitted	O
to	O
the	O
Third	O
Monoclonal	O
International	O
Workshop	O
were	O
evaluated	O
against	O
a	O
number	O
of	O
D	B
variant	O
cells	O
using	O
standard	O
serological	O
techniques	O
.	O

Interleukin	B
10	O
induced	O
c-fos	B
expression	O
in	O
human	B
B	O
cells	O
by	O
activation	O
of	O
divergent	B
protein	O
kinases	O
.	O

B	B
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	B
CD20	B
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

A	O
significant	O
2-4	O
fold	O
increase	O
of	O
c-fos	B
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL-10	B
(p	O
<	O
0.01).	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(10	O
microM)	O
a	O
complete	O
inhibition	O
of	O
IL-10	B
induced	O
c-fos	B
expression	O
was	O
observed.	O

Immunocytochemical	O
analysis	O
of	O
MNDA	B
in	O
tissue	O
sections	O
and	O
sorted	O
normal	O
bone	O
marrow	O
cells	O
documents	O
expression	O
only	O
in	O
maturing	O
normal	O
and	O
neoplastic	O
myelomonocytic	O
cells	O
and	O
a	O
subset	O
of	O
normal	O
and	O
neoplastic	O
B	O
lymphocytes.	O

Flow	O
cytometric	O
cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
established	O
that	O
MNDA	B
is	O
initially	O
expressed	O
in	O
myeloid	B
blast	O
cells	O
.	O

MNDA	B
was	O
not	O
detected	O
in	O
other	O
normal	O
bone	O
marrow	O
or	O
all	O
other	O
nonhematopoietic	B
cells	O
.	O

Peroxisome	B
proliferator-activated	O
receptors	O
(	O
PPARs	B
),	O
members	O
of	O
the	O
nuclear	B
receptor	O
superfamily	O
of	O
transcription	B
factors	O
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O

Intracellular	B
adhesion	O
molecule-1	O
induction	O
by	O
PMA	O
was	O
unaffected	O
by	O
any	O
of	O
the	O
molecules	O
tested.	O

Studies	O
with	O
motheaten	O
mice	O
,	O
which	O
lack	O
the	O
SHP1	B
protein	O
tyrosine	B
phosphatase	O
,	O
indicate	O
that	O
this	O
enzyme	O
plays	O
an	O
important	O
negative	O
role	O
in	O
T	B
cell	O
antigen	O
receptor	O
(	O
TCR	B
)	O
signaling	O
.	O

Inactive	B
SHP1	B
-D421A	O
and	O
wild-type	B
SHP2	O
were	O
without	O
effects.	O

None	O
of	O
the	O
constructs	O
influenced	O
the	O
anti-CD3-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TCR	B
zeta-chain	O
or	O
phospholipase	B
Cgamma1	O
,	O
indicating	O
that	O
Src	B
family	O
kinase	O
function	O
was	O
intact.	O

Instead,	O
we	O
propose	O
that	O
ligation	O
of	O
a	O
distinct	O
inhibitory	B
receptor	O
leads	O
to	O
the	O
recruitment	O
of	O
SHP1	B
via	O
its	O
SH2	B
domains	O
,	O
activation	O
of	O
SHP1	B
and	O
subsequently	O
inhibition	O
of	O
TCR	B
signals	O
if	O
the	O
inhibitory	B
receptor	O
is	O
juxtaposed	O
to	O
the	O
TCR	B
.	O

The	O
proteins	O
may	O
prove	O
useful	O
in	O
protecting	O
adenovirus	B
gene	O
therapy	O
vectors	O
and	O
transplanted	B
cells	O
from	O
the	O
immune	O
system	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	B
promoter	O
region	O
identified	O
a	O
C/EBP	B
(	O
CCAAT/enhancer-binding	B
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	B
site	O
in	O
the	O
MBP	B
gene	O
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C/EBP-	O
and	O
GATA-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C/EBPbeta	B
and	O
GATA-1	B
can	O
stimulate	O
the	O
MBP	B
promoter	O
in	O
the	O
C/EBPbeta	B
and	O
GATA-1	B
negative	O
Jurkat	B
T-cell	O
line	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA-1	B
and	O
C/EBPbeta	B
synergistically	O
transactivate	O
the	O
promoter	B
of	O
an	O
eosinophil-specific	B
granule	O
protein	O
gene	O
and	O
that	O
FOG	B
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	B
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O

A	O
768-bp	B
upstream	O
negative	O
regulatory	O
region	O
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte-specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244-bp	B
deoxycytidine	O
kinase	O
core	O
promoter	O
.	O

Finally,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	B
promoter	O
fragments	O
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	B
site	O
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	B
serine	O
kinases	O
also	O
phosphorylate	O
STAT3	B
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

1-(5-Isoquinolinylsulphonyl)-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
),	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	B
serine	O
kinase	O
,	O
and	O
4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)	O
1H-imidazole	O
(	O
SB	O
203580	O
),	O
an	O
inhibitor	O
of	O
p38	B
mitogen-activated	O
protein	O
(MAP)	O
kinase	O
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	B
transcription	O
factors	O
in	O
murine	B
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

The	O
GATA-1	B
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co-localization	O
with	O
nuclear	B
antigens	O
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	B
(	O
Spl	B
,	O
c-Jun	B
and	O
TBP	B
)	O
or	O
haemopoietic	O
(NF-E2)	O
transcription	O
factors	O
.	O

Eight	O
healthy	O
untrained	O
male	O
volunteers	O
pedalled	O
a	O
cycle	O
ergometer	O
according	O
to	O
two	O
exercise	O
protocols:	O
the	O
first	O
involved	O
step-wise	O
increasing	O
physical	O
exercise	O
to	O
maximal	O
(	O
MPE	O
);	O
the	O
second	O
involved	O
prolonged	O
(35	O
min)	O
submaximal	O
physical	O
exercise	O
(	O
PPE	O
)	O
at	O
70%	O
of	O
the	O
individual's	O
maximal	O
oxygen	O
uptake	O
.	O

Intravenous	O
administration	O
of	O
PCr	O
(starting	O
1	O
day	O
before	O
exercise)	O
led	O
to	O
an	O
increase	O
in	O
the	O
total	O
workload	O
(on	O
average	O
by	O
5.8%)	O
and	O
in	O
AT	O
(on	O
average	O
by	O
6.8%)	O
during	O
MPE	O
and	O
to	O
a	O
better	O
tolerance	O
of	O
exercise	O
during	O
PPE	O
.	O

Putative	B
steroid	O
binding	O
domain	O
of	O
the	O
human	B
mineralocorticoid	O
receptor	O
,	O
expressed	O
in	O
E.	O
coli	O
in	O
the	O
presence	O
of	O
heat	B
shock	O
proteins	O
shows	O
typical	O
native	O
receptor	O
characteristics.	O

After	O
incubation	O
of	O
purified	O
MBP-	O
or	O
GST-	O
HBD	O
with	O
rabbit	O
reticulocyte	O
lysate	O
,	O
known	O
to	O
be	O
rich	O
in	O
heat	B
shock	O
proteins	O
,	O
we	O
obtained	O
saturable	O
binding	O
of	O
[3H]aldosterone	O
.	O

Western-blot	O
analysis	O
of	O
the	O
sedimentation	O
peak	O
showed	O
the	O
concomitant	O
presence	O
of	O
MBP-HBD	B
by	O
a	O
monoclonal	B
anti-MBP	O
antibody	O
,	O
and	O
hsp90	B
by	O
a	O
monoclonal	B
anti-hsp	O
antibody	O
.	O

Overall,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	B
E	O
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands,	O
agonists	O
or	O
antagonists,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	B
.	O

Tumor-derived	B
soluble	O
products	O
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	B
activity	O
in	O
T	B
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus-induced	O
IkappaBalpha	B
degradation	O
in	O
these	O
cells.	O

Taken	O
together,	O
our	O
findings	O
suggest	O
that	O
tumor-derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

In	O
this	O
study,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha	B
-inducible	O
reactive	O
oxygen	O
species	O
(ROS)	O
in	O
IL-8	B
expression	O
by	O
"monocyte-like"	O
U937	B
histiocytic	O
lymphoma	O
cells	O
.	O

Pretreatment	O
(or	O
up	O
to	O
15	O
minutes	O
posttreatment)	O
relative	O
to	O
TNFalpha	B
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(2%	O
[vol/vol])	O
blocks	O
80%	O
of	O
NF-kappaB	B
-dependent	O
transcription	O
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	B
signalling	O
.	O

Estrogens	O
affect	O
vascular	O
tone	O
indirectly	O
by	O
modulating	O
release	O
of	O
endothelium-derived	B
vasoactive	O
factors	O
and	O
directly	O
by	O
modulating	O
intracellular	O
calcium	O
in	O
vascular	B
smooth	O
muscle	O
cells	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	B
D	O
receptor	O
in	O
all-trans-retinoic	O
acid	O
-induced	O
monocytic	O
differentiation	O
of	O
M2-type	B
leukemic	O
blast	O
cells	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	B
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	B
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi-1	B
cells	O
(an	O
acute	B
myeloid	O
leukemia	O
M2-type	O
cell	O
line	O
).	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B
is	O
still	O
unknown,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	B
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

By	O
using	O
Jurkat	B
and	O
primary	B
human	O
T	B
lymphocytes	O
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	B
-initiated	O
signal	O
transduction	O
,	O
protein	B
kinase	O
C	O
(	O
PKC	B
)	O
and	O
calcineurin	B
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B
kinase	O
(IKK)	O
complex	O
but	O
not	O
of	O
another	O
putative	B
IkappaBalpha	B
kinase	O
,	O
p90(rsk)	B
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	B
/CD3	B
signal	O
transduction	O
pathway	O
both	O
PKC	B
and	O
calcineurin	B
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	B
complex	O
and	O
NF-kappaB	B
in	O
T	B
lymphocytes	O
.	O

Analysis	O
of	O
cell	B
lines	O
Daudi	B
and	O
THP-1	B
that	O
differentially	O
express	O
gamma(c)	B
and	O
IL-13R	B
alpha1	O
showed	O
that	O
IL-13	B
can	O
activate	O
STAT6	B
in	O
IL-13R	B
alpha1	O
-positive	O
THP-1	O
cells	O
but	O
not	O
in	O
gamma(c)-positive,	B
IL-13R	B
alpha1	O
-negative	O
Daudi	O
cells	O
.	O

Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL-4R	B
alpha	O
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL-13	B
receptor	O
complex	O
on	O
MDMac	B
.	O

Both	O
TNF-alpha	B
and	O
NF-kappa	B
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	B
histocompatibility	O
complex	O
(MHC)	O
class	O
I	O
molecules	O
and,	O
hence,	O
antigen	O
presentation	O
to	O
the	O
T	B
cells	O
.	O

The	O
product	O
of	O
the	O
B-cell-specific	B
B29	B
gene	O
(	O
B29	B
,	O
Ig	B
beta	O
,	O
CD79b	B
)	O
is	O
essential	O
for	O
Ig-mediated	O
B-cell	O
activation	O
via	O
the	O
B-cell	B
antigen	O
receptor	O
complex	O
(	O
BCR	B
)	O
on	O
human	O
and	O
murine	O
B	O
lymphocytes	O
.	O

This	O
minimal	B
promoter	O
exhibits	O
B-cell-specific	O
activity	O
and	O
contains	O
SP1	O
,	O
ETS	O
,	O
OCT	O
,	O
and	O
IKAROS/LYF-1	O
transcription	O
factor	O
motifs	O
.	O

A	O
single	O
BCS	B
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	B
promoter	O
or	O
on	O
a	O
heterologous	O
promoter.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	B
inhibitory	O
factor	O
,	O
CIF	B
)	O
inhibits	O
interleukin	B
2	O
(	O
IL2	B
)	O
production	O
in	O
activated	O
T	B
helper	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	B
mRNA	O
.	O

CIF	B
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	B
element	O
.	O

The	O
NFAT	B
-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid,	O
sensitive	O
measurement	O
of	O
CIF	B
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV-1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	B
.	O

In	O
particular,	O
staurosporine	O
achieved	O
approximately	O
90%	O
inhibition	O
of	O
the	O
HIV-1	O
antigen	O
expression	O
in	O
heat	B
shock	O
-treated	O
OM10.1	O
at	O
a	O
non-toxic	O
concentration	O
.	O

To	O
propel	O
itself	O
in	O
infected	B
cells	O
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B
-controlled	O
machinery	O
responsible	O
for	O
actin	B
assembly	O
during	O
filopodia	O
formation	O
.	O

Activation	O
of	O
N-WASP	B
by	O
IcsA	B
unmasks	O
two	O
domains	O
acting	O
together	O
in	O
insertional	O
actin	B
polymerization	O
.	O

VASP	O
is	O
not	O
involved	O
in	O
Shigella	O
movement	O
,	O
and	O
the	O
function	O
of	O
profilin	B
does	O
not	O
require	O
its	O
binding	O
to	O
proline	B
-rich	O
regions	O
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern,	O
peaking	O
at	O
the	O
promyelocyte	B
stage	O
,	O
or	O
in	O
cell	B
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c-Maf	B
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c-Myb	B
regulated	O
targets,	O
such	O
as	O
Bcl-2	B
and	O
CD13/APN	B
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation-promoting	B
genes	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	B
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	B
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	B
promoter	O
activity	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B
and	O
BSAP	B
and	O
suggest	O
that	O
AML1	B
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	B
cell-specific	O
gene	O
,	O
blk	B
.	O

In	O
the	O
present	O
study,	O
by	O
using	O
an	O
in	O
vitro	O
model,	O
we	O
examined	O
whether	O
stimulation	O
with	O
interleukin-6	B
(IL-6)	O
,	O
an	O
immunoregulatory	B
,	O
multipotential	B
cytokine	O
,	O
modulates	O
the	O
expression	O
and	O
activities	O
of	O
the	O
MSR	B
in	O
macrophages	B
.	O

Electrophoretic	O
mobility	O
gel	O
shift	O
assay	O
also	O
showed	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
a	O
transcription	B
factor	O
to	O
the	O
MSR	B
promoter	O
AP-1/ets	O
elements	O
in	O
IL-6	B
-treated	O
cells.	O

Tumor	O
cell	O
lines	O
with	O
a	O
defective	O
retinoblastoma	B
gene	O
are	O
unable	O
to	O
transcribe	O
the	O
HLA	B
class	O
II	O
genes	O
in	O
response	O
to	O
IFN-gamma	B
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	B
rescues	O
IFN-gamma-induced	O
class	B
II	O
gene	O
expression	O
.	O

Rb	B
expression	O
led	O
to	O
phosphorylation	O
of	O
Oct-1	B
,	O
thus	O
relieving	O
its	O
repressive	O
effect.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

In	O
addition,	O
BLPs	B
stimulated	O
nuclear	B
factor-kappaB	O
,	O
a	O
transcriptional	B
activator	O
of	O
multiple	B
host	O
defense	O
genes	O
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	B
.	O

The	O
mechanism(s)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

Distinctive	O
expression	O
pattern	O
of	O
the	O
BCL-6	B
protein	O
in	O
nodular	O
lymphocyte	O
predominance	O
Hodgkin's	O
disease	O
.	O

Forty-one	O
HD	O
samples	O
(19	O
NLPHD	O
,	O
12	O
nodular	O
sclerosis	O
,	O
and	O
10	O
mixed	O
cellularity)	O
were	O
immunostained	O
with	O
the	O
monoclonal	B
antibodies	O
PG-B6	B
and	O
PG-B6p	B
that	O
react	O
with	O
a	O
fixative-sensitive	O
and	O
a	O
formalin-resistant	B
epitope	O
on	O
the	O
aminoterminal	B
region	O
of	O
the	O
BCL-6	B
gene	O
product	O
,	O
respectively.	O

This	O
staining	O
pattern	O
clearly	O
differed	O
from	O
that	O
of	O
classical	O
HD	O
,	O
whose	O
cellular	O
background	O
was	O
made	O
up	O
of	O
CD3+/CD4+	B
T	O
cells	O
showing	O
the	O
BCL-6	B
-/	O
CD40L	B
+	O
phenotype.	O

Activation	O
of	O
NF-kappa	B
B	O
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	B
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF-kappa	B
B	O
activation	O
in	O
response	O
to	O
TNF	B
was	O
significantly	O
inhibited	O
under	O
these	O
conditions.	O

The	O
involvement	O
of	O
p23	B
,	O
hsp90	B
,	O
and	O
immunophilins	B
in	O
the	O
assembly	O
of	O
progesterone	B
receptor	O
complexes	O
.	O

We	O
have	O
studied	O
two	O
pre-formed	B
hsp90	B
complexes	O
that	O
may	O
participate	O
in	O
the	O
assembly	O
of	O
PR	B
complexes	O
.	O

In	O
further	O
studies	O
we	O
have	O
shown	O
that	O
purified	O
hsp90	B
can	O
bind	O
to	O
purified	O
p23	B
and	O
this	O
interaction	O
requires	O
both	O
ATP	O
and	O
molybdate	O
.	O

Since	O
NF-kappaB/	O
IkappaB	B
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	B
genes	O
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	B
production	O
thus	O
inhibiting	O
NF-kappaB	B
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	B
,	O
in	O
vivo.	O

IkappaB	B
levels	O
in	O
MNC	B
homogenates	O
increased	O
at	O
1	O
hr,	O
peaked	O
at	O
2-4	O
hr,	O
started	O
to	O
decrease	O
at	O
8	O
hr,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr.	O

ROS	O
generation	O
inhibition	O
paralleled	O
NF-kappaB	B
levels	O
in	O
the	O
nucleus	O
.	O

Glucocorticoids	O
induce	O
apoptosis	O
in	O
human	B
monocytes	O
:	O
potential	O
role	O
of	O
IL-1	B
beta	O
.	O

Peripheral	B
blood	O
monocytes	O
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>90%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium.	O

Caspase	O
3	O
was	O
inhibited	O
with	O
caspase-3	O
inhibitor	O
(	O
DEVD-CHO	O
).	O

Continuous	O
treatment	O
of	O
monocytes	B
with	O
IL-1beta	B
,	O
but	O
not	O
with	O
TNF-alpha	B
,	O
could	O
almost	O
completely	O
prevent	O
GC	O
-induced	O
cell	O
death.	O

It	O
is	O
conceivable	O
that	O
GC	O
exert	O
their	O
anti-inflammatory	O
capacity	O
in	O
various	O
diseases,	O
at	O
least	O
in	O
part,	O
by	O
the	O
induction	O
of	O
apoptosis	O
in	O
monocytes	B
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	B
elicited	O
a	O
rapid	O
but	O
short-lived	O
induction	O
of	O
IKK	B
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK	B
-alpha	O
than	O
on	O
IKK-beta	B
,	O
peaking	O
at	O
5	O
min.	O

Furthermore,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK-alpha	B
/beta	O
heterodimer	O
with	O
NIK	B
,	O
IkappaB	B
-alpha	O
and	O
-epsilon	B
in	O
unstimulated	B
cells	O
.	O

The	O
understanding	O
of	O
LPS-	O
and	O
TNF-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis-associated	O
disease	O
.	O

To	O
accomplish	O
this,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B
and	O
IL-10	O
inhibition	O
by	O
dexamethasone	O
in	O
LPS	B
-stimulated	O
whole-blood	O
cell	O
cultures	O
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS	O
-induced	O
TNFalpha	B
and	O
IL-10	B
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B
in	O
a	O
dose-dependent	O
fashion,	O
its	O
effect	O
on	O
IL-10	B
secretion	O
was	O
biphasic,	O
producing	O
stimulation	O
at	O
lower,	O
and	O
inhibition	O
at	O
higher	O
doses.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B
and	O
IL-10	B
secretion	O
by	O
human	B
monocytes	O
in	O
a	O
LPS	O
dose-dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B
or	O
IL-10	B
pretreatment	O
;	O
TNFalpha	B
blocks	O
their	O
effects,	O
whereas	O
IL-10	B
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

The	O
chimeric	B
gene,	O
AML1/ETO	B
(MTG8)	O
,	O
generated	O
in	O
t(8;21)	B
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl-2	B
.	O

On	O
the	O
contrary,	O
32Dcl3	B
cells	O
stably	O
expressing	O
AML1/ETO	B
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G-CSF	B
.	O

Yet,	O
for	O
many	O
pathogens,	O
the	O
molecules	O
that	O
induce	O
IL-12	B
production	O
by	O
macrophages	B
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined.	O

Abnormal	O
NF-kappa	B
B	O
activity	O
in	O
T	B
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65-RelA	B
protein	O
expression	O
.	O

We	O
measured	O
the	O
NF-kappa	B
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	B
,	O
we	O
showed	O
that,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF-kappa	B
B	O
activity,	O
p65	B
complexes	O
were	O
not	O
formed.	O

Human	B
Toll-like	O
receptor	O
2	O
(	O
TLR2	B
)	O
is	O
a	O
signaling	B
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF-kappaB	B
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B
lacking	O
C-terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	B
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Tyrphostin	O
AG-490	O
inhibits	O
cytokine-mediated	O
JAK3	B
/STAT5a/b	B
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen-activated	O
human	O
T	B
cells	O
.	O

Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG-490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
5a	O
and	O
5b	O
(	O
STAT5a/b	B
)	O
.	O

Taken	O
together,	O
these	O
findings	O
suggest	O
that	O
AG-490	O
inhibits	O
the	O
JAK3	B
-mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	B
cell	O
receptor-derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	B
cell	O
-derived	O
pathologies	O
such	O
as	O
graft-versus-host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O

Rheumatoid	O
arthritis	O
synovial	O
fluid	O
and	O
blood	O
and	O
normal	O
peripheral	O
blood	O
were	O
also	O
examined.	O

Two-color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	B
and	O
fibroblast-like	B
synoviocytes	O
were	O
positive	O
for	O
nuclear	O
C/EBP	B
beta	O
.	O

The	O
intensity	O
of	O
C/EBP	B
beta	O
staining	O
was	O
greater	O
(P	O
<	O
0.001)	O
in	O
synovial	B
fluid	O
monocytes	O
than	O
in	O
those	O
from	O
normal	O
or	O
rheumatoid	O
peripheral	O
blood	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	B
interferes	O
with	O
erythroid	O
differentiation	O
.	O

Both	O
the	O
DNA	B
binding	O
and	O
transactivation	B
domains	O
of	O
PU.1	B
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	B
cells	O
.	O

IL-12	B
induces	O
IFN	B
regulating	O
factor-1	O
(	O
IRF-1	B
)	O
gene	O
expression	O
in	O
human	O
NK	B
and	O
T	B
cells	O
.	O

IRF-1	B
is	O
a	O
transcription	B
factor	O
regulated	O
by	O
IFNs	B
that	O
is	O
also	O
essential	O
for	O
Th1	B
responses	O
.	O

The	O
participation	O
of	O
STAT4	B
in	O
the	O
regulation	O
of	O
IRF-1	B
was	O
demonstrated	O
in	O
two	O
ways.	O

Targeted	O
remodeling	O
of	O
human	B
beta-globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	B
beta-globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp,	O
erythroid-specific	B
DNase	O
1	O
hypersensitive	O
site-forming	O
element	O
(	O
HSFE	B
)	O
immediately	O
upstream	O
of	O
the	O
beta-globin	O
promoter	O
and	O
gene	O
.	O

This	O
remodeling	O
of	O
promoter	B
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta-globin	B
gene	O
transcription	O
and	O
induction,	O
and	O
inhibited	O
long-term	O
beta-globin	B
gene	O
silencing	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	B
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B
cell	O
adhesion	O
molecule	O
(	O
VCAM-1	B
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell-monocyte	O
(EC-Mn)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity.	O

However,	O
cytokine-induced	O
NF-kappaB	B
activation	O
and	O
VCAM-1	B
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL-2	B
enhancer	O
known	O
as	O
the	O
antigen	B
receptor	O
response	O
element	O
2	O
(	O
ARRE-2	B
).	O

Furthermore,	O
NF90	B
was	O
phosphorylated	O
in	O
a	O
double-stranded	B
RNA	O
-dependent	O
manner	O
likely	O
by	O
the	O
interferon-induced,	O
double-stranded	B
RNA	O
-dependent	O
protein	O
kinase	O
,	O
PKR	B
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin-8	B
(	O
IL-8	B
)	O
secretion	O
from	O
peripheral	B
blood	O
mononuclear	B
cells	O
(	O
PBMC	B
).	O

The	O
correlation	O
between	O
C5a	O
-induced	O
kappaB	B
binding	O
activity	O
and	O
IL-8	B
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	B
macrophage	O
cells	O
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	B
sequence	O
from	O
IkappaBalpha	B
and	O
IL-8	B
promoter	O
regions	O
.	O

Increased	O
glucocorticoid	B
receptor	O
beta	O
in	O
airway	B
cells	O
of	O
glucocorticoid	O
-insensitive	O
asthma	O
.	O

Thus	O
increased	O
expression	O
of	O
GCRbeta	B
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O

Furthermore,	O
GCRbeta	B
expression	O
in	O
GC-insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	B
cells	O
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O

Activation	O
of	O
the	O
Janus	B
kinase	O
3	O
-STAT5a	B
pathway	O
after	O
CD40	B
triggering	O
of	O
human	B
monocytes	O
but	O
not	O
of	O
resting	B
B	O
cells	O
.	O

After	O
CD40	B
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF-kappaB	B
(but	O
not	O
of	O
the	O
AP-1	B
)	O
transcription	B
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations.	O

Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B
-induced	O
signal	O
transduction	O
.	O

In	O
the	O
present	O
study,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(the	O
interleukin-2	B
[IL-2]-dependent	O
HT-2	O
line	O
)	O
in	O
which	O
the	O
EPO	B
stimulation	O
of	O
the	O
EPOR	B
fails	O
to	O
support	O
cellular	O
proliferation,	O
STAT-5	B
induction	O
,	O
or	O
MAPK	B
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B
and	O
JAK2	B
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	B
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

Regrettably,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

HIV-1	O
expressing	O
IkappaB-alphaS32/36A	B
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B
and	O
peripheral	B
blood	O
mononuclear	O
cells	O
.	O

These	O
findings	O
illustrate	O
gain-of-function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live-attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Whereas	O
the	O
previously	O
described	O
isoform	B
NF-ATc	B
/A	O
contains	O
a	O
relatively	O
short	O
C	B
terminus	O
,	O
the	O
longer	O
isoforms,	O
B	B
and	O
C	B
,	O
span	O
extra	O
C-terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively.	O

These	O
properties	O
of	O
NF-ATc	O
/	O
B	O
and	O
-	O
C	O
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	B
T	B
lymphocytes	O
in	O
which	O
NF-ATc	O
/	O
B	O
and	O
-C	O
are	O
predominantly	O
synthesized.	O

To	O
address	O
this	O
question,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
CD8+	B
T	O
cell	O
clones	O
from	O
the	O
joint	O
of	O
a	O
rheumatoid	O
arthritis	O
patient	O
and	O
selected	O
for	O
their	O
reactivity	O
against	O
a	O
single	B
MHC/peptide	O
complex	O
.	O

We	O
found	O
a	O
wide	O
range	O
of	O
TCR	B
affinities	O
among	O
the	O
different	O
clonotypes	O
that	O
segregated	O
with	O
Vbeta	O
usage.	O

The	O
mechanisms	O
by	O
which	O
beta-catenin	B
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown.	O

The	O
nuclear	O
localization	O
of	O
Delta19	B
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta-catenin	B
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF/TCF	B
factors	O
.	O

Taken	O
together,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type.	O

Recent	O
experiments	O
suggest	O
that	O
Ikaros	B
and	O
Aiolos	B
set	O
B	O
cell	O
antigen-receptor	O
(BCR)-	O
and	O
TCR-	O
mediated	O
signaling	O
thresholds	O
and	O
that	O
the	O
molecules	O
exist	O
within	O
T	B
cells	O
in	O
nuclear	B
complexes	O
that	O
contain	O
nucleosome	O
remodeling	O
and	O
histone	B
deacetylase	O
activities	O
.	O

The	O
replaced	B
enhancer	O
is	O
propagated	O
to	O
the	O
5'	B
LTR	O
upon	O
integration	O
into	O
the	O
target	B
cell	O
genome	O
.	O

Packaging	O
of	O
viral	O
particles,	O
integration	O
into	O
the	O
target	O
genome,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	B
modification	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	B
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	B
/Fas	B
ligand	O
(	O
FasL	B
)	O
interaction	O
.	O

Fas/	O
FasL	B
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise.	O

We	O
now	O
find	O
that	O
LMP1	B
signaling	O
through	O
TRADD	B
differs	O
from	O
TNFR1	B
signaling	O
through	O
TRADD	B
.	O

Unlike	O
TNFR1	B
,	O
LMP1	B
can	O
interact	O
directly	O
with	O
receptor-interacting	B
protein	O
(	O
RIP	B
)	O
and	O
stably	O
associates	O
with	O
RIP	B
in	O
EBV	B
-transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Inhibition	O
of	O
NF-kappa	B
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase-dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase	O
-1	O
and	O
-3	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	B
inhibitor	O
Z-VAD-fmk	B
and	O
partially	O
blocked	O
by	O
Ac-DEVD-fmk	B
,	O
suggesting	O
that	O
SN50	O
-mediated	O
apoptosis	O
is	O
caspase	B
-dependent	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF-kappa	B
B	O
in	O
survival	O
of	O
naive	B
PBL	O
.	O

N-formyl-methionyl-leucyl-phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	O
and	O
44-	O
kDa	O
proteins	O
,	O
which	O
were	O
identified	O
as	O
extracellular	B
signal-regulated	O
kinase	O
(	O
ERK	B
),	O
in	O
human	B
monocytes	O
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors,	O
whereas	O
PMA	O
-induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	B
.	O

Aiolos	B
transcription	B
factor	O
controls	O
cell	O
death	O
in	O
T	B
cells	O
by	O
regulating	O
Bcl-2	B
expression	O
and	O
its	O
cellular	O
localization.	O

We	O
also	O
identified	O
functional	O
Aiolos	B
-binding	O
sites	O
in	O
the	O
Bcl-2	B
promoter	O
,	O
which	O
are	O
able	O
to	O
activate	O
the	O
luciferase	B
reporter	O
gene	O
.	O

Binding	O
of	O
YY1	B
and	O
Oct1	B
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	B
in	O
human	O
T	B
cells	O
.	O

OBJECTIVE:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	B
IL-5	O
(hIL-5)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	B
transcription	O
in	O
T	B
cells	O
.	O

Two	O
of	O
these	O
regions,	O
BR3	B
and	O
BR4	B
located	O
at	O
positions	O
-102	O
to	O
-73,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	B
expression	O
in	O
T	B
cells	O
.	O

